



HU000028085T2



(19) **HU**

(11) Lajstromszám: **E 028 085**

(13) **T2**

**MAGYARORSZÁG**  
Szellemi Tulajdon Nemzeti Hivatala

## **EURÓPAI SZABADALOM** **SZÖVEGÉNEK FORDÍTÁSA**

(21) Magyar ügyszám: **E 10 724879**

(22) A bejelentés napja: **2010. 06. 24.**

(51) Int. Cl.: **A61K 391/55**

(2006.01)

**C07K 141/35**

(2006.01)

(96) Az európai bejelentés bejelentési száma:  
**EP 20100724879**

(86) A nemzetközi (PCT) bejelentési szám:

**PCT/EP 10/059008**

(97) Az európai bejelentés közzétételi adatai:  
**EP 2445526 A1** **2010. 12. 29.**

(87) A nemzetközi közzétételi szám:

**WO 10149745**

(97) Az európai szabadalom megadásának meghirdetési adatai:  
**EP 2445526 B1** **2016. 05. 11.**

(30) Elsőbbségi adatai:

**219964 P** **2009. 06. 24.** **US**  
**334568 P** **2010. 05. 13.** **US**

(73) Jogosult(ak):

**GlaxoSmithKline Biologicals S.A., 1330  
Rixensart (BE)**  
**ID Biomedical Corporation of Quebec, Ste  
Foy, Quebec (CA)**

(72) Feltaláló(k):

**BAUDOUX, Guy Jean Marie Fernand Pierre, 1330  
Rixensart (BE)**  
**BLAIS, Normand, Laval, Quebec H7V 3S8 (CA)**  
**CYR, Sonya L, Laval, Quebec H7V 3S8 (CA)**  
**RHEAULT, Patrick, Laval, Quebec H7V 3S8 (CA)**  
**RUELLE, Jean Louis, 1330 Rixensart (BE)**

(74) Képviselő:

**Danubia Szabadalmi és Jogi Iroda Kft.,  
Budapest**

(54)

**Rekombináns RSV-antigének**

Az európai szabadalom ellen, megadásának az Európai Szabadalmi Közlönyben való meghirdetésétől számított kilenc hónapon belül, felszólalást lehet benyújtani az Európai Szabadalmi Hivatalnál. (Európai Szabadalmi Egyezmény 99. cikk(1))

A fordítást a szabadalmas az 1995. évi XXXIII. törvény 84/H. §-a szerint nyújtotta be. A fordítás tartalmi helyességét a Szellemi Tulajdon Nemzeti Hivatala nem vizsgálta.



(12)

(11)

EP 2 445 526 B1

## EUROPEAN PATENT SPECIFICATION

(45) Date of publication and mention of the grant of the patent:

11.05.2016 Bulletin 2016/19

(21) Application number: 10724879.1

(22) Date of filing: 24.06.2010

(51) Int Cl.:

A61K 39/155 (2006.01)

C07K 14/135 (2006.01)

(86) International application number:

PCT/EP2010/059008

(87) International publication number:

WO 2010/149745 (29.12.2010 Gazette 2010/52)

## (54) RECOMBINANT RSV ANTIGENS

REKOMBINANTE RSV-ANTIGENE

ANTIGÈNES RECOMBINANTS DU VRS

(84) Designated Contracting States:

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB  
GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO  
PL PT RO SE SI SK SM TR

Designated Extension States:

BA ME RS

(30) Priority: 24.06.2009 US 219964 P

13.05.2010 US 334568 P

(43) Date of publication of application:

02.05.2012 Bulletin 2012/18

(73) Proprietors:

- GlaxoSmithKline Biologicals S.A.  
1330 Rixensart (BE)
- ID Biomedical Corporation of Quebec  
Laval, QC H7V 3S8 (CA)

(72) Inventors:

- BAUDOUX, Guy Jean Marie Fernand Pierre  
1330 Rixensart (BE)
- BLAIS, Normand  
Laval, Quebec H7V 3S8 (CA)
- CYR, Sonya L  
Laval, Quebec H7V 3S8 (CA)
- RHEAULT, Patrick  
Laval, Quebec H7V 3S8 (CA)
- RUELLE, Jean Louis  
1330 Rixensart (BE)

(74) Representative: Dalton, Marcus Jonathan William  
GlaxoSmithKline  
Global Patents (CN925.1)  
980 Great West Road  
Brentford, Middlesex TW8 9GS (GB)

(56) References cited:

WO-A1-02/42326 WO-A1-2009/079796

- MARTÍN DIANA ET AL: "Sequence elements of the fusion peptide of human respiratory syncytial virus fusion protein required for activity." June 2006 (2006-06), THE JOURNAL OF GENERAL VIROLOGY JUN 2006 LNKD- PUBMED:16690930, VOL. 87, NR. PT 6, PAGE(S) 1649 - 1658 , XP002600413 ISSN: 0022-1317 abstract; introduction;; page 87; figure 1
- GONZÁLEZ-REYES L ET AL: "Cleavage of the human respiratory syncytial virus fusion protein at two distinct sites is required for activation of membrane fusion." 14 August 2001 (2001-08-14), PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA 14 AUG 2001 LNKD- PUBMED:11493675, VOL. 98, NR. 17, PAGE(S) 9859 - 9864 , XP002600414 ISSN: 0027-8424 abstract; page 9862
- YIN HSIEN-SHENG ET AL: "Structure of the parainfluenza virus 5 F protein in its metastable, prefusion conformation." 5 January 2006 (2006-01-05), NATURE 5 JAN 2006 LNKD- PUBMED:16397490, VOL. 439, NR. 7072, PAGE(S) 38 - 44 , XP002600415 ISSN: 1476-4687 abstract, introduction; page 38; figure 1

Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations. Notice of opposition shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).

- SCHMIDT A C ET AL: "Mucosal immunization of Rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone" JOURNAL OF VIROLOGY, THE AMERICAN SOCIETY FOR MICROBIOLOGY, US LNKD- DOI:10.1128/JVI.76.23.12355-12359.2002, vol. 76, no. 3, 1 February 2002 (2002-02-01), pages 1089-1099, XP002978183 ISSN: 0022-538X
- HUANG YAN ET AL: "Modulation of protective immunity, eosinophilia, and cytokine responses by selective mutagenesis of a recombinant G protein vaccine against respiratory syncytial virus." April 2005 (2005-04), JOURNAL OF VIROLOGY APR 2005 LNKD- PUBMED:15767454, VOL. 79, NR. 7, PAGE(S) 4527 - 4532 , XP002600416 ISSN: 0022-538X the whole document
- TANG RODERICK S ET AL: "Parainfluenza virus type 3 expressing the native or soluble fusion (F) Protein of Respiratory Syncytial Virus (RSV) confers protection from RSV infection in African green monkeys." October 2004 (2004-10), JOURNAL OF VIROLOGY OCT 2004 LNKD- PUBMED:15452239, VOL. 78, NR. 20, PAGE(S) 11198- 11207 , XP002600417 ISSN: 0022-538X the whole document
- VALARCHER J-F ET AL: "Bovine respiratory syncytial virus lacking the virokinin or with a mutation in furin cleavage site RA(R/K)R109 induces less pulmonary inflammation without impeding the induction of protective immunity in calves." June 2006 (2006-06), THE JOURNAL OF GENERAL VIROLOGY JUN 2006 LNKD- PUBMED:16690931, VOL. 87, NR. PT 6, PAGE(S) 1659 - 1667 , XP002600418 ISSN: 0022-1317 abstract;figure 1
- VAN DRUNEN LITTEL-VAN DEN HURK S ET AL: "Immunopathology of RSV infection: prospects for developing vaccines without this complication" REVIEWS IN MEDICAL VIROLOGY, CHICHESTER, GB LNKD- DOI:10.1002/RMV.518, vol. 17, no. 1, 1 January 2007 (2007-01-01), pages 5-34, XP002510797 ISSN: 1052-9276 [retrieved on 2006-09-27]
- OLSON MATTHEW R ET AL: "Pulmonary immunity and immunopathology: lessons from respiratory syncytial virus" EXPERT REVIEW OF VACCINES, FUTURE DRUGS, LONDON, GB, vol. 7, no. 8, 1 October 2008 (2008-10-01) , pages 1239-1255, XP009138398 ISSN: 1476-0584
- SINCLAIR ANGUS M ET AL: "Glycoengineering: the effect of glycosylation on the properties of therapeutic proteins", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 94, no. 8, 1 August 2005 (2005-08-01) , pages 1626-1635, XP002559550, ISSN: 0022-3549
- TIAN, S.: "A 20 residue motif delineates the furin cleavage site and its physical properties may influence viral fusion", BIOCHEMISTRY INSIGHTS, vol. 2, 8 April 2009 (2009-04-08), pages 9-20,
- ELLIOTT STEVE ET AL: "Enhancement of therapeutic protein in vivo activities through glycoengineering", NATURE BIOTECHNOLOGY, NATURE PUBLISHING GROUP, NEW YORK, NY, US, vol. 21, no. 4, 1 April 2003 (2003-04-01), pages 414-421, XP002354911, ISSN: 1087-0156, DOI: 10.1038/NBT799
- Stryer, L.: "Biochemistry, 3rd ed.", 1988 ISBN: 0-7167-1920-7 pages 18-20,
- Melero, J.A.: "Molecular Biology od Respiratory Syncytial Virus" In: Cane, Patricia: "Respiratory Syncytial Virus", 2007, Elsevier ISBN: 978-0-444-52030-2 pages 1-42,
- HARRISON ROBERT L ET AL: "Protein N-glycosylation in the baculovirus-insect cell expression system and engineering of insect cells to produce "mammalianized" recombinant glycoproteins.", ADVANCES IN VIRUS RESEARCH 2006, vol. 68, 2006, pages 159-191, ISSN: 0065-3527

## Remarks:

The file contains technical information submitted after the application was filed and not included in this specification

**Description****CROSS-REFERENCE TO RELATED APPLICATIONS**

5 [0001] This application claims benefit of the earlier filing dates of United States Provisional Applications 61/334,568, filed 13 May 2010 and 61/219,964, filed 24 June 2009.

**BACKGROUND**

10 [0002] This disclosure concerns the field of immunology. More particularly this disclosure relates to compositions and methods for eliciting an immune response specific for Respiratory Syncytial Virus (RSV).

[0003] Human Respiratory Syncytial Virus (RSV) is the most common worldwide cause of lower respiratory tract infections (LRI) in infants less than 6 months of age and premature babies less than or equal to 35 weeks of gestation. The RSV disease spectrum includes a wide array of respiratory symptoms from rhinitis and otitis to pneumonia and bronchiolitis, the latter two diseases being associated with considerable morbidity and mortality. Humans are the only known reservoir for RSV. Spread of the virus from contaminated nasal secretions occurs via large respiratory droplets, so close contact with an infected individual or contaminated surface is required for transmission. RSV can persist for several hours on toys or other objects, which explains the high rate of nosocomial RSV infections, particularly in paediatric wards.

20 [0004] The global annual infection and mortality figures for RSV are estimated to be 64 million and 160,000 respectively. In the U.S. alone RSV is estimated to be responsible for 18,000 to 75,000 hospitalizations and 90 to 1900 deaths annually. In temperate climates, RSV is well documented as a cause of yearly winter epidemics of acute LRI, including bronchiolitis and pneumonia. In the USA, nearly all children have been infected with RSV by two years of age. The incidence rate of RSV-associated LRI in otherwise healthy children was calculated as 37 per 1000 child-year in the first two years of life (45 per 1000 child-year in infants less than 6 months old) and the risk of hospitalization as 6 per 1000 child-years (per 1000 child-years in the first six months of life). Incidence is higher in children with cardio-pulmonary disease and in those born prematurely, who constitute almost half of RSV-related hospital admissions in the USA. Children who experience a more severe LRI caused by RSV later have an increased incidence of childhood asthma. These studies demonstrate widespread need for RSV vaccines, as well as use therof, in industrialized countries, where the costs of caring for patients with severe LRI and their sequelae are substantial. RSV also is increasingly recognized as an important cause of morbidity from influenza-like illness in the elderly.

30 [0005] Various approaches have been attempted in efforts to produce a safe and effective RSV vaccine that produces durable and protective immune responses in healthy and at risk populations. However, none of the candidates evaluated to date have been proven safe and effective as a vaccine for the purpose of preventing RSV infection and/or reducing or preventing RSV disease, including lower respiratory infections (LRIs).

**SUMMARY**

40 [0006] The present invention relates to a recombinant respiratory syncytial virus (RSV) antigen comprising an RSV F protein polypeptide without a transmembrane domain, comprising an F<sub>2</sub> domain and an F<sub>1</sub> domain of an RSV F protein polypeptide, wherein the F protein polypeptide comprises at least one modification that increases glycosylation, which at least one modification that increases glycosylation comprises a substitution wherein amino acids corresponding to positions 500-502 of SEQ ID NO:2 are selected from: NGS; NGT, to an immunogenic composition comprising the recombinant RSV antigen, a recombinant nucleic acid encoding the recombinant RSV antigen and the use of any of these as a medicament. As such, this disclosure concerns recombinant respiratory syncytial virus (RSV) antigens. More specifically, this disclosure concerns antigens including a recombinant F protein that has been modified to stabilize the trimeric prefusion conformation. The disclosed recombinant antigens exhibit superior immunogenicity, and are particularly favorably employed as components of immunogenic compositions (e.g., vaccines) for protection against RSV infection and/or disease. Also disclosed are nucleic acids that encode the recombinant antigens, immunogenic compositions containing the antigens, and methods for producing and using the antigens.

**BRIEF DESCRIPTION OF THE DRAWINGS**

55 [0007]

FIG. 1A is a schematic illustration highlighting structural features of the RSV F protein.

FIG. 1B is a schematic illustration of exemplary RSV Prefusion F (PreF) antigens.

FIG. 2 is a line graph illustrating representative results of asymmetrical field flow fractionation (AFF-MALS) analysis of PreF.

5 FIG. 3 is a bar graph showing neutralization inhibition of human serum by PreF antigen.

FIGS. 4A and B are bar graphs showing serum IgG titers elicited in mice in response to PreF antigen.

FIGS. 5A and B are bar graphs illustrating titers of neutralizing antibodies specific for RSV elicited by PreF antigen.

10 FIGS. 6A and B are graphs indicating protection against challenge provided by the RSV PreF antigen in mice.

FIG. 7 is a graph evaluating BAL leukocytes following immunization and challenge.

15 FIG. 8 is a bar graph illustrating serum IgG elicited following immunization with PreF formulated with dilutions of an oil-in-water emulsion (AS03).

FIG. 9 is a bar graph illustrating neutralizing antibody titres following immunization with PreF formulated with dilutions of an oil-in-water emulsion (AS03)

20 FIG. 10 is a graph illustrating protection against challenge following immunization with PreF formulated with dilutions of an oil-in-water emulsion (AS03).

#### DETAILED DESCRIPTION

##### 25 INTRODUCTION

**[0008]** Development of vaccines to prevent RSV infection has been complicated by the fact that host immune responses appear to play a role in the pathogenesis of the disease. Early studies in the 1960s showed that children vaccinated with a formalin-inactivated RSV vaccine suffered from more severe disease on subsequent exposure to the virus as compared to unvaccinated control subjects. These early trials resulted in the hospitalization of 80% of vaccinees and two deaths. The enhanced severity of disease has been reproduced in animal models and is thought to result from inadequate levels of serum-neutralizing antibodies, lack of local immunity, and excessive induction of a type 2 helper T-cell-like (Th2) immune response with pulmonary eosinophilia and increased production of IL-4 and IL-5 cytokines. In contrast, a successful vaccine that protects against RSV infection induces a Th1 biased immune response, characterized by production of IL-2 and  $\gamma$ -interferon (IFN).

The present invention relates to a recombinant respiratory syncytial virus (RSV) antigen comprising an RSV F protein polypeptide without a transmembrane domain, comprising an  $F_2$  domain and an  $F_1$  domain of an RSV F protein polypeptide, wherein the F protein polypeptide comprises at least one modification that increases glycosylation, which at least one modification that increases glycosylation comprises a substitution wherein amino acids corresponding to positions 500-502 of SEQ ID NO:2 are selected from: NGS; NGT. The present disclosure concerns recombinant respiratory syncytial virus (RSV) antigens that solve problems encountered with RSV antigens previously used in vaccines, and improve the immunological as well as manufacturing properties of the antigen. The recombinant RSV antigens disclosed herein involve a Fusion (F) protein analog that include a soluble F protein polypeptide, which has been modified to stabilize the prefusion conformation of the F protein, that is, the conformation of the mature assembled F protein prior to fusion with the host cell membrane. These F protein analogs are designated "PreF" or "PreF antigens", for purpose of clarity and simplicity. The PreF antigens disclosed herein are predicated on the unforeseen discovery that soluble F protein analogs that have been modified by the incorporation of a heterologous trimerization domain exhibit improved immunogenic characteristics, and are safe and highly protective when administered to a subject *in vivo*.

Details of the structure of the RSV F protein are provided herein with reference to terminology and designations widely accepted in the art, and illustrated schematically in FIG. 1A. A schematic illustration of exemplary PreF antigens is provided in FIG. 1B. It will be understood by those of skill in the art that any RSV F protein can be modified to stabilize the prefusion conformation according to the teachings provided herein. Therefore, to facilitate understanding of the principles guiding production of PreF antigens, individual structural components will be indicated with reference to an exemplary F protein, the polynucleotide and amino acid sequence of which are provided in SEQ ID NOs:1 and 2, respectively. Similarly, where applicable, G protein antigens are described in reference to an exemplary G protein, the polynucleotide and amino acid sequences of which are provided in SEQ ID NOs:3 and 4, respectively.

**[0009]** With reference to the primary amino acid sequence of the F protein polypeptide (FIG. 1A), the following terms are utilized to describe structural features of the PreF antigens.

The term F0 refers to a full-length translated F protein precursor. The F0 polypeptide can be subdivided into an F2 domain and an F1 domain separated by an intervening peptide, designated pep27. During maturation, the F0 polypeptide undergoes proteolytic cleavage at two furin sites situated between F2 and F1 and flanking pep27. For purpose of the ensuing discussion, an F2 domain includes as much as all, of amino acids 1-109, and a soluble portion of an F1 domain includes up to all, of amino acids 137-526 of the F protein. As indicated above, these amino acid positions (and all subsequent amino acid positions designated herein) are given in reference to the exemplary F protein precursor polypeptide (F0) of SEQ ID NO:2.

The prefusion F (or "PreF") antigen is a soluble (that is, not membrane bound) F protein analog that includes at least one modification that stabilizes the prefusion conformation of the F protein, such that the RSV antigen retains at least one immunodominant epitope of the prefusion conformation of the F protein. The soluble F protein polypeptide includes an F2 domain and an F1 domain of the RSV F protein (but does not include a transmembrane domain of the RSV F protein). In exemplary embodiments, the F2 domain includes amino acids 26-105 and the F1 domain includes amino acids 137-516 of an F protein. Similarly, polypeptides that include additional structural components so long as the additional components do not disrupt the three-dimensional conformation, or otherwise adversely impact stability, production or processing, or decrease immunogenicity of the antigen. The F2 and F1 domains are positioned in an N-terminal to C-terminal orientation designed to replicate folding and assembly of the F protein analog into the mature prefusion conformation. To enhance production, the F2 domain can be preceded by a secretory signal peptide, such as a native F protein signal peptide or a heterologous signal peptide chosen to enhance production and secretion in the host cells in which the recombinant PreF antigen is to be expressed.

PreF antigens can be stabilized (in the trimeric prefusion conformation) by introducing one or more modifications, such as the addition, deletion or substitution, or one or more amino acids. One such stabilizing modification is the addition of an amino acid sequence comprising a heterologous stabilizing domain. In exemplary embodiments, the heterologous stabilizing domain is a protein multimerization domain. One particularly favorable example of such a protein multimerization domain is a coiled-coil domain, such as an isoleucine zipper domain that promotes trimerization of multiple polypeptides having such a domain. An exemplary isoleucine zipper domain is depicted in SEQ ID NO:11. Typically, the heterologous stabilizing domain is positioned C-terminal to the F1 domain.

Optionally, the multimerization domain is connected to the F1 domain via a short amino acid linker sequence, such as the sequence GG. The linker can also be a longer linker (for example, including the sequence GG, such as the amino acid sequence: GGSGGSGGS; SEQ ID NO:14). Numerous conformationally neutral linkers are known in the art that can be used in this context without disrupting the conformation of the PreF antigen.

Another stabilizing modification is the elimination of a furin recognition and cleavage site that is located between the F2 and F1 domains in the native F0 protein. One or both furin recognition sites, located at positions 105-109 and at positions 133-136 can be eliminated by deleting or substituting one or more amino acid of the furin recognition sites, such that the protease is incapable of cleaving the PreF polypeptide into its constituent domains. Optionally, the intervening pep27 peptide can also be removed or substituted, e.g., by a linker peptide. Additionally, or optionally, a non-furin cleavage site (e.g., a metalloproteinase site at positions 112-113) in proximity to the fusion peptide can be removed or substituted. Another stabilizing mutation can include the addition or substitution of a hydrophilic amino acid into a hydrophobic domain of the F protein. Typically, a charged amino acid, such as lysine, will be added or substituted for a neutral residue, such as leucine, in the hydrophobic region. For example, a hydrophilic amino acid can be added to, or substituted for, a hydrophobic or neutral amino acid within the HRB coiled-coil domain of the F protein extracellular domain. In one embodiment, a charged amino acid residue, such as lysine, can be substituted for the leucine present at position 512 of the F protein. Alternatively, or in addition, a hydrophilic amino acid can be added to, or substituted for, a hydrophobic or neutral amino acid within the HRA domain of the F protein. Thus, in a further embodiment one or more charged amino acids, such as lysine, can be inserted at or near position 105-106 (e.g., following the amino acid corresponding to residue 105 of reference SEQ ID NO:2, such as between amino acids 105 and 106) of the PreF antigen. Optionally, hydrophilic amino acids can be added or substituted in both the HRA and HRB domains. Alternatively, one or more hydrophobic residues can be deleted, so long as the overall conformation of the PreF antigen is not adversely impacted.

According to the present invention, one or more modification is made, which increases the glycosylation state of the PreF antigen. Amino acids in a glycosylation site present in a native RSV F protein, at amino acid residue 500 (as compared to SEQ ID NO:2) are substituted to increase the glycosylation status of the PreF antigen. Thus the amino acids corresponding to positions 500-502 of SEQ ID NO:2 can be selected from: NGS;; NGT. Thus, in certain embodiments, the PreF antigens include a soluble F protein polypeptide comprising an F2 domain (e.g., corresponding to amino acids 26-105 of SEQ ID NO:2) and an F1 domain (e.g., corresponding to amino acids 137-516 of SEQ ID NO:2) of an RSV F protein polypeptide, in which at least one modification that alters glycosylation has been introduced. The RSV PreF antigen, typically includes an intact fusion peptide between the F2 domain and the F1 domain. Optionally, the PreF antigen includes a signal peptide.

As disclosed above, such F protein polypeptides can include at least one modification selected from: (i) an addition of an amino acid sequence comprising a heterologous trimerization domain (such as a isoleucine zipper domain); (ii) an

amino acid addition, deletion or substitution that eliminates a furin cleavage site at a position corresponding to amino acids 105-109, a position corresponding to amino acids 133-136, or at both positions corresponding to amino acids 105-109 and 133-136 of the reference F protein precursor ( $F_0$ ) of SEQ ID NO:2; (iii) a deletion of one or more amino acids of the pep27 domain; and (iv) at least one substitution or addition of a hydrophilic amino acid in a hydrophobic domain of the F protein extracellular domain by substitution of lysine for the leucine present at position 512 or addition of a lysine following the amino acid corresponding to residue 105 of reference SEQ ID NO:2. As disclosed above, such glycosylation modified RSV PreF antigens assemble into multimers, e.g., trimers.

In exemplary embodiments, the glycosylation modified PreF antigens are selected from the group of: a) a polypeptide comprising or consisting of SEQ ID NO:22; b)

10 a polypeptide encoded by SEQ ID NO:21 or by a polynucleotide sequence that hybridizes under stringent conditions over substantially its entire length to SEQ ID NO:21; c) a polypeptide with at least 95% sequence identity to SEQ ID NO:22.

**[0010]** Any and/or all of the stabilizing modifications can be used individually and/or in combination with any of the other stabilizing modifications disclosed herein to produce a PreF antigen. In exemplary embodiments the PreF protein comprising a polypeptide comprising an F2 domain and an F1 domain with no intervening furin cleavage site between the F2 domain and the F1 domain, and with a heterologous stabilizing domain (e.g., trimerization domain) positioned C-terminal to the F1 domain. In certain embodiments, the PreF antigen also includes one or more addition and/or substitution of a hydrophilic residue into a hydrophobic domain as stated above. Optionally, the PreF antigen has a modification of at least one non-furin cleavage site, such as a metalloproteinase site.

**[0011]** Optionally, any PreF antigen described above can include an additional sequence that serves as an aid to purification. One example, is a polyhistidine tag. Such a tag can be removed from the final product if desired. When expressed, the PreF antigens undergo intramolecular folding and assemble into mature protein that includes a multimer of polypeptides. Favorably, the preF antigen polypeptides assemble into a trimer that resembles the prefusion conformation of the mature, processed, RSV F protein.

Any of the PreF antigens disclosed herein can be favorably used in immunogenic compositions for the purpose of eliciting a protective immune response against RSV. Such immunogenic compositions typically include a pharmaceutically acceptable carrier and/or excipient, such as a buffer. To enhance the immune response produced following administration, the immunogenic composition typically also includes an adjuvant. In the case of immunogenic compositions for eliciting a protective immune response against RSV (e.g., vaccines), the compositions favorably include an adjuvant that predominantly elicits a Th1 immune response (a Th1 biasing adjuvant). Typically, the adjuvant is selected to be suitable for administration to the target population to which the composition is to be administered. Thus, depending on the application, the adjuvant is selected to be suitable for administration, e.g., to neonates or to the elderly.

The immunogenic compositions described herein are favorably employed as vaccines for the reduction or prevention of infection with RSV, without inducing a pathological response (such as vaccine enhanced viral disease) following administration or exposure to RSV.

**[0012]** Optionally, the immunogenic compositions can also include at least one additional antigen of a pathogenic organism other than RSV. For example, the pathogenic organism is a virus other than RSV, such as Parainfluenza virus (PIV), measles, hepatitis B, poliovirus, or influenza virus. Alternatively, the pathogenic organism can be a bacterium, such as diphtheria, tetanus, *Haemophilus influenzae*, and *Pneumococcus*.

Recombinant nucleic acids that encode any of the PreF antigens are also a feature of this disclosure. The polynucleotide sequence of the nucleic acid that encodes the PreF antigen of the nucleic acid is may be optimized for expression in a selected host (such as CHO cells, other mammalian cells, or insect cells). Accordingly, vectors, including expression vectors (including prokaryotic and eukaryotic expression vectors) are a feature of this disclosure. Likewise, host cells including such nucleic acids, and vectors, are a feature of this disclosure. Such nucleic acids can also be used in the context of immunogenic compositions for administration to a subject to elicit an immune response specific for RSV.

The PreF antigens are favorably used for the prevention and/or treatment of RSV infection. Thus, another aspect of this disclosure concerns a method for eliciting an immune response against RSV. The method involves administering an immunologically effective amount of a composition containing a PreF antigen to a subject (such as a human or animal subject). Administration of an immunologically effective amount of the composition elicits an immune response specific for epitopes present on the PreF antigen. Such an immune response can include B cell responses (e.g., the production of neutralizing antibodies) and/or T cell responses (e.g., the production of cytokines). Favorably, the immune response elicited by the PreF antigen includes elements that are specific for at least one conformational epitope present on the prefusion conformation of the RSV F protein. The PreF antigens and compositions can be administered to a subject without enhancing viral disease following contact with RSV. Favorably, the PreF antigens disclosed herein and suitably formulated immunogenic compositions elicit a Th1 biased immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following infection with a RSV.

The immunogenic compositions can be administered via a variety of routes, including routes, such as intranasal, that directly place the PreF antigen in contact with the mucosa of the upper respiratory tract. Alternatively, more traditional administration routes can be employed, such an intramuscular route of administration.

Thus, the use of any of the disclosed RSV antigens (or nucleic acids) in the preparation of a medicament for treating RSV infection (for example, prophylactically treating or preventing an RSV infection) is also contemplated. Accordingly, this disclosure provides the disclosed recombinant RSV antigens or the immunogenic compositions for use in medicine, as well as the use thereof for the prevention or treatment of RSV-associated diseases.

5 Additional details regarding PreF antigens, and methods of using them, are presented in the description and examples below.

## TERMS

10 [0013] In order to facilitate review of the various embodiments of this disclosure, the following explanations of terms are provided. Additional terms and explanations can be provided in the context of this disclosure.

[0014] Unless otherwise explained, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure belongs. Definitions of common terms in molecular biology can be found in Benjamin Lewin, *Genes V*, published by Oxford University Press, 1994 (ISBN 0-19-854287-9); 15 Kendrew *et al.* (eds.), *The Encyclopedia of Molecular Biology*, published by Blackwell Science Ltd., 1994 (ISBN 0-632-02182-9); and Robert A. Meyers (ed.), *Molecular Biology and Biotechnology: a Comprehensive Desk Reference*, published by VCH Publishers, Inc., 1995 (ISBN 1-56081-569-8).

[0015] The singular terms "a," "an," and "the" include plural referents unless context clearly indicates otherwise. Similarly, the word "or" is intended to include "and" unless the context clearly indicates otherwise. The term "plurality" refers 20 to two or more. It is further to be understood that all base sizes or amino acid sizes, and all molecular weight or molecular mass values, given for nucleic acids or polypeptides are approximate, and are provided for description. Additionally, numerical limitations given with respect to concentrations or levels of a substance, such as an antigen, are intended to be approximate. Thus, where a concentration is indicated to be at least (for example) 200 pg, it is intended that the concentration be understood to be at least approximately (or "about" or "~") 200 pg.

[0016] Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of this disclosure, suitable methods and materials are described below. The term "comprises" means "includes." Thus, unless the context requires otherwise, the word "comprises," and variations such as "comprise" and "comprising" will be understood to imply the inclusion of a stated compound or composition (e.g., nucleic acid, polypeptide, antigen) 30 or step, or group of compounds or steps, but not to the exclusion of any other compounds, composition, steps, or groups thereof. The abbreviation, "e.g." is derived from the Latin *exempli gratia*, and is used herein to indicate a non-limiting example. Thus, the abbreviation "e.g." is synonymous with the term "for example."

[0017] Respiratory syncytial virus (RSV) is a pathogenic virus of the family Paramyxoviridae, subfamily Pneumovirinae, genus Pneumovirus. The genome of RSV is a negative-sense RNA molecule, which encodes 11 proteins. Tight association of the RNA genome with the viral N protein forms a nucleocapsid wrapped inside the viral envelope. Two groups 35 of human RSV strains have been described, the A and B groups, based on differences in the antigenicity of the G glycoprotein. Numerous strains of RSV have been isolated to date. Exemplary strains indicated by GenBank and/or EMBL Accession number can be found in WO2008114149, disclosing the nucleic acid and polypeptide sequences of RSV F and G proteins suitable for use in PreF antigens (including chimeric PreF-G antigens), and in combinations with PreF antigens. Additional strains of RSV are likely to be isolated, and are encompassed within the genus of RSV. 40 Similarly, the genus of RSV encompasses variants arising from naturally occurring (e.g., previously or subsequently identified strains) by genetic drift, or artificial synthesis and/or recombination.

[0018] The term "F protein" or "Fusion protein" or "F protein polypeptide" or "Fusion protein polypeptide" refers to a polypeptide or protein having all or part of an amino acid sequence of an RSV Fusion protein polypeptide. Numerous RSV Fusion proteins have been described and are known to those of skill in the art. WO2008114149 sets out exemplary 45 F protein variants (for example, naturally occurring variants) publicly available as of the filing date of this disclosure.

[0019] A "variant" when referring to a nucleic acid or a polypeptide (e.g., an RSV F protein nucleic acid or polypeptide, or a PreF nucleic acid or polypeptide) is a nucleic acid or a polypeptide that differs from a reference nucleic acid or polypeptide. Usually, the difference(s) between the variant and the reference nucleic acid or polypeptide constitute a proportionally small number of differences as compared to the referent.

[0020] A "domain" of a polypeptide or protein is a structurally defined element within the polypeptide or protein. For example, a "trimerization domain" is an amino acid sequence within a polypeptide that promotes assembly of the polypeptide into trimers. For example, a trimerization domain can promote assembly into trimers via associations with other trimerization domains (of additional polypeptides with the same or a different amino acid sequence). The term is also used to refer to a polynucleotide that encodes such a peptide or polypeptide.

[0021] The terms "native" and "naturally occurring" refer to an element, such as a protein, polypeptide or nucleic acid, that is present in the same state as it is in nature. That is, the element has not been modified artificially. It will be understood, that in the context of this disclosure, there are numerous native/naturally occurring variants of RS V proteins or polypeptides, e.g., obtained from different naturally occurring strains or isolates of RSV.

[0022] The term "polypeptide" refers to a polymer in which the monomers are amino acid residues which are joined together through amide bonds. The terms "polypeptide" or "protein" as used herein are intended to encompass any amino acid sequence and include modified sequences such as glycoproteins. The term "polypeptide" is specifically intended to cover naturally occurring proteins, as well as those which are recombinantly or synthetically produced. The term "fragment," in reference to a polypeptide, refers to a portion (that is, a subsequence) of a polypeptide. The term "immunogenic fragment" refers to all fragments of a polypeptide that retain at least one predominant immunogenic epitope of the full-length reference protein or polypeptide. Orientation within a polypeptide is generally recited in an N-terminal to C-terminal direction, defined by the orientation of the amino and carboxy moieties of individual amino acids. Polypeptides are translated from the N or amino-terminus towards the C or carboxy-terminus.

[0023] A "signal peptide" is a short amino acid sequence (e.g., approximately 18-25 amino acids in length) that direct newly synthesized secretory or membrane proteins to and through membranes, e.g., of the endoplasmic reticulum. Signal peptides are frequently but not universally located at the N-terminus of a polypeptide, and are frequently cleaved off by signal peptidases after the protein has crossed the membrane. Signal sequences typically contain three common structural features: an N-terminal polar basic region (n-region), a hydrophobic core, and a hydrophilic c-region).

[0024] The terms "polynucleotide" and "nucleic acid sequence" refer to a polymeric form of nucleotides at least 10 bases in length. Nucleotides can be ribonucleotides, deoxyribonucleotides, or modified forms of either nucleotide. The term includes single and double forms of DNA. By "isolated polynucleotide" is meant a polynucleotide that is not immediately contiguous with both of the coding sequences with which it is immediately contiguous (one on the 5' end and one on the 3' end) in the naturally occurring genome of the organism from which it is derived. In one embodiment, a polynucleotide encodes a polypeptide. The 5' and 3' direction of a nucleic acid is defined by reference to the connectivity of individual nucleotide units, and designated in accordance with the carbon positions of the deoxyribose (or ribose) sugar ring. The informational (coding) content of a polynucleotide sequence is read in a 5' to 3' direction.

[0025] A "recombinant" nucleic acid is one that has a sequence that is not naturally occurring or has a sequence that is made by an artificial combination of two otherwise separated segments of sequence. This artificial combination can be accomplished by chemical synthesis or, more commonly, by the artificial manipulation of isolated segments of nucleic acids, e.g., by genetic engineering techniques. A "recombinant" protein is one that is encoded by a heterologous (e.g., recombinant) nucleic acid, which has been introduced into a host cell, such as a bacterial or eukaryotic cell. The nucleic acid can be introduced, on an expression vector having signals capable of expressing the protein encoded by the introduced nucleic acid or the nucleic acid can be integrated into the host cell chromosome.

[0026] The term "heterologous" with respect to a nucleic acid, a polypeptide or another cellular component, indicates that the component occurs where it is not normally found in nature and/or that it originates from a different source or species.

[0027] The term "purification" (e.g., with respect to a pathogen or a composition containing a pathogen) refers to the process of removing components from a composition, the presence of which is not desired. Purification is a relative term, and does not require that all traces of the undesirable component be removed from the composition. In the context of vaccine production, purification includes such processes as centrifugation, dialization, ionexchange chromatography, and size-exclusion chromatography, affinity-purification or precipitation. Thus, the term "purified" does not require absolute purity; rather, it is intended as a relative term. Thus, for example, a purified nucleic acid preparation is one in which the specified protein is more enriched than the nucleic acid is in its generative environment, for instance within a cell or in a biochemical reaction chamber. A preparation of substantially pure nucleic acid or protein can be purified such that the desired nucleic acid represents at least 50% of the total nucleic acid content of the preparation. In certain embodiments, a substantially pure nucleic acid will represent at least 60%, at least 70%, at least 80%, at least 85%, at least 90%, or at least 95% or more of the total nucleic acid or protein content of the preparation.

[0028] An "isolated" biological component (such as a nucleic acid molecule, protein or organelle) has been substantially separated or purified away from other biological components in the cell of the organism in which the component naturally occurs, such as, other chromosomal and extra-chromosomal DNA and RNA, proteins and organelles. Nucleic acids and proteins that have been "isolated" include nucleic acids and proteins purified by standard purification methods. The term also embraces nucleic acids and proteins prepared by recombinant expression in a host cell as well as chemically synthesized nucleic acids and proteins.

[0029] An "antigen" is a compound, composition, or substance that can stimulate the production of antibodies and/or a T cell response in an animal, including compositions that are injected, absorbed or otherwise introduced into an animal. The term "antigen" includes all related antigenic epitopes. The term "epitope" or "antigenic determinant" refers to a site on an antigen to which B and/or T cells respond. The "dominant antigenic epitopes" or "dominant epitope" are those epitopes to which a functionally significant host immune response, e.g., an antibody response or a T-cell response, is made. Thus, with respect to a protective immune response against a pathogen, the dominant antigenic epitopes are those antigenic moieties that when recognized by the host immune system result in protection from disease caused by the pathogen. The term "T-cell epitope" refers to an epitope that when bound to an appropriate MHC molecule is specifically bound by a T cell (via a T cell receptor). A "B-cell epitope" is an epitope that is specifically bound by an

antibody (or B cell receptor molecule).

[0030] An "adjuvant" is an agent that enhances the production of an immune response in a nonspecific manner. Common adjuvants include suspensions of minerals (alum, aluminum hydroxide, aluminum phosphate) onto which antigen is adsorbed; emulsions, including water-in-oil, and oil-in-water (and variants thereof, including double emulsions and reversible emulsions), liposaccharides, lipopolysaccharides, immunostimulatory nucleic acids (such as CpG oligonucleotides), liposomes, Toll-like Receptor agonists (particularly, TLR2, TLR4, TLR7/8 and TLR9 agonists), and various combinations of such components.

[0031] An "immunogenic composition" is a composition of matter suitable for administration to a human or animal subject (e.g., in an experimental setting) that is capable of eliciting a specific immune response, e.g., against a pathogen, such as RSV. As such, an immunogenic composition includes one or more antigens (for example, polypeptide antigens) or antigenic epitopes. An immunogenic composition can also include one or more additional components capable of eliciting or enhancing an immune response, such as an excipient, carrier, and/or adjuvant. In certain instances, immunogenic compositions are administered to elicit an immune response that protects the subject against symptoms or conditions induced by a pathogen. In some cases, symptoms or disease caused by a pathogen is prevented (or reduced or ameliorated) by inhibiting replication of the pathogen (e.g., RSV) following exposure of the subject to the pathogen. In the context of this disclosure, the term immunogenic composition will be understood to encompass compositions that are intended for administration to a subject or population of subjects for the purpose of eliciting a protective or palliative immune response against RSV (that is, vaccine compositions or vaccines).

[0032] An "immune response" is a response of a cell of the immune system, such as a B cell, T cell, or monocyte, to a stimulus. An immune response can be a B cell response, which results in the production of specific antibodies, such as antigen specific neutralizing antibodies. An immune response can also be a T cell response, such as a CD4+ response or a CD8+ response. In some cases, the response is specific for a particular antigen (that is, an "antigen-specific response"). If the antigen is derived from a pathogen, the antigen-specific response is a "pathogen-specific response." A "protective immune response" is an immune response that inhibits a detrimental function or activity of a pathogen, reduces infection by a pathogen, or decreases symptoms (including death) that result from infection by the pathogen. A protective immune response can be measured, for example, by the inhibition of viral replication or plaque formation in a plaque reduction assay or ELISA-neutralization assay, or by measuring resistance to pathogen challenge *in vivo*.

[0033] A "Th1" biased immune response is characterized by the presence of CD4+ T helper cells that produce IL-2 and IFN- $\gamma$ , and thus, by the secretion or presence of IL-2 and IFN- $\gamma$ . In contrast, a "Th2" biased immune response is characterized by a preponderance of CD4+ helper cells that produce IL-4, IL-5, and IL-13.

[0034] An "immunologically effective amount" is a quantity of a composition (typically, an immunogenic composition) used to elicit an immune response in a subject to the composition or to an antigen in the composition. Commonly, the desired result is the production of an antigen (e.g., pathogen)-specific immune response that is capable of or contributes to protecting the subject against the pathogen. However, to obtain a protective immune response against a pathogen can require multiple administrations of the immunogenic composition. Thus, in the context of this disclosure, the term immunologically effective amount encompasses a fractional dose that contributes in combination with previous or subsequent administrations to attaining a protective immune response.

[0035] The adjective "pharmaceutically acceptable" indicates that the referent is suitable for administration to a subject (e.g., a human or animal subject). Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 15th Edition (1975), describes compositions and formulations (including diluents) suitable for pharmaceutical delivery of therapeutic and/or prophylactic compositions, including immunogenic compositions.

[0036] The term "modulate" in reference to a response, such as an immune response, means to alter or vary the onset, magnitude, duration or characteristics of the response. An agent that modulates an immune response alters at least one of the onset, magnitude, duration or characteristics of an immune response following its administration, or that alters at least one of the onset, magnitude, duration or characteristic as compared to a reference agent.

[0037] The term "reduces" is a relative term, such that an agent reduces a response or condition if the response or condition is quantitatively diminished following administration of the agent, or if it is diminished following administration of the agent, as compared to a reference agent. Similarly, the term "prevents" does not necessarily mean that an agent completely eliminates the response or condition, so long as at least one characteristic of the response or condition is eliminated. Thus, an immunogenic composition that reduces or prevents an infection or a response, such as a pathological response, e.g., vaccine enhanced viral disease, can, but does not necessarily completely eliminate such an infection or response, so long as the infection or response is measurably diminished, for example, by at least about 50%, such as by at least about 70%, or about 80%, or even by about 90% of (that is to 10% or less than) the infection or response in the absence of the agent, or in comparison to a reference agent.

[0038] A "subject" is a living multi-cellular vertebrate organism. In the context of this disclosure, the subject can be an experimental subject, such as a non-human animal, e.g., a mouse, a cotton rat, or a non-human primate. Alternatively, the subject can be a human subject.

PreF ANTIGENS

**[0039]** In nature, the RSV F protein is expressed as a single polypeptide precursor 574 amino acids in length, designated F0. *In vivo*, F0 oligomerizes in the endoplasmic reticulum and is proteolytically processed by a furin protease at two conserved furin consensus sequences (furin cleavage sites), RARR<sup>109</sup> (SEQ ID NO:15) and RKRR<sup>136</sup> (SEQ ID NO:16) to generate an oligomer consisting of two disulfide-linked fragments. The smaller of these fragments is termed F2 and originates from the N-terminal portion of the F0 precursor. It will be recognized by those of skill in the art that the abbreviations F0, F1 and F2 are commonly designated F<sub>0</sub>, F<sub>1</sub> and F<sub>2</sub> in the scientific literature. The larger, C-terminal F1 fragment anchors the F protein in the membrane via a sequence of hydrophobic amino acids, which are adjacent to a 24 amino acid cytoplasmic tail. Three F2-F1 dimers associate to form a mature F protein, which adopts a metastable prefusogenic ("prefusion") conformation that is triggered to undergo a conformational change upon contact with a target cell membrane. This conformational change exposes a hydrophobic sequence, known as the fusion peptide, which associates with the host cell membrane and promotes fusion of the membrane of the virus, or an infected cell, with the target cell membrane.

5 The F1 fragment contains at least two heptad repeat domains, designated HRA and HRB, and situated in proximity to the fusion peptide and transmembrane anchor domains, respectively. In the prefusion conformation, the F2-F1 dimer forms a globular head and stalk structure, in which the HRA domains are in a segmented (extended) conformation in the globular head. In contrast, the HRB domains form a three-stranded coiled coil stalk extending from the head region. During transition from the prefusion to the postfusion conformations, the HRA domains collapse and are brought into 10 proximity to the HRB domains to form an anti-parallel six helix bundle. In the postfusion state the fusion peptide and transmembrane domains are juxtaposed to facilitate membrane fusion.

15 Although the conformational description provided above is based on molecular modeling of crystallographic data, the structural distinctions between the prefusion and postfusion conformations can be monitored without resort to crystallography. For example, electron microscopy can be used to distinguish between the prefusion and postfusion (alternatively designated prefusogenic and fusogenic) conformations, as demonstrated by Calder et al., *Virology*, 271:122-131 (2000) and Morton et al., *Virology*, 311:275-288. The prefusion conformation can also be distinguished from the fusogenic (postfusion) conformation by liposome association assays as described by Connolly et al., *Proc. Natl. Acad. Sci. USA*, 103:17903-17908 (2006). Additionally, prefusion and fusogenic conformations can be distinguished using antibodies (e.g., monoclonal antibodies) that specifically recognize conformation epitopes present on one or the other of the prefusion 20 or fusogenic form of the RSV F protein, but not on the other form. Such conformation epitopes can be due to preferential exposure of an antigenic determinant on the surface of the molecule. Alternatively, conformational epitopes can arise from the juxtaposition of amino acids that are non-contiguous in the linear polypeptide.

25 The PreF antigens disclosed herein are designed to stabilize and maintain the prefusion conformation of the RSV F protein, such that in a population of expressed protein, a substantial portion of the population of expressed protein is in the prefusogenic (prefusion) conformation (e.g., as predicted by structural and/or thermodynamic modeling or as assessed by one or more of the methods disclosed above). Stabilizing modifications are introduced into a native (or synthetic) F protein, such as the exemplary F protein of SEQ ID NO:2, such that the major immunogenic epitopes of the prefusion conformation of the F protein are maintained following introduction of the PreF antigen into a cellular or extracellular environment (for example, *in vivo*, e.g., following administration to a subject).

30 **[0040]** First, a heterologous stabilizing domain can be placed at the C-terminal end of the construct in order to replace the membrane anchoring domain of the F0 polypeptide. This stabilizing domain is predicted to compensate for the HRB instability, helping to stabilize the -prefusion conformer. In exemplary embodiments, the heterologous stabilizing domain is a protein multimerization domain. One particularly favorable example of such a protein multimerization domain is a trimerization domain. Exemplary trimerization domains fold into a coiled-coil that promotes assembly into trimers of 35 multiple polypeptides having such coiled-coil domains. One favorable example of a trimerization domain is an isoleucine zipper. An exemplary isoleucine zipper domain is the engineered yeast GCN4 isoleucine variant described by Harbury et al. *Science* 262:1401-1407 (1993). The sequence of one suitable isoleucine zipper domain is represented by SEQ ID NO:11, although variants of this sequence that retain the ability to form a coiled-coil stabilizing domain are equally suitable. Alternative stabilizing coiled coil trimerization domains include: TRAF2 (GENBANK® Accession No. Q12933 40 [gi:23503103]; amino acids 299-348); Thrombospondin 1 (Accession No. P07996 [gi:135717]; amino acids 291-314); Matrilin-4 (Accession No. 095460 [gi:14548117]; amino acids 594-618; CMP (matrilin-1) (Accession No. NP\_002370 [gi:4505111]; amino acids 463-496; HSF1 (Accession No. AAX42211 [gi:61362386]; amino acids 165-191; and Cubilin (Accession No. NP\_001072 [gi:4557503]; amino acids 104-138. It is expected that a suitable trimerization domain results 45 in the assembly of a substantial portion of the expressed protein into trimers. For example, at least 50% of a recombinant PreF polypeptide having a trimerization domain will assemble into a trimer (e.g., as assessed by AFF-MALS). Typically, at least 60%, more favorably at least 70%, and most desirably at least about 75% or more of the expressed polypeptide exists as a trimer.

50 In order to stabilize HRB even more, the leucine residue located at position 512 (relative to the native F0 protein) of the

PreF can be substituted by a lysine (L482K of the PreF antigen polypeptide of SEQ ID NO:6). This substitution improves the coiled coil hydrophobic residue periodicity. Similarly, a lysine can be added following the amino acid at position 105. Secondly, pep27 can be removed. Analysis of a structural model of the RSV F protein in the prefusion state suggests that pep27 creates a large unconstrained loop between F1 and F2. This loop does not contribute to stabilization of the prefusion state, and is removed following cleavage of the native protein by furin.

5 Third, one or both furin cleavage motifs can be deleted. With this design, the fusion peptide is not cleaved from F2, preventing release from the globular head of the prefusion conformer and accessibility to nearby membranes. Interaction between the fusion peptide and the membrane interface is predicted to be a major issue in the prefusion state instability. During the fusion process, interaction between the fusion peptide and the target membrane results in the exposure of 10 the fusion peptide from within the globular head structure, enhancing instability of the prefusion state and folding into post-fusion conformer. This conformation change enables the process of membrane fusion. Removal of one or both of the furin cleavage sites is predicted to prevent membrane accessibility to the N-terminal part of the fusion peptide, stabilizing the prefusion state. Thus, in exemplary embodiments disclosed herein, removal of the furin cleavage motifs 15 results in a PreF antigen that comprises an intact fusion peptide, which is not cleaved by furin during or following processing and assembly.

10 Optionally, at least one non-furin cleavage site can also be removed, for example by substitution of one or more amino acids. For example, experimental evidence suggests that under conditions conducive to cleavage by certain metallo-proteinases, the PreF antigen can be cleaved in the vicinity of amino acids 110-118 (for example, with cleavage occurring 15 between amino acids 112 and 113 of the PreF antigen; between a leucine at position 142 and glycine at position 143 of the reference F protein polypeptide of SEQ ID NO:2). Accordingly, modification of one or more amino acids within 20 this region can reduce cleavage of the PreF antigen. For example, the leucine at position 112 can be substituted with a different amino acid, such as isoleucine, glutamine or tryptophan (as shown in SEQ ID NO:20). Alternatively or additionally, the glycine at position 113 can be substituted by a serine or alanine.

25 According to the present invention, a recombinant RSV F protein polypeptide includes one or more modifications that alters the glycosylation pattern or status (e.g., by increasing the proportion of molecules glycosylated at one the glycosylation sites present in a native F protein polypeptide. The native F protein polypeptide of SEQ ID NO:2 is predicted to be glycosylated at amino acid positions 27, 70 and 500 (corresponding to positions 27, 70 and 470 of the PreF antigen 30 of SEQ ID NO:6). According to the invention, a modification is introduced in the glycosylation site at amino acid position 500 (designated N470)-502 that increases glycosylation efficiency at this glycosylation site. Examples of suitable modifications include at positions 500-502, the following amino acid sequences: NGS; NGT. Interestingly, it has been found 35 that modifications of this glycosylation site that result in increased glycosylation also result in substantially increased PreF production. Thus, in certain embodiments, the PreF antigens have a modified glycosylation site at the position corresponding to amino acid 500 of the reference PreF sequence (SEQ ID NO:2), e.g., at position 470 of the PreF antigen of SEQ ID NO:6). Suitable, modifications include the sequences: NGS;; NGT at amino acids corresponding to 40 positions 500-502 of the reference F protein polypeptide sequence. The amino acid of an exemplary embodiment that includes an "NGT" modification is provided in SEQ ID NO:18. One of skill in the art can easily determine similar modifications for corresponding NGS, , modifications. Such modifications are favorably combined with any of the stabilizing mutations disclosed herein (e.g., a heterologous coiled-coil, such as an isoleucine zipper, domain and/or a modification 45 in a hydrophobic region, and/or removal of pep27, and/or removal of a furin cleavage site, and/or removal of a non-furin cleavage site, and/or removal of a non-furin cleavage site). For example, in one specific embodiment, the PreF antigen includes a substitution that eliminates a non-furin cleavage site and a modification that increases glycosylation. An 50 exemplary sequence is provided in SEQ ID NO:22 (which exemplary embodiment includes an "NGT" modification and the substitution of glutamine in the place of leucine at position 112).

55 More generally, any one of the stabilizing modifications disclosed herein, e.g., addition of a heterologous stabilizing domain, such as a coiled-coil (for example, an isoleucine zipper domain), preferably situated at the C-terminal end of the soluble PreF antigen; modification of a residue, such as leucine to lysine, in the hydrophobic HRB domain; removal of pep27; removal of one or both furin cleavage motifs; removal of a non-furin cleavage site; and/or modification of a glycosylation site can be employed in combination with any one or more (or up to all-in any desired combination) of the other stabilizing modifications. For example, a heterologous coiled-coil (or other heterologous stabilizing domain) can be utilized alone or in combination with any of: a modification in a hydrophobic region, and/or removal of pep27, and/or removal of a furin cleavage site, and/or removal of a non-furin cleavage site, and/or removal of a non-furin cleavage site. In certain specific embodiments, the PreF antigen includes a C-terminal coiled-coil (isoleucine zipper) domain, a stabilizing substitution in the HRB hydrophobic domain, and removal of one or both furin cleavage sites. Such an antigen includes the intact fusion peptide that is not removed by furin cleavage. In one specific embodiment, the PreF antigen also includes a modified glycosylation site at amino acid position 500.

The native F protein polypeptide can be selected from any F protein of an RSV A or RSV B strain, or from variants thereof (as defined above). In certain exemplary embodiments, the F protein polypeptide is the F protein represented by SEQ ID NO:2. To facilitate understanding of this disclosure, all amino acid residue positions, regardless of strain, are

given with respect to (that is, the amino acid residue position corresponds to) the amino acid position of the exemplary F protein. Comparable amino acid positions of any other RSV A or B strain can be determined easily by those of ordinary skill in the art by aligning the amino acid sequences of the selected RSV strain with that of the exemplary sequence using readily available and well-known alignment algorithms (such as BLAST, e.g., using default parameters). Numerous additional examples of F protein polypeptides from different RSV strains are disclosed in WO2008114149. Additional variants can arise through genetic drift, or can be produced artificially using site directed or random mutagenesis, or by recombination of two or more preexisting variants. Such additional variants are also suitable in the context of the PreF antigens disclosed herein.

In selecting F2 and F1 domains of the F protein, one of skill in the art will recognize that it is not strictly necessary to include the entire F2 and/or F1 domain. Typically, conformational considerations are of importance when selecting a subsequence (or fragment) of the F2 domain. Thus, the F2 domain typically includes a portion of the F2 domain that facilitates assembly and stability of the polypeptide. In certain exemplary variants, the F2 domain includes amino acids 26-105. However, variants having minor modifications in length (by addition, or deletion of one or more amino acids) are also possible.

Typically, the F1 domain is selected and designed to maintain a stable conformation that includes immunodominant epitopes of the F protein. For example, the F1 polypeptide domain includes epitopes recognized by neutralizing antibodies in the regions of amino acids 262-275 (palivizumab neutralization) and 423-436 (Centocor's ch101F MAb). Additionally, desirable to include T cell epitopes, e.g., in the region of amino acids 328-355. Most commonly, as a single contiguous portion of the F1 subunit (e.g., spanning amino acids 262-436). Thus, an F1 domain polypeptide comprises at least about amino acids 262-436 of an RSV F protein polypeptide. In one non-limiting example provided herein, the F1 domain comprises amino acids 137 to 516 of a native F protein polypeptide.

**[0041]** Favorably, the PreF antigens include a signal peptide corresponding to the expression system, for example, a mammalian or viral signal peptide, such as an RSV F0 native signal sequence (e.g., amino acids 1-25 of SEQ ID NO:2 or amino acids 1-25 of SEQ ID NO:6). Typically, the signal peptide is selected to be compatible with the cells selected for recombinant expression. For example, a signal peptide (such as a baculovirus signal peptide, or the melittin signal peptide, can be substituted for expression, in insect cells. Suitable plant signal peptides are known in the art, if a plant expression system is preferred. Numerous exemplary signal peptides are known in the art, (see, e.g., see Zhang & Henzel, Protein Sci., 13:2819-2824 (2004), which describes numerous human signal peptides) and are catalogued, e.g., in the SPdb signal peptide database, which includes signal sequences of archaea, prokaryotes and eukaryotes (<http://proline.bic.nus.edu.sg/spdb/>). Optionally, any of the preceding antigens can include an additional sequence or tag, such as a His-tag to facilitate purification.

**[0042]** With respect to selection of sequences corresponding to naturally occurring strains, one or more of the domains can correspond in sequence to an RSV A or B strain, such as the common laboratory isolates designated A2 or Long, or any other naturally occurring strain or isolate (as disclosed in the aforementioned WO2008114149). In addition to such naturally occurring and isolated variants, engineered variants that share sequence similarity with the aforementioned sequences can also be employed in the context of PreF antigens. It will be understood by those of skill in the art, that the similarity between PreF antigen polypeptide (and polynucleotide sequences as described below), as for polypeptide (and nucleotide sequences in general), can be expressed in terms of the similarity between the sequences, otherwise referred to as sequence identity. Sequence identity is frequently measured in terms of percentage identity (or similarity); the higher the percentage, the more similar are the primary structures of the two sequences. In general, the more similar the primary structures of two amino acid (or polynucleotide) sequences, the more similar are the higher order structures resulting from folding and assembly. Variants of a PreF polypeptide (and polynucleotide) sequences typically have one or a small number of amino acid deletions, additions or substitutions but will nonetheless share a very high percentage of their amino acid, and generally their polynucleotide sequence. More importantly, the variants retain the structural and, thus, conformational attributes of the reference sequences disclosed herein.

Methods of determining sequence identity are well known in the art, and are applicable to PreF antigen polypeptides, as well as the nucleic acids that encode them (e.g., as described below). Various programs and alignment algorithms are described in: Smith and Waterman, Adv. Appl. Math. 2:482, 1981; Needleman and Wunsch, J. Mol. Biol. 48:443, 1970; Higgins and Sharp, Gene 73:237, 1988; Higgins and Sharp, CABIOS 5:151, 1989; Corpet et al., Nucleic Acids Research 16:10881, 1988; and Pearson and Lipman, Proc. Natl. Acad. Sci. USA 85:2444, 1988. Altschul et al., Nature Genet. 6:119, 1994, presents a detailed consideration of sequence alignment methods and homology calculations. The NCBI Basic Local Alignment Search Tool (BLAST) (Altschul et al., J. Mol. Biol. 215:403, 1990) is available from several sources, including the National Center for Biotechnology Information (NCBI, Bethesda, MD) and on the internet, for use in connection with the sequence analysis programs blastp, blastn, blastx, tblastn and tblastx. A description of how to determine sequence identity using this program is available on the NCBI website on the internet.

Modification of recombinant RSV F can include a deletion of one or more amino acids and/or an addition of one or more amino acids. Indeed, if desired, one or more of the polypeptide domains can be a synthetic polypeptide that does not correspond to any single strain, but includes component subsequences from multiple strains, or even from a consensus

sequence deduced by aligning multiple strains of RSV virus polypeptides. In certain embodiments, one or more of the polypeptide domains is modified by the addition of an amino acid sequence that constitutes a tag, which facilitates subsequent processing or purification. Such a tag can be an antigenic or epitope tag, an enzymatic tag or a polyhistidine tag. Typically the tag is situated at one or the other end of the protein, such as at the C-terminus or N-terminus of the antigen or fusion protein.

#### NUCLEIC ACIDS THAT ENCODE PREF ANTIGENS

[0043] Another aspect of this disclosure concerns recombinant nucleic acids that encode PreF antigens as described above. More explicitly, such nucleic acids encode polypeptides that include a soluble F protein polypeptide antigen that includes an F2 domain and an F1 domain of an RSV F protein polypeptide, which includes at least one modification selected from: (i) an addition of an amino acid sequence comprising a heterologous trimerization domain; (ii) an amino acid addition, deletion or substitution that eliminates a furin cleavage site at a position corresponding to amino acids 105-109, a position corresponding to amino acids 133-136, or at both positions corresponding to amino acids 105-109 and 133-136 of the reference F protein precursor (F<sub>0</sub>) of SEQ ID NO:2; (iii) a deletion of one or more amino acids of the pep27 domain; and (iv) at least one substitution or addition of a hydrophilic amino acid in a hydrophobic domain of the F protein extracellular domain by substitution of lysine for the leucine present at position 512 or addition of a lysine following the amino acid corresponding to residue 105 of reference SEQ ID NO:2. The polynucleotide encodes a PreF antigen with a modification in a glycosylation site. The nature and structural details of such polypeptides are disclosed in detail above. One of skill in the art will readily be able to determine nucleotide sequences that encode any and all of the described polypeptide sequences based on the teachings herein, including the exemplary sequences provided in the sequence listing, and otherwise included in this disclosure.

[0044] The recombinant nucleic acids may be codon optimized for expression in a selected prokaryotic or eukaryotic host cell. For example, SEQ ID NOs: 5, 12, 17, 19 and 21 are different illustrative, non-limiting, examples of sequences that encode a PreF antigen, which have been codon optimized for expression in mammalian, e.g., CHO, cells. To facilitate replication and expression, the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector. Host cells including recombinant PreF antigen-encoding nucleic acids are also a feature of this disclosure. Favorable host cells include prokaryotic (i.e., bacterial) host cells, such as *E. coli*, as well as numerous eukaryotic host cells, including fungal (e.g., yeast) cells, insect cells, and mammalian cells (such as CHO, VERO and HEK293 cells).

[0045] To facilitate replication and expression, the nucleic acids can be incorporated into a vector, such as a prokaryotic or a eukaryotic expression vector. Although the nucleic acids disclosed herein can be included in any one of a variety of vectors (including, for example, bacterial plasmids; phage DNA; baculovirus; yeast plasmids; vectors derived from combinations of plasmids and phage DNA, viral DNA such as vaccinia, adenovirus, fowl pox virus, pseudorabies, adenovirus, adeno-associated virus, retroviruses and many others), most commonly the vector will be an expression vector suitable for generating polypeptide expression products. In an expression vector, the nucleic acid encoding the PreF antigen is typically arranged in proximity and orientation to an appropriate transcription control sequence (promoter, and optionally, one or more enhancers) to direct mRNA synthesis. That is, the polynucleotide sequence of interest is operably linked to an appropriate transcription control sequence. Examples of such promoters include: the immediate early promoter of CMV, LTR or SV40 promoter, polyhedrin promoter of baculovirus, *E. coli* lac or trp promoter, phage T7 and lambda P<sub>L</sub> promoter, and other promoters known to control expression of genes in prokaryotic or eukaryotic cells or their viruses. The expression vector typically also contains a ribosome binding site for translation initiation, and a transcription terminator. The vector optionally includes appropriate sequences for amplifying expression. In addition, the expression vectors optionally comprise one or more selectable marker genes to provide a phenotypic trait for selection of transformed host cells, such as dihydrofolate reductase or neomycin resistance for eukaryotic cell culture, or such as kanamycin, tetracycline or ampicillin resistance in *E. coli*.

[0046] The expression vector can also include additional expression elements, for example, to improve the efficiency of translation. These signals can include, e.g., an ATG initiation codon and adjacent sequences. In some cases, for example, a translation initiation codon and associated sequence elements are inserted into the appropriate expression vector simultaneously with the polynucleotide sequence of interest (e.g., a native start codon). In such cases, additional translational control signals are not required. However, in cases where only a polypeptide-coding sequence, or a portion thereof, is inserted, exogenous translational control signals, including an ATG initiation codon is provided for translation of the nucleic acid encoding PreF antigen. The initiation codon is placed in the correct reading frame to ensure translation of the polynucleotide sequence of interest. Exogenous transcriptional elements and initiation codons can be of various origins, both natural and synthetic. If desired, the efficiency of expression can be further increased by the inclusion of enhancers appropriate to the cell system in use (Scharf et al. (1994) *Results Probl Cell Differ* 20:125-62; Bitter et al. (1987) *Methods in Enzymol* 153:516-544).

In some instances, the nucleic acid (such as a vector) that encodes the PreF antigen includes one or more additional

sequence elements selected to increase and/or optimize expression of the PreF encoding nucleic acid when introduced into a host cell. For example, in certain embodiments, the nucleic acids that encode the PreF antigen include an intron sequence, such as a Human Herpesvirus 5 intron sequence (see, e.g., SEQ ID NO:13). Introns have been repeatedly demonstrated to enhance expression of homologous and heterologous nucleic acids when appropriately positioned in a recombinant construct. Another class of expression-enhancing sequences includes an epigenetic element such as a Matrix Attachment Region (or MAR), or a similar epigenetic element, e.g., STAR elements (for example, such as those STAR elements disclosed in Otte et al., *Biotechnol. Prog.* 23:801-807, 2007). Without being bound by theory, MARs are believed to mediate the anchorage of a target DNA sequence to the nuclear matrix, generating chromatin loop domains that extend outwards from the heterochromatin cores. While MARs do not contain any obvious consensus or recognizable sequence, their most consistent feature appears to be an overall high A/T content, and C bases predominating on one strand. These regions appear to form bent secondary structures that may be prone to strand separation, and may include a core-unwinding element (CUE) that can serve as the nucleation point for strand separation. Several simple AT-rich sequence motifs have been associated with MAR sequences: e.g., the A-box, the T-box, DNA unwinding motifs, SATB1 binding sites (H-box, A/T/C25) and consensus Topoisomerase II sites for vertebrates or *Drosophila*. Exemplary MAR sequences are described in published US patent application no. 20070178469, and in international patent application no. WO02/074969. Additional MAR sequences that can be used to enhance expression of a nucleic acid encoding a PreF antigen include chicken lysozyme MAR, MARp1-42, MARp1-6, MARp1-68, and MARpx-29, described in Girod et al., *Nature Methods*, 4:747-753, 2007 (disclosed in GenBank Accession Nos. EA423306, DI107030, DI106196, DI107561, and DI106512, respectively). One of skill will appreciate that expression can further be modulated by selecting a MAR that produces an intermediate level of enhancement, as is reported for MAR 1-9. If desired, alternative MAR sequences for increasing expression of a PreF antigen can be identified by searching sequence databases, for example, using software such as MAR-Finder (available on the web at [futuresoft.org/MarFinder](http://futuresoft.org/MarFinder)), SMARTTest (available on the web at [genomatix.de](http://genomatix.de)), or SMARScan I (Levitsky et al., *Bioinformatics* 15:582-592, 1999). In certain embodiments, the MAR is introduced (e.g., transfected) into the host cell on the same nucleic acid (e.g., vector) as the PreF antigen-encoding sequence. In an alternative embodiment, the MAR is introduced on a separate nucleic acid (e.g., in trans) and it can optionally cointegrate with the PreF antigen-encoding polynucleotide sequence.

**[0047]** Exemplary procedures sufficient to guide one of ordinary skill in the art through the production of recombinant PreF antigen nucleic acids can be found in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, 2d ed., Cold Spring Harbor Laboratory Press, 1989; Sambrook et al., *Molecular Cloning: Laboratory Manual*, 3d ed., Cold Spring Harbor Press, 2001; Ausubel et al., *Current Protocols in Molecular Biology*, Greene Publishing Associates, 1992 (and Supplements to 2003); and Ausubel et al., *Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology*, 4th ed., Wiley & Sons, 1999.

**[0048]** Exemplary nucleic acids that encode PreF antigen polypeptides are represented by SEQ ID NOs: 17 and 21. Modification in a glycosylation site, at the amino acid corresponding to position 500 of SEQ ID NO:2 can be produced by altering (e.g., mutating) the nucleotides in the vicinity of positions 1408-1414 (as compared, for example, to the polynucleotide sequence of SEQ ID NO: 12, e.g., SEQ ID NOs: 17 and 21). Suitable sequences of nucleotides to encode glycosylation variants (e.g., that increase glycosylation efficiency) include: aacgggt, aacaagt, aacggga, and aacaaga. Alternative sequences, such as cagcagt, which eliminate a glycosylation site are also possible. Additional variants of can be produced by assembling analogous F protein polypeptide sequences selected from any of the known (or subsequently) discovered strains of RSV, e.g., as disclosed in WO2008114149. Additional sequence variants that share sequence identity with the exemplary variants can be produced by those of skill in the art. It will be immediately understood by those of skill in the art, that the polynucleotide sequences encoding the PreF polypeptides, can themselves share less sequence identity due to the redundancy of the genetic code.

**[0049]** In addition to the variant nucleic acids previously described, nucleic acids that hybridize to one or more of the nucleic acids represented by SEQ ID NOs: 1, 3, 5, 7, 9, 12, 13, 17, 19 and/or 21 can also be used to encode PreF antigens. One of skill in the art will appreciate that in addition to the % sequence identity measure discussed above, another indicia of sequence similarity between two nucleic acids is the ability to hybridize. The more similar are the sequences of the two nucleic acids, the more stringent the conditions at which they will hybridize. The stringency of hybridization conditions are sequence-dependent and are different under different environmental parameters. Thus, hybridization conditions resulting in particular degrees of stringency will vary depending upon the nature of the hybridization method of choice and the composition and length of the hybridizing nucleic acid sequences. Generally, the temperature of hybridization and the ionic strength (especially the  $\text{Na}^+$  and/or  $\text{Mg}^{++}$  concentration) of the hybridization buffer will determine the stringency of hybridization, though wash times also influence stringency. Generally, stringent conditions are selected to be about 5°C to 20°C lower than the thermal melting point ( $T_m$ ) for the specific sequence at a defined ionic strength and pH. The  $T_m$  is the temperature (under defined ionic strength and pH) at which 50% of the target sequence hybridizes to a perfectly matched probe. Conditions for nucleic acid hybridization and calculation of stringencies can be found, for example, in Sambrook et al., *Molecular Cloning: A Laboratory Manual*, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 2001; Tijssen, *Hybridization With Nucleic Acid Probes, Part I: Theory and*

Nucleic Acid Preparation, Laboratory Techniques in Biochemistry and Molecular Biology, Elsevier Science Ltd., NY, NY, 1993. and Ausubel et al. Short Protocols in Molecular Biology, 4th ed., John Wiley & Sons, Inc., 1999.

**[0050]** For purposes of the present disclosure, "stringent conditions" encompass conditions under which hybridization will only occur if there is less than 25% mismatch between the hybridization molecule and the target sequence. "Stringent conditions" can be broken down into particular levels of stringency for more precise definition. Thus, as used herein, "moderate stringency" conditions are those under which molecules with more than 25% sequence mismatch will not hybridize; conditions of "medium stringency" are those under which molecules with more than 15% mismatch will not hybridize, and conditions of "high stringency" are those under which sequences with more than 10% mismatch will not hybridize. Conditions of "very high stringency" are those under which sequences with more than 6% mismatch will not hybridize. In contrast, nucleic acids that hybridize under "low stringency conditions include those with much less sequence identity, or with sequence identity over only short subsequences of the nucleic acid. It will, therefore, be understood that the various variants of nucleic acids that are encompassed by this disclosure are able to hybridize to at least one of SEQ ID NOs: 1, 3, 5, 7, 9, 12, 13, 17, 19 and/or 21 over substantially their entire length.

15 **METHODS OF PRODUCING RSV ANTIGENIC POLYPEPTIDES**

**[0051]** The PreF antigens disclosed herein are produced using well established procedures for the expression and purification of recombinant proteins. Procedures sufficient to guide one of skill in the art can be found in the following references: Sambrook et al., Molecular Cloning: A Laboratory Manual, Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, 200; and Ausubel et al. Short Protocols in Molecular Biology, 4th ed., John Wiley & Sons, Inc., 999. Additional and specific details are provided hereinbelow.

**[0052]** Recombinant nucleic acids that encode the PreF antigens are introduced into host cells by any of a variety of well-known procedures, such as electroporation, liposome mediated transfection (e.g., using a commercially available liposomal transfection reagent, such as LIPOFECTAMINE™2000 or TRANSFECTIN™), Calcium phosphate precipitation, infection, transfection and the like, depending on the selection of vectors and host cells. Nucleic acids that encode PreF antigens are disclosed in SEQ ID NOs:5, 7, 9, 12, 13, 17, 19 and 21. One of skill in the art will appreciate that SEQ ID NOs:5, 7, 9, 12, 13, 17, 19 and 21 are illustrative and not intended to be limiting. For example, polynucleotide sequences that encode the same proteins as SEQ ID NOs:5, 7 and 9, (e.g., represented by SEQ ID NOs: 6, 8 and 10), but that differ only by the redundancy of the genetic code (such as by alternative codon optimization, as shown in SEQ ID NO:12), can easily be used instead of the exemplary sequences of SEQ ID NOs:5, 7, and 9. The same is true of SEQ ID NOs:17, 19 and 21. Similarly, polynucleotide sequences that include expression-enhancing elements, such as internally positioned introns (or by the addition of promoter, enhancer, intron or other similar elements), as illustrated in SEQ ID NO:13, can be employed. One of ordinary skill in the art will recognize that combinations of such modifications are likewise suitable. Similarly, homologous sequences selected from any RSV A or RSV B strain, and/or other sequences that share substantial sequence identity, as discussed above, can also be used to express PreF antigens. Indeed, any of the variant nucleic acids previously disclosed can suitably be introduced into host cells and used to produce PreF antigens (including PreF-G antigens) and where applicable G polypeptides.

**[0053]** Nucleic acids encoding the recombinant antigen of the present invention are modified to alter the glycosylation pattern as described above by substitution of one or more amino acids in the vicinity of amino acid position 500 (with respect to SEQ ID NO:2, e.g., SEQ ID NO:17). It has been found that modifying the glycosylation pattern, e.g., in combination with modifying a cleavage recognition site, increases production of the PreF antigen in cell culture. In such cases, the methods described hereinbelow for expressing and isolating recombinant PreF antigens disclose a process for increasing the production of a PreF antigen by altering the glycosylation pattern of a PreF antigen by substituting one or more amino acids of a glycosylation recognition site, optionally in combination with modifying one or more cleavage sites (such as a non-furin or furin cleavage recognition site) as described above.

**[0054]** Host cells that include recombinant PreF antigen-encoding nucleic acids are, thus, also a feature of this disclosure. Favorable host cells include prokaryotic (*i.e.*, bacterial) host cells, such as *E. coli*, as well as numerous eukaryotic host cells, including fungal (e.g., yeast, such as *Saccharomyces cerevisiae* and *Pichia pastoris*) cells, insect cells, plant cells, and mammalian cells (such as CHO and HEK293 cells). Recombinant PreF antigen nucleic acids are introduced (e.g., transduced, transformed or transfected) into host cells, for example, via a vector, such as an expression vector. As described above, the vector is most typically a plasmid, but such vectors can also be, for example, a viral particle, a phage, etc. Examples of appropriate expression hosts include: bacterial cells, such as *E. coli*, *Streptomyces*, and *Salmonella typhimurium*; fungal cells, such as *Saccharomyces cerevisiae*, *Pichia pastoris*, and *Neurospora crassa*; insect cells such as *Drosophila* and *Spodoptera frugiperda*; mammalian cells such as 3T3, COS, CHO, BHK, HEK 293 or Bowes melanoma; plant cells, including algae cells, etc. In some instances, transiently transfected cells can be used to produce recombinant PreF antigens. In certain embodiments, cells (e.g., clones) that have stably integrated the PreF nucleic acid are selected and used to produce the recombinant PreF antigen.

**[0055]** The host cells can be cultured in conventional nutrient media modified as appropriate for activating promoters,

selecting transformants, or amplifying the inserted polynucleotide sequences. The culture conditions, such as temperature, pH and the like, are typically those previously used with the host cell selected for expression, and will be apparent to those skilled in the art and in the references cited herein, including, e.g., Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein. Optionally, the host cells are cultured in serum-free and/or animal product-free medium.

**[0056]** Expression products corresponding to the nucleic acids of the disclosure can also be produced in non-animal cells such as plants, yeast, fungi, bacteria and the like. In addition to Sambrook, Berger and Ausubel, details regarding cell culture can be found in Payne et al. (1992) *Plant Cell and Tissue Culture in Liquid Systems* John Wiley & Sons, Inc. New York, NY; Gamborg and Phillips (eds) (1995) *Plant Cell, Tissue and Organ Culture; Fundamental Methods* Springer 10 Lab Manual, Springer-Verlag (Berlin Heidelberg New York) and Atlas and Parks (eds) *The Handbook of Microbiological Media* (1993) CRC Press, Boca Raton, FL.

**[0057]** In bacterial systems, a number of expression vectors can be selected depending upon the use intended for the expressed product. For example, when large quantities of a polypeptide or fragments thereof are needed for the production of antibodies, vectors which direct high level expression of fusion proteins that are readily purified are favorably employed. 15 Such vectors include, but are not limited to, multifunctional *E. coli* cloning and expression vectors such as BLUESCRIPT (Stratagene), in which the coding sequence of interest, e.g., a polynucleotide of the invention as described above, can be ligated into the vector in-frame with sequences for the amino-terminal translation initiating Methionine and the subsequent 7 residues of beta-galactosidase producing a catalytically active beta galactosidase fusion protein; pIN vectors (Van Heeke & Schuster (1989) *J Biol Chem* 264:5503-5509). In certain examples, the nucleic acids are introduced into 20 cells via vectors suitable for introduction and expression in prokaryotic cells, e.g., *E. coli* cells. For example, a nucleic acid including a polynucleotide sequence that encodes a PreF antigen can be introduced into any of a variety of commercially available or proprietary vectors, such as the pET series of expression vectors (e.g., pET9b and pET2d). Expression of the coding sequence is inducible by IPTG, resulting in high levels of protein expression. The polynucleotide sequence encoding the PreF antigen is transcribed under the phage T7 promoter. Alternate vectors, such as pURV22 25 that include a heat-inducible lambda pL promoter are also suitable.

**[0058]** The expression vector is then introduced (e.g., by electroporation) into a suitable bacterial host. Numerous suitable strains of *E. coli* are available and can be selected by one of skill in the art (for example, the Rosetta and BL21 (DE3) strains have proven favorable for expression of recombinant vectors containing polynucleotide sequences that encode PreF antigens.

**[0059]** Similarly, in yeast, such as *Saccharomyces cerevisiae*, a number of vectors containing constitutive or inducible promoters such as alpha factor, alcohol oxidase and PGH can be used for production of the desired expression products. For reviews, see Berger, Ausubel, and, e.g., Grant et al. (1987; *Methods in Enzymology* 153:516-544). In mammalian host cells, a number of expression systems, including both plasmid and viral-based systems, can be utilized.

**[0060]** In another example, the polynucleotide sequence that encodes the PreF antigen is introduced into insect cells 35 using a Baculovirus Expression Vector System (BEVS). Recombinant baculovirus capable of infecting insect cells can be generated using commercially available vectors, kits and/or systems, such as the BD BaculoGold system from BD BioScience. Briefly, the polynucleotide sequence encoding the antigen is inserted into the pAcSG2 transfer vector. Then, host cells SF9 (*Spodoptera frugiperda*) are co-transfected by pAcSG2-chimeric plasmid and BD BaculoGold, containing the linearized genomic DNA of the baculovirus *Autographa californica nuclear polyhedrosis virus* (AcNPV). Following 40 transfection, homologous recombination occurs between the pACSG2 plasmid and the Baculovirus genome to generate the recombinant virus. In one example, the PreF antigen is expressed under the regulatory control of the polyhedrin promoter (pH). Similar transfer vectors can be produced using other promoters, such as the basic (Ba) and p10 promoters. Similarly, alternative insect cells can be employed, such as SF21 which is closely related to the Sf9, and the High Five cell line derived from a cabbage looper, *Trichoplusia ni*.

**[0061]** More typically, the polynucleotides that encode the PreF antigens are incorporated into expression vectors that are suitable for introduction and expression in eukaryotic (e.g., insect or mammalian cells). Favorably, such nucleic acids are codon optimized for expression in the selected vector/host cell (for example, the sequences illustrated in SEQ ID NOs:5, 7, 9, 12, 13, 17, 19 and 21 are codon optimized for expression in CHO cells). In one exemplary embodiment, the polynucleotide sequence that encodes the PreF antigen is introduced into a vector, such as the pEE14 vector 50 developed by Lonza Biologicals. The polypeptide is expressed under a constitutive promoter, such as the immediate early CMV (CytoMegalovirus) promoter. Selection of the stably transfected cells expressing the polypeptide is made based on the ability of the transfected cells to grow in the absence of a glutamine source. Cells that have successfully integrated the pEE14 are able to grow in the absence of exogenous glutamine, because the pEE14 vector expresses the GS (Glutamine Synthetase) enzyme. Selected cells can be clonally expanded and characterized for expression of the desired PreF polypeptide.

**[0062]** A host cell is optionally chosen for its ability to modulate the expression of the inserted sequences or to process the expressed protein in the desired fashion. Such modifications of the protein include, but are not limited to, glycosylation, (as well as, e.g., acetylation, carboxylation, phosphorylation, lipidation and acylation). Post-translational processing for

example, which cleaves a precursor form into a mature form of the protein (for example, by a furin protease) is optionally performed in the context of the host cell. Different host cells such as 3T3, COS, CHO, HeLa, BHK, MDCK, 293, WI38, etc. have specific cellular machinery and characteristic mechanisms for such post-translational activities and can be chosen to ensure the correct modification and processing of the introduced, foreign protein.

5 [0063] For long-term, high-yield production of recombinant PreF antigens disclosed herein, stable expression systems are typically used. For example, cell lines which stably express a PreF antigen polypeptide are introduced into the host cell using expression vectors which contain viral origins of replication or endogenous expression elements and a selectable marker gene. Following the introduction of the vector, cells are allowed to grow for 1-2 days in an enriched media before they are switched to selective media. The purpose of the selectable marker is to confer resistance to selection, and its presence allows growth and recovery of cells which successfully express the introduced sequences. For example, resistant groups or colonies of stably transformed cells can be proliferated using tissue culture techniques appropriate to the cell type. Host cells transformed with a nucleic acid encoding a PreF antigen are optionally cultured under conditions suitable for the expression and recovery of the encoded protein from cell culture. As indicated above, if desired, the host cells can be cultured in serum-free (and/or animal product-free) medium.

10 [0064] Following transduction of a suitable host cell line and growth of the host cells to an appropriate cell density, the selected promoter is induced by appropriate means (e.g., temperature shift or chemical induction) and cells are cultured for an additional period. Optionally, the medium includes components and/or additives that decrease degradation of expressed proteins by proteinases. For example, the medium used for culturing cells to produce PreF antigen can include a protease inhibitor, such as a chelating agent or small molecule inhibitor (e.g., AZ11557272, AS 111793, etc.), to reduce or eliminate undesired cleavage by cellular, or extracellular (e.g., matrix) proteinases.

15 [0065] The secreted polypeptide product is then recovered from the culture medium. Alternatively, cells can be harvested by centrifugation, disrupted by physical or chemical means, and the resulting crude extract retained for further purification. Eukaryotic or microbial cells employed in expression of proteins can be disrupted by any convenient method, including freeze-thaw cycling, sonication, mechanical disruption, or use of cell lysing agents, or other methods, which are well known to those skilled in the art.

20 [0066] Expressed PreF antigens can be recovered and purified from recombinant cell cultures by any of a number of methods well known in the art, including ammonium sulfate or ethanol precipitation, acid extraction, filtration, ultrafiltration, centrifugation, anion or cation exchange chromatography, phosphocellulose chromatography, hydrophobic interaction chromatography, affinity chromatography (e.g., using any of the tagging systems noted herein), hydroxylapatite chromatography, and lectin chromatography. Protein refolding steps can be used, as desired, in completing configuration of the mature protein. Finally, high performance liquid chromatography (HPLC) can be employed in the final purification steps. In addition to the references noted above, a variety of purification methods are well known in the art, including, e.g., those set forth in Sandana (1997) Bioseparation of Proteins, Academic Press, Inc.; and Bollag et al. (1996) Protein Methods, 2nd Edition Wiley-Liss, NY; Walker (1996) The Protein Protocols Handbook Humana Press, NJ, Harris and Angal (1990) Protein Purification Applications: A Practical Approach IRL Press at Oxford, Oxford, U.K.; Scopes (1993) Protein Purification: Principles and Practice 3rd Edition Springer Verlag, NY; Janson and Ryden (1998) Protein Purification: Principles High Resolution Methods and Applications, Second Edition Wiley-VCH, NY; and Walker (1998) Protein Protocols on CD-ROM Humana Press, NJ.

25 [0067] In one exemplary embodiment, the PreF proteins are recovered from cells according to the following purification scheme. Following introduction of a recombinant nucleic acid encoding the PreF polypeptide into host CHO cells, transiently transfected host cells or expanded stable populations comprising the introduced polynucleotide sequence are grown in medium and under conditions suitable for growth at an acceptable scale for the desired purpose (e.g., as generally described in Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein). Typically, the cells are grown in serum-free medium at 37°C and passaged at 2-3 day intervals in shake flasks or in bioreactors. New cultures established from cells expanded in these conditions, are typically carried out in bioreactors in serum-free medium and incubated at 27 °C with pO2 maintained at 20% for 5 to 7 days in order to produce the preF antigen.

30 [0068] To recover recombinant PreF antigen, the cell culture is centrifuged and the cell culture supernatant stored at minus 70°C until further use. Following thawing of culture supernatants, the supernatants are diluted 2 x with MilliQ water and adjusted to pH 6.0 with HCl. Diluted supernatant is loaded at 75 cm/h onto a 3 L CM Ceramic HyperD FF resin packed in BPG 140/500 column, equilibrated in 20 mM phosphate pH 6.0. After loading of the sample, equilibration buffer is processed through the column to get back to UV baseline. After washing with 5 column volumes (CV) of 25 mM phosphate pH 7.0 buffer, elution is performed using a 50 mM Phosphate pH 7.0 buffer containing 0.1 M NaCl.

35 [0069] The CM Hyper D eluate is diluted 3.3 x with 20 mM phosphate, pH 7.0 to be processed onto a 270 ml Hydroxylapatite Type II column (packed in XK 50), equilibrated with 20 mM PO4 (Na) buffer pH 7.0, at 50 mL/min. After washing the column with the equilibration buffer (~3 CV), elution is performed using a 20 mM PO4 (Na) pH 7.0 buffer containing 0.5 M NaCl.

40 [0070] The HA eluate is processed at 15 mL/min (to respect a 10 minutes contact time with the resin), onto a 150 mL

Campo Adhere column (packed in XK 26), equilibrated in 20 mM phosphate pH 7.0. After washing with 5 CV of 10 mM phosphate pH 7.0 containing 0.1 M arginine buffer, elution is performed using a 10 mM Phosphate pH 7.0 buffer containing 0.6 M arginine.

**[0071]** The Campo Adhere eluate is then concentrated approximately 10 x for processing onto a preparative size exclusion chromatography (SEC) column. Concentration is performed using a 50 kD Pellicon polyethersulfone membrane. Before being processed onto the SEC column, the material is filtered through a PLANANOVA 20N 100 cm<sup>2</sup> filter, used as a viral clearance step. This nanofiltration step can be either placed after or before concentration on Pellicon membrane.

**[0072]** Preparative SEC is then performed using a 500 mL Superdex S200 column and 10 mM phosphate (Na/K<sub>2</sub>), 160 mM NaCl, pH 6.5 buffer (corresponding to final buffer) as mobile phase. A volume of concentrated PreF corresponding to 5% of SEC column volume is loaded onto the resin at ~2.6 mL/min. Typically, fractions of 10 mL are collected. Analytical pools of fractions can be analyzed on SDS gel by silver staining and western blot anti HCP (Host cell proteins) if desired to optimize yields while minimizing HCP levels.

**[0073]** Purified bulk is obtained after filtration on 0.22 µm Millex filters (alternatively a Sterivex filter can be used). If desired the purified PreF antigen preparation can be stored at minus 70°C prior to use.

**[0074]** Alternatively, PreF proteins can include a polyhistidine (e.g., six histidine) tag, which can be used to facilitate purification. For such histidine tagged PreF polypeptides, the following purification protocol can be employed. Prior to purification using immobilized metal ion affinity chromatography (IMAC), the cell culture supernatant is diluted twofold in buffer A (20 mM Bicine, pH 8.5) and pH is adjusted to 8.5. The resulting solution is loaded on a Q sepharose FF column (GE Healthcare), e.g., of 23 ml of column volume, previously equilibrated with Buffer A. PreF proteins are captured on the column, along with some host cell contaminants. The culture media components that would interfere with the IMAC purification step are not retained and are eliminated in the flow through. The proteins are separated and eluted by a stepwise elution of 200 mM, 400 mM, 600 mM, 800 mM and 1 M NaCl. PreF proteins of interest are eluted during the first step at 200 mM NaCl. Optionally, recovery can be monitored using SDS PAGE and western blotting using an anti His-tag antibody to detect the tagged PreF protein. Fractions can be pooled prior to continuing the purification.

**[0075]** The (pooled) PreF protein containing eluate is diluted threefold in buffer B (20 mM Bicine, 500 mM NaCl, pH 8.3) and pH is adjusted to 8.3. The resulting solution is loaded on IMAC sepharose FF resin loaded with Nickel chloride (GE Healthcare) (e.g., of 5 ml of column volume), previously equilibrated with buffer B. PreF are bound to the resin and the majority of host cell contaminants are eluted in the flow through. The column is washed with 20 mM Imidazole in order to remove weakly bound contaminants. PreF proteins are eluted by a step elution of 250 mM Imidazole. SDS PAGE stained with coomassie blue and western blot anti His-tag can be performed to identify positive fractions.

**[0076]** The pool from IMAC can then be concentrated to a concentration of at least 150 µg/ml using a centricon concentration device (Millipore) and the protein can be dialysed in PBS buffer supplemented with 500 mM L-Arginine. Resulting protein is quantified using RCDC protein assay (BioRad) and stored at -70 or -80°C until use.

### IMMUNOGENIC COMPOSITIONS AND METHODS

**[0077]** Also provided are immunogenic compositions including any of the PreF antigens disclosed above (such as those exemplified by SEQ ID NOS: 18 and 22) and a pharmaceutically acceptable carrier or excipient.

**[0078]** According to the disclosure the immunogenic composition can include an isolated, recombinant and/or purified G protein. Numerous suitable G proteins have been described in the art, and include full length recombinant G proteins and chimeric proteins made up of a portion of the G protein (such as amino acids 128-229 or 130-230) and a fusion partner (such as thioredoxin), or a signal and/or leader sequence, that facilitates expression and/or purification. Exemplary G proteins for use in admixture with a PreF antigen can be found in WO2008114149, US Patent No. 5,149,650, US Patent No. 6,113,911, US Published Application No. 20080300382, and US Patent No. 7,368,537. As indicated with respect to the chimeric PreF-G proteins, a smaller fragment of the G protein, such as the portion between amino acids 149-229, or the portion between approximately 128 to approximately 229 can favorably be employed in the context of mixtures involving a PreF (without G) and G. As discussed above, the important consideration is the presence of immunodominant epitopes, e.g., included within the region of amino acids 183-197. Alternatively, a full-length G protein can be employed in such compositions.

**[0079]** Pharmaceutically acceptable carriers and excipients are well known and can be selected by those of skill in the art. For example, the carrier or excipient can favorably include a buffer. Optionally, the carrier or excipient also contains at least one component that stabilizes solubility and/or stability. Examples of solubilizing/stabilizing agents include detergents, for example, lauroyl sarcosine and/or tween. Alternative solubilizing/stabilizing agents include arginine, and glass forming polyols (such as sucrose, trehalose and the like). Numerous pharmaceutically acceptable carriers and/or pharmaceutically acceptable excipients are known in the art and are described, e.g., in Remington's Pharmaceutical Sciences, by E. W. Martin, Mack Publishing Co., Easton, PA, 5th Edition (975). Accordingly, suitable excipients and carriers can be selected by those of skill in the art to produce a formulation suitable for delivery to a subject by a

selected route of administration.

**[0080]** Suitable excipients include, without limitation: glycerol, Polyethylene glycol (PEG), Sorbitol, Trehalose, N-lauroylsarcosine sodium salt, L -proline, Non detergent sulfobetaine, Guanidine hydrochloride, Urea, Trimethylamine oxide, KCl, Ca<sup>2+</sup>, Mg<sup>2+</sup>, Mn<sup>2+</sup>, Zn<sup>2+</sup> and other divalent cation related salts, Dithiothreitol, Dithioerytrol, and  $\beta$ -mercaptoethanol.

5 Other excipients can be detergents (including: Tween80, Tween20, Triton X-00, NP-40, Empigen BB, Octylglucoside, Lauroyl maltoside, Zwittergent 3-08, Zwittergent 3-0, Zwittergent 3-2, Zwittergent 3-4, Zwittergent 3-6, CHAPS, Sodium deoxycholate, Sodium dodecyl sulphate, Cetyltrimethylammonium bromide).

10 **[0081]** Optionally, the immunogenic compositions also include an adjuvant. In the context of an immunogenic composition suitable for administration to a subject for the purpose of eliciting a protective immune response against RSV, the adjuvant is selected to elicit a Th1 biased or Th1/Th2 balanced immune response, characterized by the production of interferon-gamma (IFN- $\gamma$ ).

15 **[0082]** The adjuvant is typically selected to enhance a Th1 biased immune response (or a Th1/Th2 balanced immune response), characterized by the production and secretion of IFN- $\gamma$ , in the subject, or population of subjects, to whom the composition is administered. For example, when the immunogenic composition is to be administered to a subject of a particular age group susceptible to (or at increased risk of) RSV infection, the adjuvant is selected to be safe and effective in the subject or population of subjects. Thus, when formulating an immunogenic composition containing an RSV PreF antigen for administration in an elderly subject (such as a subject greater than 65 years of age), the adjuvant is selected to be safe and effective in elderly subjects. Similarly, when the immunogenic composition containing the RSV PreF antigen is intended for administration in neonatal or infant subjects (such as subjects between birth and the age of two years), the adjuvant is selected to be safe and effective in neonates and infants. In the case of an adjuvant selected for safety and efficacy in neonates and infants, an adjuvant dose can be selected that is a dilution (e.g., a fractional dose) of a dose typically administered to an adult subject.

20 **[0083]** Additionally, the adjuvant is typically selected to enhance a Th1 immune response when administered via a route of administration, by which the immunogenic composition is administered. For example, when formulating an immunogenic composition containing a PreF antigen for nasal administration, proteosome and protollin are favorable Th1-biasing adjuvants. In contrast, when the immunogenic composition is formulated for intramuscular administration, adjuvants including one or more of 3D-MPL, squalene (e.g., QS21), liposomes, and/or oil and water emulsions are favorably selected.

25 **[0084]** One suitable adjuvant for use in combination with PreF antigens is a non-toxic bacterial lipopolysaccharide derivative. An example of a suitable non-toxic derivative of lipid A, is monophosphoryl lipid A or more particularly 3-Deacylated monophosphoryl lipid A (3D-MPL). 3D-MPL is sold under the name MPL by GlaxoSmithKline Biologicals N.A., and is referred throughout the document as MPL or 3D-MPL. See, for example, US Patent Nos. 4,436,727; 4,877,611; 4,866,034 and 4,912,094. 3D-MPL primarily promotes CD4+ T cell responses with an IFN- $\gamma$  (Th1) phenotype. 3D-MPL can be produced according to the methods disclosed in GB2220211 A. Chemically it is a mixture of 3-deacylated monophosphoryl lipid A with 3, 4, 5 or 6 acylated chains. In the compositions of the present invention small particle 3D-MPL can be used. Small particle 3D-MPL has a particle size such that it can be sterile-filtered through a 0.22 $\mu$ m filter. Such preparations are described in WO94/21292.

30 **[0085]** A lipopolysaccharide, such as 3D-MPL, can be used at amounts between 1 and 50 $\mu$ g, per human dose of the immunogenic composition. Such 3D-MPL can be used at a level of about 25 $\mu$ g, for example between 20-30 $\mu$ g, suitably between 21-29 $\mu$ g or between 22 and 28 $\mu$ g or between 23 and 27 $\mu$ g or between 24 and 26 $\mu$ g, or 25 $\mu$ g. In another embodiment, the human dose of the immunogenic composition comprises 3D-MPL at a level of about 10 $\mu$ g, for example between 5 and 15 $\mu$ g, suitably between 6 and 14 $\mu$ g, for example between 7 and 13 $\mu$ g or between 8 and 12 $\mu$ g or between 9 and 11 $\mu$ g, or 10 $\mu$ g. In a further embodiment, the human dose of the immunogenic composition comprises 3D-MPL at a level of about 5 $\mu$ g, for example between 1 and 9 $\mu$ g, or between 2 and 8 $\mu$ g or suitably between 3 and 7 $\mu$ g or 4 and 5 $\mu$ g, or 5 $\mu$ g.

35 **[0086]** In other embodiments, the lipopolysaccharide can be a  $\beta$ (1-6) glucosamine disaccharide, as described in US Patent No. 6,005,099 and EP Patent No. 0 729 473 B1. One of skill in the art would be readily able to produce various lipopolysaccharides, such as 3D-MPL, based on the teachings of these references. In addition to the aforementioned immunostimulants (that are similar in structure to that of LPS or MPL or 3D-MPL), acylated monosaccharide and disaccharide derivatives that are a sub-portion to the above structure of MPL are also suitable adjuvants. In other embodiments, the adjuvant is a synthetic derivative of lipid A, some of which are described as TLR-4 agonists, and include, but are not limited to: OM174 (2-deoxy-6-o-[2-deoxy-2-[(R)-3-dodecanoyloxytetra-decanoylamino]-4-o-phosphono- $\beta$ -D-glucopyranosyl]-2-[(R)-3-hydroxytetradecanoylamino]- $\alpha$ -D-glucopyranosyldihydrogenphosphate), (WO 95/14026); OM 294 DP (3S, 9 R) -3-[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9(R)-[(R)-3-hydroxytetradecanoylamino]decan-1,10-diol,1,10-bis(dihydrogenophosphate) (WO 99/64301 and WO 00/0462); and OM 197 MP-Ac DP (3S-; 9R) -3-[(R)-dodecanoyloxytetradecanoylamino]-4-oxo-5-aza-9-[(R)-3-hydroxytetradecanoylamino]decan-1,10-diol,1-dihydrogenophosphate 10-(6-aminohexanoate) (WO 01/46127).

40 **[0087]** Other TLR4 ligands which can be used are alkyl Glucosaminide phosphates (AGPs) such as those disclosed

in WO 98/50399 or US Patent No. 6,303,347 (processes for preparation of AGPs are also disclosed), suitably RC527 or RC529 or pharmaceutically acceptable salts of AGPs as disclosed in US Patent No. 6,764,840. Some AGPs are TLR4 agonists, and some are TLR4 antagonists. Both are thought to be useful as adjuvants.

**[0088]** Other suitable TLR-4 ligands, capable of causing a signaling response through TLR-4 (Sabroe et al, JI 2003 p1630-5) are, for example, lipopolysaccharide from gram-negative bacteria and its derivatives, or fragments thereof, in particular a non-toxic derivative of LPS (such as 3D-MPL). Other suitable TLR agonists are: heat shock protein (HSP) 10, 60, 65, 70, 75 or 90; surfactant Protein A, hyaluronan oligosaccharides, heparan sulphate fragments, fibronectin fragments, fibrinogen peptides and b-defensin-2, and muramyl dipeptide (MDP). In one embodiment the TLR agonist is HSP 60, 70 or 90. Other suitable TLR-4 ligands are as described in WO 2003/011223 and in WO 2003/099195, such as compound I, compound II and compound III disclosed on pages 4-5 of WO2003/011223 or on pages 3-4 of WO2003/099195 and in particular those compounds disclosed in WO2003/011223 as ER803022, ER803058, ER803732, ER804053, ER804057, ER804058, ER804059, ER804442, ER804680, and ER804764. For example, one suitable TLR-4 ligand is ER804057.

**[0089]** Additional TLR agonists are also useful as adjuvants. The term "TLR agonist" refers to an agent that is capable of causing a signaling response through a TLR signaling pathway, either as a direct ligand or indirectly through generation of endogenous or exogenous ligand. Such natural or synthetic TLR agonists can be used as alternative or additional adjuvants. A brief review of the role of TLRs as adjuvant receptors is provided in Kaisho & Akira, *Biochimica et Biophysica Acta* 1589:1-13, 2002. These potential adjuvants include, but are not limited to agonists for TLR2, TLR3, TLR7, TLR8 and TLR9. Accordingly, in one embodiment, the adjuvant and immunogenic composition further comprises an adjuvant which is selected from the group consisting of: a TLR-1 agonist, a TLR-2 agonist, TLR-3 agonist, a TLR-4 agonist, TLR-5 agonist, a TLR-6 agonist, TLR-7 agonist, a TLR-8 agonist, TLR-9 agonist, or a combination thereof.

**[0090]** In one embodiment of the present invention, a TLR agonist is used that is capable of causing a signaling response through TLR-1. Suitably, the TLR agonist capable of causing a signaling response through TLR-1 is selected from: Tri-acylated lipopeptides (LPs); phenol-soluble modulin; *Mycobacterium tuberculosis* LP; S-(2,3-bis(palmitoyloxy)-(2-RS)-propyl)-N-palmitoyl-(R)-Cys-(S)-Ser-(S)-Lys(4)-OH, trihydrochloride (Pam3Cys) LP which mimics the acetylated amino terminus of a bacterial lipoprotein and OspA LP from *Borrelia burgdorferi*.

**[0091]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-2. Suitably, the TLR agonist capable of causing a signaling response through TLR-2 is one or more of a lipoprotein, a peptidoglycan, a bacterial lipopeptide from *M tuberculosis*, *B burgdorferi* or *T pallidum*; peptidoglycans from species including *Staphylococcus aureus*; lipoteichoic acids, mannuronic acids, *Neisseria* porins, bacterial fimbriae, *Yersina* virulence factors, CMV virions, measles haemagglutinin, and zymosan from yeast.

**[0092]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-3. Suitably, the TLR agonist capable of causing a signaling response through TLR-3 is double stranded RNA (dsRNA), or polyinosinic-polycytidyllic acid (Poly IC), a molecular nucleic acid pattern associated with viral infection.

**[0093]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-5. Suitably, the TLR agonist capable of causing a signaling response through TLR-5 is bacterial flagellin.

**[0094]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-6. Suitably, the TLR agonist capable of causing a signaling response through TLR-6 is mycobacterial lipoprotein, di-acylated LP, and phenol-soluble modulin. Additional TLR6 agonists are described in WO 2003/043572.

**[0095]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-7. Suitably, the TLR agonist capable of causing a signaling response through TLR-7 is a single stranded RNA (ssRNA), loxoribine, a guanosine analogue at positions N7 and C8, or an imidazoquinoline compound, or derivative thereof. In one embodiment, the TLR agonist is imiquimod. Further TLR7 agonists are described in WO 2002/085905.

**[0096]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-8. Suitably, the TLR agonist capable of causing a signaling response through TLR-8 is a single stranded RNA (ssRNA), an imidazoquinoline molecule with anti-viral activity, for example resiquimod (R848); resiquimod is also capable of recognition by TLR-7. Other TLR-8 agonists which can be used include those described in WO 2004/071459.

**[0097]** In an alternative embodiment, a TLR agonist is used that is capable of causing a signaling response through TLR-9. In one embodiment, the TLR agonist capable of causing a signaling response through TLR-9 is HSP90. Alternatively, the TLR agonist capable of causing a signaling response through TLR-9 is bacterial or viral DNA, DNA containing unmethylated CpG nucleotides, in particular sequence contexts known as CpG motifs. CpG-containing oligonucleotides induce a predominantly Th1 response. Such oligonucleotides are well known and are described, for example, in WO 96/02555, WO 99/33488 and U.S. Patent Nos. 6,008,200 and 5,856,462. Suitably, CpG nucleotides are CpG oligonucleotides. Suitable oligonucleotides for use in the immunogenic compositions of the present invention are CpG containing oligonucleotides, optionally containing two or more dinucleotide CpG motifs separated by at least three, suitably at least six or more nucleotides. A CpG motif is a Cytosine nucleotide followed by a Guanine nucleotide. The CpG oligonucleotides of the present invention are typically deoxynucleotides. In a specific embodiment the internucleotide in the oligonucleotide is phosphorodithioate, or suitably a phosphorothioate bond, although phosphodiester and other internucleotide bonds

are within the scope of the invention. Also included within the scope of the invention are oligonucleotides with mixed internucleotide linkages. Methods for producing phosphorothioate oligonucleotides or phosphorodithioate are described in US Patent Nos. 5,666,153, 5,278,302 and WO 95/26204.

**[0098]** Other adjuvants that can be used in immunogenic compositions with a PreF antigens, e.g., on their own or in combination with 3D-MPL, or another adjuvant described herein, are saponins, such as QS21.

**[0099]** Saponins are taught in: Lacaille-Dubois, M and Wagner H. (1996. A review of the biological and pharmacological activities of saponins. *Phytomedicine* vol 2 pp 363-386). Saponins are steroid or triterpene glycosides widely distributed in the plant and marine animal kingdoms. Saponins are noted for forming colloidal solutions in water which foam on shaking, and for precipitating cholesterol. When saponins are near cell membranes they create pore-like structures in the membrane which cause the membrane to burst. Haemolysis of erythrocytes is an example of this phenomenon, which is a property of certain, but not all, saponins.

**[0100]** Saponins are known as adjuvants in vaccines for systemic administration. The adjuvant and haemolytic activity of individual saponins has been extensively studied in the art (Lacaille-Dubois and Wagner, *supra*). For example, Quil A (derived from the bark of the South American tree *Quillaja Saponaria Molina*), and fractions thereof, are described in US 5,057,540 and "Saponins as vaccine adjuvants", Kensil, C. R., *Crit Rev Ther Drug Carrier Syst*, 1996, 12 (1-2):1-55; and EP 0 362 279 B1. Particulate structures, termed Immune Stimulating Complexes (ISCOMS), comprising fractions of Quil A are haemolytic and have been used in the manufacture of vaccines (Morein, B., EP 0 109 942 B1; WO 96/11711; WO 96/33739). The haemolytic saponins QS21 and QS17 (HPLC purified fractions of Quil A) have been described as potent systemic adjuvants, and the method of their production is disclosed in US Patent No. 5,057,540 and EP 0 362 279 B1. Other saponins which have been used in systemic vaccination studies include those derived from other plant species such as *Gypsophila* and *Saponaria* (Bomford et al., *Vaccine*, 10(9):572-577, 1992).

**[0101]** QS21 is an Hplc purified non-toxic fraction derived from the bark of *Quillaja Saponaria Molina*. A method for producing QS21 is disclosed in US Patent No. 5,057,540. Non-reactogenic adjuvant formulations containing QS21 are described in WO 96/33739. Said immunologically active saponin, such as QS21, can be used in amounts of between 1 and 50 $\mu$ g, per human dose of the immunogenic composition. Advantageously QS21 is used at a level of about 25 $\mu$ g, for example between 20-30 $\mu$ g, suitably between 21-29 $\mu$ g or between 22 -28 $\mu$ g or between 23-27 $\mu$ g or between 24 -26 $\mu$ g, or 25 $\mu$ g. In another embodiment, the human dose of the immunogenic composition comprises QS21 at a level of about 10 $\mu$ g, for example between 5 and 15 $\mu$ g, suitably between 6 -14 $\mu$ g, for example between 7 -13 $\mu$ g or between 8 -12 $\mu$ g or between 9 -11 $\mu$ g, or 10 $\mu$ g. In a further embodiment, the human dose of the immunogenic composition comprises QS21 at a level of about 5 $\mu$ g, for example between 1-9 $\mu$ g, or between 2 -8 $\mu$ g or suitably between 3-7 $\mu$ g or 4 -6pg, or 5 $\mu$ g. Such formulations comprising QS21 and cholesterol have been shown to be successful Th1 stimulating adjuvants when formulated together with an antigen. Thus, for example, PreF polypeptides can favorably be employed in immunogenic compositions with an adjuvant comprising a combination of QS21 and cholesterol.

**[0102]** Optionally, the adjuvant can also include mineral salts such as an aluminium or calcium salts, in particular aluminium hydroxide, aluminium phosphate and calcium phosphate. For example, an adjuvant containing 3D-MPL in combination with an aluminium salt (e.g., aluminium hydroxide or "alum") is suitable for formulation in an immunogenic composition containing a PreF antigen for administration to a human subject.

**[0103]** Another class of suitable Th1 biasing adjuvants for use in formulations with PreF antigens includes OMP-based immunostimulatory compositions. OMP-based immunostimulatory compositions are particularly suitable as mucosal adjuvants, e.g., for intranasal administration. OMP-based immunostimulatory compositions are a genus of preparations of outer membrane proteins (OMPs, including some porins) from Gram-negative bacteria, such as, but not limited to, *Neisseria* species (see, e.g., Lowell et al., *J. Exp. Med.* 167:658, 1988; Lowell et al., *Science* 240:800, 1988; Lynch et al., *Biophys. J.* 45:104, 1984; Lowell, in "New Generation Vaccines" 2nd ed., Marcel Dekker, Inc., New York, Basil, Hong Kong, page 193, 1997; U.S. Pat. No. 5,726,292; U.S. Pat. No. 4,707,543), which are useful as a carrier or in compositions for immunogens, such as bacterial or viral antigens. Some OMP-based immunostimulatory compositions can be referred to as "Proteosomes," which are hydrophobic and safe for human use. Proteosomes have the capability to auto-assemble into vesicle or vesicle-like OMP clusters of about 20 nm to about 800 nm, and to noncovalently incorporate, coordinate, associate (e.g., electrostatically or hydrophobically), or otherwise cooperate with protein antigens (Ags), particularly antigens that have a hydrophobic moiety. Any preparation method that results in the outer membrane protein component in vesicular or vesicle-like form, including multi-molecular membranous structures or molten globular-like OMP compositions of one or more OMPs, is included within the definition of Proteosome. Proteosomes can be prepared, for example, as described in the art (see, e.g., U.S. Pat. No. 5,726,292 or U.S. Pat. No. 5,985,284). Proteosomes can also contain an endogenous lipopolysaccharide or lipooligosaccharide (LPS or LOS, respectively) originating from the bacteria used to produce the OMP porins (e.g., *Neisseria* species), which generally will be less than 2% of the total OMP preparation.

**[0104]** Proteosomes are composed primarily of chemically extracted outer membrane proteins (OMPs) from *Neisseria meningitidis* (mostly porins A and B as well as class 4 OMP), maintained in solution by detergent (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, *New Generation Vaccines*. New York: Marcel Dekker, Inc. 1997; 193-206). Proteosomes can be formulated with a variety of antigens

such as purified or recombinant proteins derived from viral sources, including the PreF polypeptides disclosed herein, e.g., by diafiltration or traditional dialysis processes. The gradual removal of detergent allows the formation of particulate hydrophobic complexes of approximately 100-200nm in diameter (Lowell GH. Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. In: Levine MM, Woodrow GC, Kaper JB, Cobon GS, eds, New Generation Vaccines. New York: Marcel Dekker, Inc. 1997; 193-206).

**[0105]** "Proteosome: LPS or Protollin" as used herein refers to preparations of proteosomes admixed, e.g., by the exogenous addition, with at least one kind of lipo-polysaccharide to provide an OMP-LPS composition (which can function as an immunostimulatory composition). Thus, the OMP-LPS composition can be comprised of two of the basic components of Protollin, which include (1) an outer membrane protein preparation of Proteosomes (e.g., Projuvant) prepared from Gram-negative bacteria, such as *Neisseria meningitidis*, and (2) a preparation of one or more liposaccharides. A lipo-oligosaccharide can be endogenous (e.g., naturally contained with the OMP Proteosome preparation), can be admixed or combined with an OMP preparation from an exogenously prepared lipo-oligosaccharide (e.g., prepared from a different culture or microorganism than the OMP preparation), or can be a combination thereof. Such exogenously added LPS can be from the same Gram-negative bacterium from which the OMP preparation was made or from a different Gram-negative bacterium. Protollin should also be understood to optionally include lipids, glycolipids, glycoproteins, small molecules, or the like, and combinations thereof. The Protollin can be prepared, for example, as described in U.S. Patent Application Publication No. 2003/0044425.

**[0106]** Combinations of different adjuvants, such as those mentioned hereinabove, can also be used in compositions with PreF antigens. For example, as already noted, QS21 can be formulated together with 3D-MPL. The ratio of QS21 : 3D-MPL will typically be in the order of 1 : 10 to 10 : 1; such as 1:5 to 5 : 1, and often substantially 1 : 1. Typically, the ratio is in the range of 2.5 : 1 to 1 : 1 3D-MPL: QS21. Another combination adjuvant formulation includes 3D-MPL and an aluminium salt, such as aluminium hydroxide. When formulated in combination, this combination can enhance an antigen-specific Th1 immune response.

**[0107]** In some instances, the adjuvant formulation a mineral salt, such as a calcium or aluminium (alum) salt, for example calcium phosphate, aluminium phosphate or aluminium hydroxide. Where alum is present, e.g., in combination with 3D-MPL, the amount is typically between about 100 $\mu$ g and 1mg, such as from about 100 $\mu$ g, or about 200 $\mu$ g to about 750 $\mu$ g, such as about 500 $\mu$ g per dose.

**[0108]** In some embodiments, the adjuvant includes an oil and water emulsion, e.g., an oil-in-water emulsion. One example of an oil-in-water emulsion comprises a metabolisable oil, such as squalene, a tocol such as a tocopherol, e.g., alpha-tocopherol, and a surfactant, such as sorbitan trioleate (Span 85<sup>TM</sup>) or polyoxyethylene sorbitan monooleate (Tween 80<sup>TM</sup>), in an aqueous carrier. In certain embodiments, the oil-in-water emulsion does not contain any additional immunostimulants(s), (in particular it does not contain a non-toxic lipid A derivative, such as 3D-MPL, or a saponin, such as QS21). The aqueous carrier can be, for example, phosphate buffered saline. Additionally the oil-in-water emulsion can contain span 85 and/or lecithin and/or tricaprylin.

**[0109]** In another embodiment of the invention there is provided a vaccine composition comprising an antigen or antigen composition and an adjuvant composition comprising an oil-in-water emulsion and optionally one or more further immunostimulants, wherein said oil-in-water emulsion comprises 0.5-10 mg metabolisable oil (suitably squalene), 0.5-11 mg tocol (suitably a tocopherol, such as alpha-tocopherol) and 0.4-4 mg emulsifying agent.

**[0110]** In one specific embodiment, the adjuvant formulation includes 3D-MPL prepared in the form of an emulsion, such as an oil-in-water emulsion. In some cases, the emulsion has a small particle size of less than 0.2 $\mu$ m in diameter, as disclosed in WO 94/21292. For example, the particles of 3D-MPL can be small enough to be sterile filtered through a 0.22micron membrane (as described in European Patent number 0 689 454). Alternatively, the 3D-MPL can be prepared in a liposomal formulation. Optionally, the adjuvant containing 3D-MPL (or a derivative thereof) also includes an additional immunostimulatory component.

**[0111]** The adjuvant is selected to be safe and effective in the population to which the immunogenic composition is administered. For adult and elderly populations, the formulations typically include more of an adjuvant component than is typically found in an infant formulation. In particular formulations using an oil-in-water emulsion, such an emulsion can include additional components, for example, such as cholesterol, squalene, alpha tocopherol, and/or a detergent, such as tween 80 or span85. In exemplary formulations, such components can be present in the following amounts: from about 1-50mg cholesterol, from 2 to 10% squalene, from 2 to 10% alpha tocopherol and from 0.3 to 3% tween 80. Typically, the ratio of squalene: alpha tocopherol is equal to or less than 1 as this provides a more stable emulsion. In some cases, the formulation can also contain a stabilizer.

**[0112]** When an immunogenic composition with a PreF polypeptide antigen is formulated for administration to an infant, the dosage of adjuvant is determined to be effective and relatively non-reactogenic in an infant subject. Generally, the dosage of adjuvant in an infant formulation is lower (for example, the dose may be a fraction of the dose provided in a formulation to be administered to adults) than that used in formulations designed for administration to adult (e.g., adults aged 65 or older). For example, the amount of 3D-MPL is typically in the range of 1 $\mu$ g-200 $\mu$ g, such as 10-100 $\mu$ g, or 10 $\mu$ g-50 $\mu$ g per dose. An infant dose is typically at the lower end of this range, e.g., from about 1 $\mu$ g to about 50 $\mu$ g,

such as from about 2 $\mu$ g, or about 5 $\mu$ g, or about 10 $\mu$ g, to about 25 $\mu$ g, or to about 50 $\mu$ g. Typically, where QS21 is used in the formulation, the ranges are comparable (and according to the ratios indicated above). In the case of an oil and water emulsion (e.g., an oil-in-water emulsion), the dose of adjuvant provided to a child or infant can be a fraction of the dose administered to an adult subject. A demonstration of the efficacy of immunogenic compositions containing a PreF antigen in combination various doses of an exemplary oil-in-water adjuvant is provided in Example 9.

**[0113]** An immunogenic composition typically contains an immunoprotective quantity (or a fractional dose thereof) of the antigen and can be prepared by conventional techniques. Preparation of immunogenic compositions, including those for administration to human subjects, is generally described in *Pharmaceutical Biotechnology*, Vol.61 *Vaccine Design-the subunit and adjuvant approach*, edited by Powell and Newman, Plenum Press, 1995. *New Trends and Developments in Vaccines*, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.

**[0114]** Typically, the amount of protein in each dose of the immunogenic composition is selected as an amount which induces an immunoprotective response without significant, adverse side effects in the typical subject. Immunoprotective in this context does not necessarily mean completely protective against infection; it means protection against symptoms or disease, especially severe disease associated with the virus. The amount of antigen can vary depending upon which specific immunogen is employed. Generally, it is expected that each human dose will comprise 1-1000 $\mu$ g of protein, such as from about 1 $\mu$ g to about 100 $\mu$ g, for example, from about 1 $\mu$ g to about 50 $\mu$ g, such as about 1 $\mu$ g, about 2 $\mu$ g, about 5 $\mu$ g, about 10 $\mu$ g, about 15 $\mu$ g, about 20 $\mu$ g, about 25 $\mu$ g, about 30 $\mu$ g, about 40 $\mu$ g, or about 50 $\mu$ g. The amount utilized in an immunogenic composition is selected based on the subject population (e.g., infant or elderly). An optimal amount for a particular composition can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects can receive a boost in about 4 weeks.

**[0115]** It should be noted that regardless of the adjuvant selected, the concentration in the final formulation is calculated to be safe and effective in the target population. For example, immunogenic compositions for eliciting an immune response against RSV in humans are favorably administered to infants (e.g., infants between birth and 1 year, such as between 0 and 6 months, at the age of initial dose). Immunogenic compositions for eliciting an immune response against RSV are also favorably administered to elderly humans (e.g., alone or in a combination with antigens of other pathogens associated with COPD). It will be appreciated that the choice of adjuvant can be different in these different applications, and the optimal adjuvant and concentration for each situation can be determined empirically by those of skill in the art.

**[0116]** In certain embodiments, the immunogenic compositions are vaccines that reduce or prevent infection with RSV. In some embodiments, the immunogenic compositions are vaccines that reduce or prevent a pathological response following infection with RSV. Optionally, the immunogenic compositions containing a PreF antigen are formulated with at least one additional antigen of a pathogenic organism other than RSV. For example, the pathogenic organism can be a pathogen of the respiratory tract (such as a virus or bacterium that causes a respiratory infection). In certain cases, the immunogenic composition contains an antigen derived from a pathogenic virus other than RSV, such as a virus that causes an infection of the respiratory tract, such as influenza or parainfluenza. In other embodiments, the additional antigens are selected to facilitate administration or reduce the number of inoculations required to protect a subject against a plurality of infectious organisms. For example, the antigen can be derived from any one or more of influenza, hepatitis B, diphtheria, tetanus, pertussis, *Hemophilus influenza*, poliovirus, *Streptococcus* or *Pneumococcus*, among others.

**[0117]** Accordingly, the use of PreF antigens or nucleic acids that encode them in the preparation of a medicament for treating (either therapeutically following or prophylactically prior to) exposure to or infection by RSV is also a feature of this disclosure. Likewise, methods for eliciting an immune response against RSV in a subject are a feature of this disclosure. Such methods include administering an immunologically effective amount of a composition comprising a PreF antigen to a subject, such as a human subject. Commonly, the composition includes an adjuvant that elicits a Th1 biased immune response. The composition is formulated to elicit an immune response specific for RSV without enhancing viral disease following contact with RSV. That is, the composition is formulated to and results in a Th1 biased immune response that reduces or prevents infection with a RSV and/or reduces or prevents a pathological response following infection with a RSV. Although the composition can be administered by a variety of different routes, most commonly, the immunogenic compositions are delivered by an intramuscular or intranasal route of administration.

**[0118]** An immunogenic composition typically contains an immunoprotective quantity (or a fractional dose thereof) of the antigen and can be prepared by conventional techniques.

**[0119]** Preparation of immunogenic compositions, including those for administration to human subjects, is generally described in *Pharmaceutical Biotechnology*, Vol.61 *Vaccine Design-the subunit and adjuvant approach*, edited by Powell and Newman, Plenum Press, 1995. *New Trends and Developments in Vaccines*, edited by Voller et al., University Park Press, Baltimore, Maryland, U.S.A. 1978. Encapsulation within liposomes is described, for example, by Fullerton, U.S. Patent 4,235,877. Conjugation of proteins to macromolecules is disclosed, for example, by Likhite, U.S. Patent 4,372,945 and by Armor et al., U.S. Patent 4,474,757.

**[0120]** Typically, the amount of protein in each dose of the immunogenic composition is selected as an amount which

induces an immunoprotective response without significant, adverse side effects in the typical subject. Immunoprotective in this context does not necessarily mean completely protective against infection; it means protection against symptoms or disease, especially severe disease associated with the virus. The amount of antigen can vary depending upon which specific immunogen is employed. Generally, it is expected that each human dose will comprise 1-1000 $\mu$ g of protein, such as from about 1 $\mu$ g to about 100 $\mu$ g, for example, from about 1 $\mu$ g to about 50 $\mu$ g, such as about 1 $\mu$ g, about 2 $\mu$ g, about 5 $\mu$ g, about 10 $\mu$ g, about 15 $\mu$ g, about 20 $\mu$ g, about 25 $\mu$ g, about 30 $\mu$ g, about 40 $\mu$ g, or about 50 $\mu$ g. The amount utilized in an immunogenic composition is selected based on the subject population (e.g., infant or elderly). An optimal amount for a particular composition can be ascertained by standard studies involving observation of antibody titres and other responses in subjects. Following an initial vaccination, subjects can receive a boost in about 4-12 weeks. For example, when administering an immunogenic composition containing a PreF antigen to an infant subject, the initial and subsequent inoculations can be administered to coincide with other vaccines administered during this period.

**[0121]** The following examples are provided to illustrate certain particular features and/or embodiments.

#### EXAMPLES

##### Example 1: Exemplary PreF antigens

**[0122]** The PreF antigen was modified as compared to a native RSV F protein in order to stabilize the protein in its prefusion conformation, based on the prediction that an immune response generated to the prefusion conformation of F would preferentially include antibodies that would prevent binding, conformation shifting and/or other events involved in membrane fusion, thereby increasing the efficacy of the protective response.

**[0123]** FIG. 1A and B schematically illustrate features of RSV F0 and exemplary PreF recombinant antigens. FIG. 1A is a representation of the RSV F0 protein. F0 is a pre-protein consisting of 574 amino acids. The F0 pre-protein is proteolytically processed and glycosylated following translation. A signal peptide, which is later removed by a signal peptidase, targets translation of the F0 pre-protein to the reticulum endoplasmic (RE). Nascent peptide in the RE is then N-glycosylated at multiple sites (represented by triangles). Furin cleavage of F0 generates F2 and F1 peptide domains, which are folded and assembled together as a trimer of F2-F1 heterodimers (that is, 3 times F2-F1). In its native state, the F protein is anchored to the membrane by a transmembrane helix in the C-terminal region. Additional features of the F0 polypeptide include, 15 Cysteine residues, 4 characterized neutralizing epitopes, 2 coiled-coil regions, and a lipidation motif. FIG. 1B illustrates features of exemplary PreF antigens. To construct the PreF antigen, the F0 polypeptide was modified to stabilize the prefusion conformation of the F protein, thereby retaining the predominant immunogenic epitopes of the F protein as presented by the RSV virus prior to binding to and fusion with host cells. The following stabilizing mutations were introduced into the PreF antigen relative to the F0 polypeptide. First, a stabilizing coiled-coil domain was placed at the C-terminal end of the extracellular domain of the F0 polypeptide, replacing the membrane anchoring domain of F0. Second, the pep27 peptide (situated between the F2 and F1 domains in the native protein) was removed. Third, both furin motifs were eliminated. In alternative embodiments (designated PreF\_V1 and PreF\_V2), an immunologically active portion (e.g., amino acids 149-229) of the RSV G protein was added to the C-terminal domain.

**[0124]** In other embodiments, modifications were introduced to alter (increase or decrease) glycosylation and/or to reduce cleavage by a protease other than furin.

##### Example 2: Production and Purification of PreF recombinant protein from CHO cells.

**[0125]** A recombinant polynucleotide sequence encoding an exemplary PreF antigen was introduced into host CHO cells for the production of PreF antigen. Transiently transfected host cells or expanded stable populations comprising the introduced polynucleotide sequence were grown in medium and under conditions suitable for growth at an acceptable scale for the desired purpose (e.g., as generally described in Freshney (1994) Culture of Animal Cells, a Manual of Basic Technique, third edition, Wiley- Liss, New York and the references cited therein). Typically, the cells were grown in serum-free medium in shake flasks at 37°C with 5% CO<sub>2</sub> and passaged at 2-3 day intervals, or in bioreactors at 29°C with pO<sub>2</sub> maintained at 20%.

**[0126]** To recover recombinant PreF antigen, the cell culture was centrifuged and the cell culture supernatant stored at about -80°C until further use. For further analysis, two liter aliquots of cell culture supernatant were diluted 2x with purified water and adjusted to pH 9.5 with NaOH. The supernatant was loaded at a rate of 14 ml/min. onto a Q Sepharose FF ion exchange column (60 ml, 11.3 cm), equilibrated in 20 mM piperazine pH 9.5. After washing the column with the starting buffer, elution was performed with a NaCl gradient from 0 to 0.5 M NaCl in 20 column volumes (fraction size 10 ml). Fractions were analyzed on SDS PAGE gel by silver staining and western blot. Fractions containing substantial PreF protein were then pooled prior to further processing.

**[0127]** The pooled elution of the Q step (~130 mls) was subjected to buffer exchange into 10 mM phosphate, pH 7.0 using the bench-scale TFF system from Millipore with the Pelllicon XL PES Biomax 100 (MWCO 10,000 Da) membrane

5 cassette. The resulting material had a pH of 7.0 and a conductivity of 1.8 mS/cm. 100 ml of this sample was loaded at 5 ml/min. on a 10 ml Hydroxy apatite Type II (HA TII) gel (XK 16, height=5cm) equilibrated with 10 mM PO<sub>4</sub> (Na) buffer pH 7.0. After washing the column with the starting buffer, elution was performed with a gradient from 10 mM to 200 mM PO<sub>4</sub> (Na) pH 7.0 in 20 column volumes. Fractions were again analysed on SDS PAGE with silver staining and coomassie blue, and the positive fractions were pooled.

10 [0128] Following affinity chromatography, the pooled fractions were concentrated and the buffer exchanged into DPBS (pH ~7.4) using a Vivaspin 20 concentrator unit, 10,000 Da MWCO. The final product was about 13 ml. Protein concentration was 195 µg/ml, assessed by Lowry assay. Purity was greater than 95%. This purified PreF antigen preparation was filter sterilized and stored at -20°C prior to use.

15 Example 3: Characterization of the PreF recombinant protein produced in CHO cells.

[0129] PreF recombinant protein produced in CHO cells was characterized by asymmetrical field flow fractionation (AFF-MALS) and compared to a chimeric antigen including RSV F and G protein components. AFF-MALS allows separation of protein species according to their molecular size in a liquid flow with minimal matrix interaction and further analysis by multi-angle light scattering for accurate molecular weight determination. FIG. 2A shows that more than 65% of purified FG material is found as high molecular weight oligomers (1000-100000 KDa) in its final PBS buffer while 3% remain in monomeric form.

20 [0130] FIG. 2B shows that the purified PreF protein is folded in its trimeric form to a proportion of 73% in PBS buffer. 10% of the material is found as 1000 to 20 000 KDa oligomers. These results indicate that the recombinant PreF protein expressed in CHO cells is folded as a trimer as predicted for the native state.

25 [0131] Purified PreF protein was also crosslinked with glutaraldehyde for the double purpose of confirming the soluble nature of the protein in phosphate buffer solution and of generating aggregates for comparative in vivo evaluation with FG protein (see Example 7 below). Glutaraldehyde crosslinking is known for providing a good assessment of the quaternary structure of a protein, and is described in (Biochemistry, 36:10230-10239 (1997); Eur. J. Biochem., 271:4284-4292 (2004)).

30 [0132] Protein was incubated with 1%, 2% and 5% of glutaraldehyde crosslinking agent for four hours at 4°C and the reaction was blocked by addition of NaBH<sub>4</sub>. Excess glutaraldehyde was removed by column desalting in PBS buffer. Resulting protein was quantified by absorbance at 280nm and evaluated by SDS PAGE in denaturing and reducing condition. The majority of purified recombinant PreF was determined to migrate as a trimer in PBS solution. Increasing the incubation temperature to 23°C was required to convert majority of trimeric protein to high molecular weight aggregates, as confirmed by SDS PAGE.

35 Example 4: *In vitro* Neutralization Inhibition by the PreF antigen

[0133] Human sera obtained from volunteers were screened for reactivity against RSV A by ELISA and used in the neutralization inhibition (NI) assay at relevant dilution based on prior RSV neutralization potential titration established for each serum sample. Briefly, Sera were mixed with inhibitor proteins (PreF or a control protein corresponding essentially to the chimeric FG disclosed in US Patent No. 5,194,595, designated RixFG) at concentrations of 25 µg/ml in DMEM with 50% 199-H medium, with 0.5% FBS, 2 mM glutamine, 50 µg/ml genamycin (all Invitrogen), and incubated 1.5 to 2 hours at 37°C on a rotating wheel. 20 µl the serial dilutions of sera and proteins were mixed in a round bottom 96-well plate with a RSV A titred to optimize the range of inhibition for each serum sample. The resulting mixtures were incubated for 20 minutes at 33°C under 5% CO<sub>2</sub> to maintain pH.

45 [0134] The sera-inhibitor-virus mixtures were then placed into previously Vero cell-seeded flat bottom 96-well plates and incubated for 2 hours at 33°C prior to addition of 160 µl of medium. The plates were further incubated for 5-6 days at 33°C with 5% CO<sub>2</sub> until immunofluorescence assay for NI titer detection. Following fixation for 1 hour with 1% paraformaldehyde in phosphate buffered saline (PBS), plates were blocked with 2% milk/PBS and Block biffer. Goat anti-RSV antibody (Biodesign Internation; 1:400) was added to each well without rinsing and incubated for 2 hours at room temperature (RT). Samples were washed 2x with PBS and anti-goat IgG-FITC (Sigma; 1:400) in blocking buffer was added to the wells. The plates were again incubated for 2 hours at RT and washed 2x as above prior to reading. A well was considered positive when ≥ 1 fluorescent syncytium was detected. The 50% tissue culture infective dose (TCID<sub>50</sub>) calculations were performed using the Spearman-Karber (SK) method and percentages of NI calculated as follow: [(Neut titer of 0 µg/ml inhibitor - Neut titer of 25 µg/ml inhibitor)/Neut titer of 0 µg/ml inhibitor] X 100. Exemplary results shown in FIG. 3 indicate that PreF is superior to FG in NI in 16/21 donors tested.

55 Example 5: PreF antigen is immunogenic

[0135] To demonstrate immunogenicity of the PreF antigen, mice were immunized twice IM at two weeks interval with

preF (6.5, 3.1, 0.63, 0.13, and 0.025  $\mu$ g/ml) and a Th1 adjuvant containing 3D MPL and QS21 at 1/20 of human dose ("AS01E") or preF (1, 0.2 and 0.04  $\mu$ g/ml) and a Th1 adjuvant containing 3D MPL and alum 1/10 of human dose ("AS04C") and serum was collected three weeks later.

**[0136]** Antigen-specific IgG antibody titers were determined on pooled serum samples by ELISA according to standard procedures. Briefly, 96-well plates were coated with purified inactivated RSV A, RSV B and homologous preF protein and incubated overnight at 4°C. Serum samples were serially diluted in blocking buffer starting at an initial concentration of 1:50, along with purified mouse IgG Sigma, ON) at starting concentrations of 200 ng/ml and incubated for 2h at room temperature. Bound antibody was detected with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Sigma, ON). 3,3A,5,5A-tetramethylbenzidine (TMB, BD Opt EIATM, BD Biosciences, ON) was used as the substrate for HRP. 50 $\mu$ l of 1M H<sub>2</sub>SO<sub>4</sub> was added to each well to stop the reaction. Absorbance values for each well were detected at 450 nm with a Molecular Devices microplate reader (Molecular Devices, USA).

**[0137]** Representative results detailed in FIGS. 4A and 4B show that strong titers are elicited against both RSV A and RSV B following immunization with preF antigen.

**15** Example 6: PreF elicits neutralizing antibodies

**[0138]** The presence and quantity of neutralizing antibodies was assessed in serum samples of mice immunized as described above in Example 5. Pooled sera from immunized animals were serially diluted from a starting dilution of 1:8 in RSV medium in 96-well plates (20  $\mu$ l/well). Control wells contained RSV medium only, or goat anti-RSV antibody at 1:50 (Biodesign international). 500-1000 infectious doses of a representative RSV A or B strain were added to the wells, and the plates were incubated for 20 minutes at 33°C, 5% CO<sub>2</sub>, before the mixture was transferred to 96-well flat-bottomed plates previously seeded with 1x10<sup>5</sup> cells/mL Vero cells. Cells were incubated for approximately 2 hours at 33°C, 5% CO<sub>2</sub> and refed, prior to incubation for 5-6 days at the same temperature. Supernatants were removed; plates were washed with PBS and adhering cells fixed with 1% paraformaldehyde in PBS for 1 hour, followed by indirect immunofluorescence (IFA) using a goat anti RSV primary antibody and anti-goat IgG-FITC for detection.

**[0139]** Representative results shown in FIGS 5A and 5B, respectively, demonstrate that significant neutralizing antibodies against both RSV strains are detected in sera of animals immunized with preF.

**30** Example 7: PreF protects against RSV challenge

**[0140]** Mice were immunized twice IM at a two week interval as described above, and challenged three weeks after the second injection with RSV A. Protection against RSV was evaluated by measuring the virus present in lungs following challenge. In brief, lungs from immunized animals were aseptically removed following euthanasia and washed in RSV medium using 2 volumes of 10 ml/lung in 15 ml tubes. Lungs were then weighed and homogenized individually in RSV medium with an automated Potter homogenizer (Fisher, Nepean ON), and centrifuged at 2655 x g for 2 minutes at 4°C. The virus present in the supernatants was titrated by serial dilution (eight replicates starting at 1:10) on a previously seeded Vero cell (ATCC# CCL-81) monolayer in 96-well plates and incubated for 6 days. RSV was detected by indirect IFA following fixing in 1% paraformaldehyde/PBS pH7.2, with goat anti-RSV primary antibody and FITC labeled anti-goat IgG secondary antibody.

**[0141]** Representative results shown in FIGS. 6A and B demonstrate that doses equal to or higher than 0.04 $\mu$ g when given in presence of adjuvant elicit strong protection against RSV.

**45** Example 8: PreF does not induce pulmonary eosinophil recruitment following challenge

**[0142]** To assess the potential of the PreF antigen to provoke exacerbated disease following immunization and subsequent challenge, groups of mice (5 mice/group) were immunized twice each with (a) 10  $\mu$ g gluteraldehyde-treated preF, (b) 10  $\mu$ g preF or (c) 10  $\mu$ g FG without adjuvant. Mice were challenged with RSV A 3 weeks post-boost and bronchoalveolar lavage (BAL) was performed 4 days post challenge. Total leukocyte infiltrates in BAL were enumerated per mouse as well as differential enumerations (300 cells) based on cell morphology of macrophages/monocytes, neutrophils, eosinophils and lymphocytes.

**[0143]** Total cell numbers were multiplied by differential percentages of eosinophils for each animal. Represented are geometric means per group with 95% confidence limits. Representative results shown in FIG. 7 demonstrate that eosinophils are not recruited to the lungs following immunization with preF and challenge. Furthermore, these results suggest that the soluble nature of the preF antigen, as compared to a deliberately aggregated form of preF (gluteraldehyde treatment) or FG antigen (naturally aggregated) does not favour eosinophils.

Example 9: Immunogenicity of PreF antigen formulated with dilutions of an oil-in-water emulsion adjuvant.

5 [0144] Mice received 250ng preF formulated with the exemplary oil-in-water adjuvant, AS03A, at a 1/10 of the human "full" dose (AS03A) of 10.70 mg squalene, 11.88 mg DL- $\alpha$ -tocopherol, 4.85 mg polysorbate 80, 1/2 dose (AS03B), 1/4 dose (AS03C), or no adjuvant.

10 [0145] Control mice received AS03A alone or PBS. The mice were immunized on days 0 and 14. Blood, splenocyte collection and challenge were performed on Day 39 (25 days post dose 2). Lungs were homogenized for titration of RSV 4 days post challenge.

15 [0146] Antigen-specific IgG antibody titers were determined on individual serum samples by ELISA. Briefly, 96-well plates were coated with purified inactivated RSV A and incubated overnight at 4°C. Serum samples were serially diluted in blocking buffer starting at 1:200, along with purified mouse IgG (Sigma, ON), at starting concentrations of 200 ng/ml and incubated for 2h at 37°C. Bound antibody was detected with horseradish peroxidase (HRP)-conjugated anti-mouse IgG (Sigma, ON). 3,3A,5,5A-tetramethylbenzidine (TMB, BD OptEIATM, BD Biosciences, ON) was used as the substrate for HRP. 50  $\mu$ l of 1M H<sub>2</sub>SO<sub>4</sub> was added to each well to stop the reaction. Absorbance values for each well were detected at 450 nm with a Molecular Devices microplate reader (Molecular Devices, USA). Results are illustrated in FIG. 8. Anti-RSV IgG concentration of approximately 250,000 ng/mL was observed in serum from mice immunised with preF in combination with AS03A, AS03B or AS03C, whereas very little (1828 ng/ml) was observed in serum from mice immunised with preF alone.

20 [0147] Pooled sera from immunized animals were serially diluted from a starting dilution of 1:8 in RSV medium in 96-well plates (20  $\mu$ l/well). Control wells contained RSV medium only or goat anti-RSV antibody at 1:50 (Biodesign international). RSV Long strain was added, the plates were incubated for 20 minutes at 33°C and the mixture was transferred to 96-well flat-bottomed plates previously seeded with 1x10<sup>5</sup> cells/mL Vero cells. After 5-6 days at the same temperature, supernatants were removed; plates were washed with PBS and adhering cells fixed with 1% paraformaldehyde in PBS for 1 hour, followed by indirect immunofluorescence (IFA). FIG. 9 shows that regardless of the amount of AS03 administered in combination with preF the RSV neutralising antibody titres remained the same (~ 11 log2), whereas the RSV neutralising antibody titre in the mice immunised without AS03 were significantly lower (~6 log2).

25 [0148] Lungs from immunized animals were aseptically removed following euthanasia and washed in RSV medium using 2 volumes of 10 ml / lung in 15 ml tubes. They were then weighed and homogenized individually in RSV medium with an automated Potter homogenizer (Fisher, Nepean ON), and centrifuged at 2655 x g for 2 minutes at 4°C. The virus present in the supernatants was titrated. Briefly, lung homogenates were serially diluted in eight replicates starting at a 1:10 on a previously seeded Vero cell (ATCC# CCL-81) monolayer in 96-well plates and incubated for 5-6 days. RSV was detected by indirect IFA. FIG. 10 illustrates results demonstrating that no difference in protection was observed between mice immunised with preF in combination with AS03A, AS03B or AS03C, whereas less protection was observed in mice immunised in absence of AS03. These results demonstrate that the PreF antigen can be formulated across a broad range of adjuvant concentrations to produce a composition that elicits an immune response against RSV.

## Sequence Listing

30 [0149]

40 SEQ ID NO:1

Nucleotide sequence encoding RSV reference Fusion protein Strain A2 GenBank Accession No. U50362

45

50

55

25 SEQ ID NO:2  
Amino acid sequence of RSV reference F protein precursor F0 Strain A2 GenBank Accession No. AAB86664

30 MELLILKANAITTILTAVTFCFASGQNITEEFYQSTCSAVSKGYL SALRTGWYTSVITIELSNIKENKCGNT  
DAVKLIKQELDKYKNAVTELQLLMQSTPATNNRARRELPRFMNYTLNAKKTNTVTLSSKKRKKRFLGFLGV  
GSAIASGVAVSKVLHLEGEVNIKIKSALLSTNKAVVSLSGVSVLTSKVL DLKNYIDKQLLPIVNKQSCSISN  
IATVIEFQQKNNRLEITREFSVNAGVTPVSTYMLTNSELLSINDMPI TNDQKQLMSNNVQIVRQSYSI  
MSIIKEEVLAYVQLPLYGVIDTPCWKLHTSPLCTNTKEGSNICLRTDRGWYCDNAGSVSFFPQAETCKV  
QSNRVCFCDMNSLTLPEVNLCNVDIFNPKYDCKIMTSKTDVSSSVITSLGAI VSCYGKTKCTASNKNRGII  
35 KTFSGCDYVSNKGVDTSGVNTLYYVINKQEGKSLYVKGEPIINFYDPLVFP SDEFDASISQVNEKINQSLA  
FIRKSDELLHNVNAGKSTINIMITTIIVIIVILLSLIAVGLLLYCKARSTPVTLSKDKQLSGINNIAFSN

SEQ ID NO:3  
Nucleotide sequence encoding RSV reference G protein Strain Long

40 Atgtccaaaaacaaggaccacgcaccgctaagacactagaaaagacctgggacactctcaatcatttata  
ttcatatcatcggcttatataagttaatcttaatctatagcacaaatcacattatcattctggcaatg  
ataatctcaacttcacttataattacagccatcatattcatagcctcgccaaaccacaaagtcaactaaca  
actgcaatcatacaagatgcaacaagccagatcaagaacacacaaccccaacatacctcactcaggatcctcag  
45 cttggaatcagcttcattctgtctgaaattacatcacaaaccaccacccatactagcttcaacaacacca  
ggagtcaagtcaaacctgcaacccacaacagtcaagactaaaaacacaacaacccaaacacaacccaggc  
aagcccaactacaaaacaacgccaaaacaacccacccaaacaaacccaaataatgatttcacttcgaagtgttt  
aactttgtaccctgcagcatatgcagcaacaatccaacctgctggctatctgcaaaaagaataccaaacaaa  
aaaccaggaaagaaaaccaccaccaagccataaaaaaaccacccatcaagacacccaaaaagatctcaaa  
50 cctcaaaaccactaaaccaaaaggaagtaccaccaccaagccacaccaagagccaaacccatcaacaccacccaaa  
acaaacatcacaactacactgctcaccacaaacaccacagggaaatccaaaactcacaagtcaatggaaacc  
ttccactcaacctcccgaaaggcaatctaagcccttcaagtctccacaacatccggcagccatcaca  
ccctcatctccacccaaacacaacacgcccagtag

SEQ ID NO:4  
55 Amino acid sequence of RSV reference G protein

5 MSKNKDQRTAKTLEKTWDTLNHLLFISSGLYKLNLKSIAQITLSILAMIISTSLIITAIIFIASANHKVTLT  
 TAIIQDATSQIKNTTPTYLTQDPQLGISFSNLSEITSQTTILASTTPGVKSNLQPTTVKTKNTTTQTQPS  
 KPTTKQRQNKPNNKPNNDHFEEVFNFVPCSICSNNPTCWAICKRIPNKKPGKTTKPTKPTFKTTKDLK  
 PQTTKPKEVPTTKPTEPTINTTKTNITTLTNNTGNPKLTSQMETFHSTSSEGNLSPSQVSTTSEHPSQ  
 PSSPPNTTRQ

Seq ID NO:5

Nucleotide sequence of PreF analog optimized for CHO

10 aagcttgcaccatggagctgctgatcctgaaaaccaacgcacatcaccgcacatcctggccgcgtgaccctg  
 tgcttcgcctcctccagaacatcaccgaggagttctaccagtccacatcgctccgcgtgtccaaagggtac  
 ctgtccgcctgcggaccggctgttacacccctcgatcaccatcgagctgtccaaacatcaaggaaaacaag  
 tgcaacggcaccgacgccaagggtgaagctgatcaagcaggagctggacaaggtaaaagagcgcgcgtgaccgaa  
 ctccagctgtatgcagtcacccctgcccaccaacaacaagttctggcttgcgtggcgtggcgtcc  
 15 gccatgcgcctccggcatgcgcgtgagcaagggtgctgcacctggaggcgaggtaacaagatcaagagcgc  
 ctgtgtccaccaacaaggccgtgggtccctgtccaaacggcgtgtccgtgtgacccctcaagggtctgat  
 ctgaagaactacatcgacaaggcagctgtgcctatcgtaacaaggcagtcctgtccatctccaacatcgag  
 accgtgatcgagttccagcagaagaacaaccggctgtggagatcaccgcgagttctccgtgaacgcggc  
 20 gtgaccacccctgtgtccacatcgatcggactccgagctgtccctgatcaacgcacatgcctatc  
 accaacgaccagaaaaactgatgtccaaacaacgtgcagatcgtgcggcagcagtccatcagacatcatgagc  
 atcatcaaggaagagggtctggcttacgtggcagatgcctctgtacggcgtgatcgacacccctgtctgg  
 aagctgcacacccctccctgtgcaccaccaacaccaaggagggtccaaacatctgcctgacccggaccgac  
 25 cggggctggtaactgcgacaacgcggctccgtgtccttctccctctggccgagacctgcaaggtgcagtc  
 aaccgggttctgcgacaccatgaaactccctgaccctgccttccgaggtaacctgtgcaacatcgacatc  
 ttcaaccccaagtacgactgcaagatcatgaccaggcaagaccgcgtgtcctccagcgtgatcacccctg  
 ggcgcacatcgatgcctgtacggcaagaccaaggcgtgcaccgcctcaacaagaaccgggaatcatcaagacc  
 30 ttctccaaacggcgtgcactacgtgtccaaataaggcggtggacaccgtgtccgtggcaacacactgtactac  
 gtgaataaggcaggaggcaagagccctgtacgtgaaggcgagcctatcatcaactctacgaccctctgt  
 ttccctccgacgagttcgacgcctccatcagccaggtaacgagaagatcaaccaggatccctggccatc  
 cggaaatccgacgagaagctgcataacgtggaggacaagatcgaggagatctgtccaaatctaccacatc  
 gagaacgagatcgcccgatcaagaagctgatcgccgaggctgataatctaga

SEQ ID NO:6

Amino acid sequence of PreF analog

35 MELLILKTNAITAILAAVTLCFASSQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKNGT  
 DAKVKLIKQELDKYKSAVTELQLMMQSTPATNNKFLGFLLGVSIAIASGIAVSKVLHLEGEVNKIKSALLST  
 NKAVVSLNSNGVSVLTSKVLIDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLITREFSVNAGVTP  
 VSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVILAYVQLPLYGVIDTPCWKLHT  
 40 SPLCTTNTKEGSNICLRTDRGWYCDNAGSVSFFPLAETCKVQSNRVCFTDMNSLTLPEVNLCNIDIFNPK  
 YDCKIMTSKTDVSSSVITSLGAIIVSCYGKTKCTASKNRGIIKTFNSNGCDYVSNKGVDTVSVGNTLYYVNQ  
 EGKSLYVKGEIINFYDPLVFPSEFDASISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENEI  
 ARIKKLIGEA

Seq ID NO:7

45 Nucleotide sequence encoding PreFG\_V1 optimized for CHO

50

55

aagcttgcaccatggagctgatcccaagaccaacgcacaccgcacccatcaccgcacccatggccgcgtgaccctg  
 tgcttcgcctcctcccagaacatcaccgaagagtctaccagtccacccgtgtccgcgtgtccaagggtac  
 ctgtccgcgcgtggaccggctgttacacccgtgtccgcgtgtccaacatcaaaagaaaacaag  
 tgcaacggcaccgacgccaaggtaagctgatcaacgcaggaactggacaagtacaagagcgcgcgtgaccgaa  
 ctccagctgatgcagtcaccgcgtgtccaccaacaagaagttctggcttcgtctggcgatggc  
 tccgcacatgcgcgtgtccgcgtgtccaccaacaaggccgtgtccgttccaacccgtgtccgtgtccgtac  
 gcccgtgtccaccaacaaggccgtgtccgtgtccgtgtccgtgtccgtac  
 gatctgaagaactacatcgacaaacgcagctgatgcctatcgtaacaagcagtcctgtccatctcaacatc  
 gagaccgtgatcgagttccacccgtgtccacccatgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 ggcgtgaccacccgtgtccacccatgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 atcaccaacgacaaaaaaagctgatgtccacaacgtcagatcggtccgtgtccgtgtccgt  
 agcatcatcaaggaagaagtcctggctacgtcgacgtccgtgtacggcgatcgacaccccttgc  
 tggaaagctgcacacccctggctgtccgtgtccgtgtccgtgtccgtgtccgt  
 gaccggggctgttactgcgacaacgcggctccgtgtcccttcgtggccgagacatcgac  
 gaggtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 15

tccaaaccgggtgttctgcgacaccatgaactccctgaccctgcctccggatgtgacacatcgac  
 atcttcaaccccaagtacgactgcaagatcatgaccagcaagaccgacgtgtccctcagcgtgatcacctcc  
 ctggcgccatcggtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 accttctcaacccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 tacgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 gtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 atcccgaaagtccgacgagaagctgcataacgtggagggatcgaaagatccgtgtccgtgtccgtgtccgt  
 atcgagaacgagatcgccggatcaagaagctgatcggtggcgacttccacttcgtgtccgtgtccgt  
 aagcagcggcagaacaagcttcaacaagcccaacaacgacttccacttcgtgtccgtgtccgtgtccgt  
 tgctccatctgtccacaacccctactgtgtccgtgtccgtgtccgtgtccgtgtccgtgtccgt  
 aaaaccaccaccaagcctaccaagaacgcctacccatcaagaccaccaagaaggaccacaaggcc  
 aacccatcaccactgataatcta

Seq ID NO:8

PreFG\_V1 peptide for CHO

MELLILKTNIAITAILAAVTLCFASSQNITEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGT  
 DAKVKLIKQELDKYKSAVTELQLMQSTPATNNKFLGFLGVGSIAISGIAVSKVLHLEGEVNKIKSALLS  
 TNKAVVSLNSNGVSVLTSKVLDDKNYIDKQLLPIVNQKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTT  
 35 PVSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVILAYVQPLYGVIDTPCWKLH  
 TSPLCTNTKEGSNCLTRTDRGWYCDNAGSVSFPLAETCKVQSNRVFCDTMNSLTLPEVNLCNIDIFNP  
 KYDCKIMTSKTDVSSSVITSLGAIIVSCYGKTKCTASNKNRGIIKTFSNGCDYVSNKGVDTVSVGNTLYVNK  
 QEGKSLYVKGEPIINFYDPLVFPSEFDASISQVNEKINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENE  
 IARIKKLIGEAGGSGGSGGSKQRQNKPNNDFHFEVFNFVPCSICSNNPTCWAICKRIPNKKPGKTTT  
 40 KPTKKPTFKTTKDHKPQTTKPKEVPTTK

Seq ID NO:9

Nucleotide Sequence encoding PreFG\_V2 for CHO

45

50

55

5 aagcttgcaccatggagctgtatcctcaagaccaacgcacccatcaccgcacccatctggccgtgacccttgcttcggccgtac  
ctgtccgcctccagaacatcaccgaagagtttaccatcgatcaccatcgagctgtccaacatcaaagaaaacaag  
tgcaacgcaccgacgcaaggtaagctgtatcaagcaggaactggacaagttacaagagcgcgtgaccgaa  
ctccagctgtatgcagtccacccctgcaccaacaagaagttctggcttctgtctggcgtggcc  
tccgccatgcctccggcatgcggctgagaaggctgtgcacctggagggcgaggtgaacaagatcaagagc  
gccctgtgtccaccaacaaggccgtgggtccctgtccacggcgtgtccgtctgacccatcaaggtgctg  
gatctgaagaactacatcgacaaggcagctgtgcctatcgtaacaaggcagtcctgtccatctccaacatc  
gagaccgtgatcgagggtccacccatcgatgtccacccatcgatgtccacccatcgatgtccatcgacccatcg  
ggcgtgaccacccctgtgtccacccatcgatgtccacccatcgatgtccacccatcgatgtccatcgacccatcg  
atcaccaacgaccaaaaaaaagctgtatgtccacccatcgatgtccacccatcgatgtccacccatcg  
agcatcatcaaggaagaaggctgtccacccatcgatgtccacccatcgatgtccacccatcg  
tggaaagctgcacacccatccccctgtgcaccaccaacacccaaaggaggcttccacatctgcctgaccggacc  
gaccggggctggactcgaccaacgcggctccgttccttctcccttgccgagacactgcaaggtgca  
tccaacccgggtttctgcacccatgaactccctgaccctgcctccgaggtgaactctgtgcacacatcgac  
atctcaaccccaagtgactcgactgcacccatgcaccacccatcgatgtccctccagctgtatcacctcc  
ctggggccatcgatgtccctgtacggcaagaccaaggcgtgcaccgcctccacacaaggacccggaaatcatcaag  
acccatcgatgtccacccggatcgactacgtgtccacccatcgatgtccacccatcgatgtcccttgccgagacactgtac  
tacgtgaataagcaggaaggcaagacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
gtgttcccttcgcacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
atccggaaatcgacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
atcgagaacgacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
cctaacaacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
cctacccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
aagaaggccatcgatgtccacccatcgatgtccacccatcgatgtcccttgcc  
accaaggccatcgatgtccacccatcgatgtcccttgcc

Seq ID NO:10  
PreFG\_V2 peptide for CHO

30 MELLILKTNIAITAILAAVTLCAFSSQNITEEFYQSTCSAVSKGYSALRTGWTTSVITIELSNIKENKCNGT  
DAKVKLICKQELDKYKSAVTELQLLMQSTPATNNKKFLGFLLGVSIAIASGIAVSKVLHLEGEVNKIKSALLS  
TNKAVVSLNSNGVSVLTSKVLIDLKNYIDKQLLPIVNKQSCSISNIETVIEFQQKNNRLLEITREFSVNAGVTT  
PVSTYMLTNSELLSILINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVLAYVVQLPLYGVIDTPCWCWKLH  
35 TSPLCTTNTKEGSNICLRTDRGWYCDNAGSVSFFPLAETCKVQSNRVCDFTMNSLTLPSEVNLCNIDIFNP

KYDCKIMTSKTDVSSSVITSLGAI VSCY GKTCTASNKNRGI KTFNSNGCDYVSNKGVDTVSVGNTLYVNQ  
QEGKSLYVKGEPI INFYDPLVFP SDEF DASISQVNKEINQSLAFIRKSDEKLHNVEDKIEEILSKIYHIENE  
IARIKKLIGEAGGGKQRQNKP PPNKPNNDFHFEVFN FVPCSIC SNNPTCWAICKRIPNKKPGKTTKPTKPT  
FKTTKKDHKPQTTKPKEVPTTK

SEQ ID NO:11  
Exemplary coiled-coil (isoleucine zipper)  
EDKIEEILSKIYHIENEIARIKKLIGEA

45 SEQ ID NO:12  
PreF antigen polynucleotide CHO2

50

55

5 atggagctgcccattcctgaagaccaacgcacatcaccaccatccgcgcgtgaccctgtgcttcgcccagg  
agccagaacatcacggaggagtctaccagagcacgtgcagcgcgtgagcaagggtcacctgagcgcgctg  
cgcacgggctggtacacgagcgtatcacgatcgagctgagcaacatcaaggagaacaagtgcacgcac  
gacgcgaaggtgaagctgatcaagcaggagctggacaagttacaagagcgcgggtacggagctgcagctgctg  
atgcagagcacgcggcgacgaacaacaagttccctcggttccctgtggggcgtggcagcgcgatcgcgagc  
ggcatcgcgtgagaaggtgtcacctggagggcagggtaacaagatcaagtcgcgtgtgagcagc  
aacaaggcggtcgtaggcctgagcaacgcgtgagcgtgtgacgagcaaggtgtcgacactgaagaactac  
atcgacaaggcagctgtccgatcgtgaacaaggcagagctgcagcatcagaacatcgagaccgtgatcgag  
ttccagcagaagaacaaccgcgtctggagatcacgcggagttctccgtgaacgcaggcgtgacgcacccc  
gtgtctacgtacatgtgacgaacagcagcgtctcagcgtatcaacgcacatgcgcgtacacgacc  
aagaagctgatgagcaacaacgtgcagatcgtgcgcacgcagagctacagcatcatgagcatcatcaaggag  
gaggtgtccatacgtggcagctgcccgtgtacggcgtatcgcacgcgcgtgtggaaagctgcacac  
agcccgctgtgcacgaccaacacgaaggaggcagcaacatctgcgtgcgcggacggaccgggctggta  
tgcgacaacgcggcagcgtgagcttccctgcgcggagacgtgcaaggtgcagagcaacccgtcttc  
tgcgacacgatgaacacgcgtgcgcgagcgtgaggtgaaacctgtgcaacatcgacatctcaacccgaag  
tacgactgcaagatcatgacgagcaagacgcgtgtcagcagcgcgtatcagcgcgcgt  
agctgctacggcaagacgaaagtgcacggcagcaacaagaaccgcggcatcatcaagacgttca  
tgcgactatgtgagcaacaaggcgtggacactgtgagcgtcggcaacacgcgtactacgt  
gagggcaagacgcgtacgtgaagggcagccgatcatcaacttctacgacccgcgtgttcccgagc  
gagttcgcacgcgagcatcagccaagtgaacgagaagatcaaccagagcgcgttcatccgca  
gagaagctgcacaacgtggaggacaagatcgaggagatcgtgagcaagatctaccacatcgaga  
acgcgcacatcaagaagctgatcggcgaggcgcacatcattaccatcaccattga

SEQ ID NO:13  
PreF antigen polynucleotide with intron  
25  
atggagctgctgatcctgaaaaccAACGCCatcaccGCCatcctggccgcgtgaccctgtgcttcgcctcc  
tcccagaacatcaccggaggagtctaccagtccacatgcgtccgcgtgtccaaagggtacactgtccgcctcg  
30  
cgaggccggctggtacacccctcgatcaccatcgagctgtccaaacatcaaggaaaacaagtgcAACGCCacc  
gacGCCaaggtaagctgatcaaggcaggagctggacaaggtaacaagagcgcgcgtgaccgaactccagctgt  
atgcagtccaccctgcccaccaacaacaaaggatctgggcttcctgtgggcgtggctccgcattcgccatcgcc  
35  
ggcatcgccgtgagaaggtaacgtgtcgggacttgcgttcccttttaataaaaaaggatataatcttaat  
gttatatacatatttctgtatgtgatccatgtgcttatgacttgcgttcatgtgttaggtgtgcacc  
tggaggccggaggtaacaagatcaaggcgcctgtgtccaccaacaaggccgtgggtccctgtccaaac  
gcgtgtccgtgctgacccctcaagggtctggatctgaagaactacatcgacaaaggcgtctgcctatcgta  
acaaggcagtccgtctccatctccaaacatcgaggaccgtgatcgaggatccagcagaagaacaaccggctgtgg  
40  
agatcccccgcgaggctccgtgaccccgccgtgaccaccctgtgtccacccatgctgaccaactcc  
agctgtgtccctgatcaacgcacatgcctatcaccaacgaccaggaaaaactgtatgtccaccaacgtgcaga  
tcgtgcggcagcagtcctacagcatcatgagcatcatcaaggaaagggtgtggctacgtggcagctgc  
ctctgtacggcgtgatcgacaccctgtgtggaaaggctgcacacccctgtgcaccaccaacaccagg  
45  
aggcgtccaaacatctgcctgaccggaccggaccggggctgttactgcgacacccggctccgtgtccct  
tccctctggccgagacctgcaagggtcagtcacccgggtgttctgcgacaccatgaactccctgaccctgc  
cttccggaggtaacccgtgtcaacatcgacatctcaaccccaaggtaacgtgacactgcacatgaccaggcaaga  
ccgacgtgtccctccagcgtgatcaccctggccatcggtctgtgtacggcaaggaccaggtaacgtgcacc  
cctccaaacaaaggaccggggaaatcatcaaggaccccttcacccggctgcgactacgtgtccaaataaggccgtgg  
acaccgtgtccgtggcaacacactgtactacgtgaataaggaggaggcaaggccgtacgtgaaggcc  
50  
aggcctatcatcaactctacgaccctctgggtttccctccgacgaggatccgcacgcgcctccatcagccaggta  
acgagaagatcaaccaggccctggccttcatccggaaaggccgcacgagaaggctgcataacgtggaggacaaga  
tcgaggagatccctgtccaaaatctaccacatcgagaacgagatcgcccgatcaagaaggctgtacgtgaaggcc  
ccggagggtcaccaccacatcaccactga

50 SEQ ID NO:14  
Synthetic linker sequence  
GGSGGGSGGS

55 SEQ ID NO:15  
Furin cleavage site  
RARR

SEQ ID NO:16

Furin cleavage site

RKRR

SEQ ID NO:17

5 Nucleotide Sequence encoding PreF\_NGTL

atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgcgtgaccctgtgcttcgcctcc  
 tcccaacatcaccgaggagttctaccaggatcaccatcgagctgtcccaacatcaaggaaaacaagtgcacggcacc  
 10 cggaccggctggatcacccctcgatcaccatcgagctgtcccaacatcaaggaaaacaagtgcacggcacc  
 gacgcaccaaggtgaagctgatcaagcaggagctggacaagtgacaaggagcgcgcgtgaccgaactccagctgctg  
 atgcagttccacccctgcccaccacaacaagttctggcttcgtctggcgtggctccgcctcc  
 15 ggcacatcgccgtgagcaagggtgtcaccctggaggggcaggtgaacaagatcaagagcgcgcctgtgtccacc  
 aacaaggccgtgggtccctgtcccaacggcgtgtccgtctggatctgaagaactac  
 atcgacaaggcagctgtccatcgtaacaagcagtcctgtccatctccaaacatcgagacaccgtatcgag  
 ttccagcagaagaacaaccggctgtggagatcaccccgagttctccgtgaacgcgcgtgaccaccct  
 20 gtgtccacccatcgatcgaccactccgagctgtgtccctgtatcaacgcacatgcctatcacaacgcacc  
 aaaaaactgtatgtccaaacacgtgcagatcgtgcggcagcagtcctacagcatcatgagcatcatcaaggaa  
 gaggtgtggcctacgtggcagctgcctctgtacggcgtgatcgacacccctgtggaaagctgcacacc  
 tccccctgtgcaccaccaacaccaaggagggtccaaacatcgctgaccggaccgaccggggctggta  
 25 tgcacacaacgcggctccgtgtccctctccctggccgagacctgcaagggtgcagttccaaacccgggttcc  
 tgcacaccatgaactccctgaccctgcctccgagggtgaacctgtgcaacatcgacatctcaacccaaag  
 tacgactgcaagatcatgaccaggcaagaccgcacgtgtccctcagcgtgatcacctccctggcgcctatcg  
 30 tcctgctacggcaagaccaagtgcaccgcctccaaacagaacccgggaatcatcaagacaccccttc  
 tgcaactacgtgtccaaataaggcggtggacaccgtgtccgtggcaacacactgtactacgtgaataagc  
 gagggcaagagcctgtacgtgaaggcgagcctatcatcaacttctacgaccctctgggttccctcc  
 35 gagttcgacgcctccatcagccaggtgaacgagaagatcaacggaccctggccatccgaaagtc  
 gagaagctgcataacgtggaggacaagatcgaggagatcctgtccaaatctaccacatcgagaacgc  
 gcccggatcaagaagctgatcgccggcc

SEQ ID NO:18

30 Amino Acid Sequence of PreF\_NGTL

MELLILKTNAITAILAAVTLCFASSQNI~~TEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGT~~  
 DAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLGVGSIAISGIAVSKVLHLEGEVNKIKSALLST  
 35 NKAVVSLNSNGVSVLTSKVLDLKNYIDKQLLPIVNQKQSCSISNIETVIEFQQKNNRILEITREFSVNAGVTP  
 VSTYMLTNSELLSLINDMPITNDQKKLMSNNVQIVRQQSYSIMSIIKEEVILAYVQLPLYGVIDTPCWKLHT  
 SPLCTTNKEGSNCLTRTDRGWYCDAGSVSFFPLAETCKVQSNRVCFCDMNSLTLPSEVNLCNIDIFNPK  
 YDCKIMTSKTDVSSVITSGLAIVSCYGKTKCTASNKNRGIIKTFNSNGCDYVSNKGVDTVSVGNL~~YYVNQ~~  
 EGKSLYVKGEPIINFYDPLVFP~~DEF~~DAISQVNEKINGTLAFIRKSDEKLHNVEDKIEEILSKIYHIENEI  
 ARIKKLIGEA

40

SEQ ID NO:19

Nucleotide Sequence encoding PreF\_L112Q

45

atggagctgctgatcctgaaaaccaacgccatcaccgccatcctggccgcgtgaccctgtgcttcgcctcc  
 tcccaacatcaccgaggagttctaccaggatcaccatcgagctgtcccaacatcaaggaaaacaagtgcacggcacc  
 cggaccggctggatcacccctcgatcaccatcgagctgtcccaacatcaaggaaaacaagtgcacggcacc  
 gacgcaccaaggtgaagctgatcaagcaggagctggacaagtgacaaggagcgcgcgtgaccgaactccagctgctg  
 atgcagttccacccctgcccaccacaacaagttctggcttcgtctggcgtggctccgcctcc  
 50 ggcacatcgccgtgagcaagggtgtccctgtccaaacggcgtgtccgtgatcaccatctccaaacatcgagacaccgtatcgag  
 aacaaggccgtgggtccctgtccaaacggcgtgtccgtgatcaccatctccaaacatcgagacaccgtatcgag  
 atcgacaaggcagctgtccatcgtaacaagcagtcgtccctgcacatcgagacaccgtatcgag  
 ttccagcagaagaacaaccggctgtggagatcaccccgagttctccgtgaacgcgcgtgaccaccct  
 gtgtccacccatcgatcgaccactccgagctgtgtccctgtatcaacgcacatgcctatcacaacgcacc  
 aaaaaactgtatgtccaaacacgtgcagatcgccggcagcagtcctacagcatcatcaaggaa

55

5 gaggtgctggctacgtggcagctgcctctgtacggcgtatgcacacccctgtggaaagctgcacacc  
tccccctgtgcaccaccaacaccaaggaggcgtccacatctgcctgaccggaccggggctggta  
tgcgacaacgcggcgtccgttccttccctctgcccggagacactgcaaggtgcagtccaaaccgggtttc  
tgcgacaccatgaactccctgaccctgccttccggaggtgaacctgtgcaacatcgacatcttcaacccaaag  
tacgactgcaagatcatgaccagcaagacccgacgtgtccctccacgcgtatcacccctggccatcg  
tcctgtctacggcaagaccaagtgcaccgcctccaacaagaacccggaaatcatcaagaccccttccaaacggc  
tgcgactacgtgtccataaggcggtggacaccgtgtccgtggcaacacactgtactacgtgaataagcag  
gagggcaagagcctgtacgtgaaggcgagcctatcatcaacttctacgaccctctgtgttcccttccgac  
gagttcgacgcctccatcagccaggtgaacgagaagatcaaccagtccctggccttcatccggaaagtccgac  
gagaagctgcataacgtggaggacaagatcgaggagatctgtccaaaatctaccacatcgagaacgagatc  
10 gcccggatcaagaagctgatcgccgaggcc

SEQ ID NO:20  
Amino Acid Sequence of PreF\_L112Q

15 MELLILKTNAITAILAAVTLCFASSQN<sup>1</sup>TEEFYQSTCSAVSKGYLSALRTGWYTSVITIELSNIKENKCNGT  
DAKVKL<sup>1</sup>IKQELDKYKSAVTELQLLMQSTPATNNKFLGFLQVGSAIASGIAVSKVLHLEGEVNKIKSALLST  
NKA<sup>1</sup>VSLSGVS<sup>1</sup>VLTSKVL<sup>1</sup>DLKNY<sup>1</sup>DKQLP<sup>1</sup>IVNKQSCS<sup>1</sup>SNIE<sup>1</sup>TFQ<sup>1</sup>QKNNR<sup>1</sup>LEITREFSVNAGVTTP  
20 VSTYMLTNSELLS<sup>1</sup>INDMP<sup>1</sup>TN<sup>1</sup>DQKKLMSNNVQIVRQQS<sup>1</sup>YS<sup>1</sup>IMSI<sup>1</sup>KEEV<sup>1</sup>LAYV<sup>1</sup>VQLPL<sup>1</sup>YGV<sup>1</sup>DT<sup>1</sup>PCWKL<sup>1</sup>H<sup>1</sup>  
SPLCTNTKEGSN<sup>1</sup>CLTRTDRGWYCDNAGSV<sup>1</sup>FFPLAETCKVQSNRVFC<sup>1</sup>DMNS<sup>1</sup>TL<sup>1</sup>PSEVNL<sup>1</sup>CN<sup>1</sup>ID<sup>1</sup>FNP<sup>1</sup>  
YDCKIMTSKTDV<sup>1</sup>SS<sup>1</sup>VITSLGAIV<sup>1</sup>SCYG<sup>1</sup>KTKCTAS<sup>1</sup>KNR<sup>1</sup>GI<sup>1</sup>KT<sup>1</sup>FSNGCDYV<sup>1</sup>SNKG<sup>1</sup>V<sup>1</sup>D<sup>1</sup>T<sup>1</sup>V<sup>1</sup>SG<sup>1</sup>NT<sup>1</sup>LYYV<sup>1</sup>NK<sup>1</sup>  
EGK<sup>1</sup>SLYV<sup>1</sup>KGEPI<sup>1</sup>INFYDPLV<sup>1</sup>FPSDEF<sup>1</sup>DAS<sup>1</sup>ISQVNE<sup>1</sup>KINQSLAF<sup>1</sup>IRKS<sup>1</sup>DEKL<sup>1</sup>H<sup>1</sup>N<sup>1</sup>V<sup>1</sup>ED<sup>1</sup>K<sup>1</sup>IEE<sup>1</sup>I<sup>1</sup>LSK<sup>1</sup>IY<sup>1</sup>H<sup>1</sup>IE<sup>1</sup>NI<sup>1</sup>  
ARIKKLIGEA

25 SEQ ID NO:21  
Nucleotide Sequence encoding PreF NGTL L112Q

30 atggagctgatccctgaaaaccaacgcacccatcaccggccatctggccgcgtgaccctgtgcttcgcctcc  
tcccagaacatcaccgaggagtctaccatccacgtccacgtccgcgtgtccaagggtacctgtccgcctcc  
cgagccggctggtacacccctcgatcaccatcgagctgtccaacatcaaggaaaacaagtgcacacggcacc  
gacgccaaggtaagctgatcaagcaggagctggacaagtaaaagagcgcgtgaccgaactccagctgctg  
atgcagtccacccctgcccaccaacaacaagtttctggcttcctgcagggcgtgggtccgcctccatgcctcc  
ggcatcgccgtgagcaagggtctgcacctggagggcggaggtgaaacaagatcaagagcgcctgtgtccacc  
aacaaggccgtggtgtccctgtccaacggcgtgtccctgacccctcaaggtctggatctgaagaactac  
atgcacaaggcagctgtgcctatcgtaacaaggcagtcgtccatctccaacatcgagaccgtgatcgag  
ttccagcagaagaacaacccggctgctggagatcaccgcgagttctccgtgaacgcggcgtgaccacccct  
gtgtccacccatgtgaccaactcccgagctgtgtccctgatcaacgcacatgcctatccaacacgaccag  
aaaaaaactgtatgtccaaacaacgtgcagatcgccggcagcagtcgtccatcagcatcatgagcatcatcaaggaa  
gaggtgtccgttgcacgtggcagctgcctctgtacccgtgatcgacaccccttgcgtggaaagctgcacacc  
tccccccctgtgcacccaccaacaccaaggagggctccaacatctgcctgaccggaccggggctgttac  
tgcgacacccatgtgacccatgtccgttgcacccgtccgttccgaggtgaaacctgtgacacatcgacatcttcaaccccaag  
tacgactgaccaagatcatgaccagcaagacccgtgtccacgcgtgatcacccctggcgccatcg  
tcctgtgtccgttgcacccgtccgttgcacccgtccgttccgaggtgaaacctgtgacacatcgacatcttcaaccccaag  
tgcgactacgtgtccaaataaggccgtggacaccgtgtccgtggcaacacactgtactacgtgaaataagcag  
gagggcaagagccctgtacgtgaagggcggcgcacccatcatcaacttctacgaccctctgggtgttccctccgac  
gagttcgacgcctccatcagccaggtaacgagaagatcaacgggaccctggccttcatccgaaagtccgac  
gagaagctgcataacgtggaggacaagatcgaggagatcgtccaaatctaccacatcgagaacgagatc  
ggccggatcaagaagctgatcgccggc

50 SEQ ID NO:22  
Amino Acid Sequence of PreF\_NGTL\_L112Q

MELLILKTNAITAILAAVTLCAASSQNI~~TEEFY~~QSTCSAVSKGYLSALRTGWT~~SVIT~~IELSNIKENKCNGT  
 DAKVKLIKQELDKYKSAVTELQLLMQSTPATNNKFLGFLQGVGSAIASGIAVSKVLHLEG~~EVNKIKSALL~~ST  
 NKAVVSLNSNGVS~~VL~~TSKVLDLKNYIDKQLLPIVNQSCSISNIETVIEFQ~~QKNNR~~LLEITREFSVNAGVT~~TP~~  
 5 SPLCTTN~~T~~KEGSNICLRTDRGWYCDNAGSVSFFPLAETCKVQS~~NR~~FC~~TM~~NSLTLPSEVNLCNIDIFNPK  
 YDCKIMTSKTDVSSSVITSLGAI~~V~~SCY~~G~~KTKCTAS~~N~~KNRGI~~I~~KTF~~S~~NGCDY~~V~~SNKG~~D~~TV~~S~~VG~~N~~TLYVNQ  
 EGKSLYV~~K~~GEPI~~I~~NFYDPLVFP~~S~~DEF~~D~~ASISQVN~~E~~INGTLAFIRKSDEKLHNVEDKIEEILSKIYH~~I~~NEI  
 ARIKKLIGEA

10

## SEQUENCE LISTING

## [0150]

15 <110> GlaxoSmithKline Biologicals S.A.  
 ID Biomedical Corporation of Quebec  
 BAUDOUX, Guy J-M  
 BLAIS, Normand  
 Rheault, Patrick  
 20 RUELLE, Jean-Louis  
 CYR, Sonya

<120> Recombinant RSV Antigens

25 <130> VU62788-1 PCT

<150> 61/219,964  
 <151> 2009-06-24

30 <150> 61/334,568  
 <151> 2010-05-13

<160> 22

35 <170> PatentIn version 3.5

<210> 1  
 <211> 1697  
 <212> DNA  
 40 <213> respiratory syncytial virus

<400> 1

45

50

55

	atggagttgc taatcctcaa agcaaatgca attaccacaa tcctcaactgc agtcacattt	60
	gttttgcttc tggtaaaaac atcactgaag aatttttatca atcaacatgc agtgcagtag	120
5	caaaggctat ctttagtgctc tgagaactgg ttggtataacc agtgttataa ctatagatta	180
	agtaatatca aggaaaataa gtgtaatgga acagatgcta aggtaaaatt gataaacaag	240
	aatttagataa atataaaaat gctgtAACAG aattgcagtt gctcatgcaa agcACCCAGC	300
10	aacaaacaat cgagccagaa gagaactacc aaggTTATG aattatacac tcaaaatGCC	360
	aaaaaaACCA atgtAACATT aagcaagaaa aggaaaAGAA gatttCTTGG tttttGTTAG	420
15	gtgttggatc tgcaatcgcc agtggcgTTG ctgtatctaa ggtcctgcac ctgaAGGGGA	480
	agtgaacaag atcaaaaAGT ctctactatC cacaACACAA gctgtAGTCA gttatCAAAT	540
	ggagttAGTg tcttaACCAG caaaAGTGTa gacCTCAAAA actatataGA aaACAATTGT	600
20	tacctATTGT gaacaAGCAA agCTGCAGCA tatCAAATAT agcaACTGTA tagAGTTCCA	660
	acaaaAGAAC aacAGACTAC tagAGATTAC cAGGGAATTt agtGTTAAGC aggtGTAact	720
	acACCTGTAa gcACTTACAT GTTAACtAAT agtGAATTAT tGTCATTATC aatGATATGC	780
25	ctataACAAA tGATCAGAAA aAGTtaATGT ccaACAAATGT tcaAAATGTa gacAGCAAAG	840
	ttACTCTATC atGTCATAA taaaAGAGGA agtCTTAGCA tatGtGTACA attACCACTA	900
	tatGGTGTta tagataCACc CTGTTGGAAA CTACACACAT CCCCCATGT acaACCAACa	960
30	caAAAGAAGG GTCCAACATC tGTTAACAA gaACTGACAG aggtGGTACT GTGACAATGC	1020
	aggATCAGTA tCTTCTTCC cacaAGCTGA AACATGTAAA GTCAATCAAAC TCGAGTATTt	1080
35	tgtgacacAA tgaACAGTT AACATTACCA agtGAAGTAA actCTGCAAT gttGACATAT	1140
	tcaACCCAA atATGATTGT AAAATTATGA CTTCAAAAAC gatGTAAGCA gCTCCGTTAT	1200
	cACATCTCTA ggAGCCATTG tGTCATGCTA tggCAAAACA aatGTAACAGC atCCAAATAAA	1260
40	aATCGTGGAA tCATAAAGAC ATTTCTAAC gggTGCgATA tGtATCAAAT aaAGGGTGG	1320
	acACTGTGTC tGTAAGTAAc ACATTATATT ATGTAAAAAG CAAGAAGGTA aaAGTCTCTA	1380
	tGTAAAAGGT GAACCAATAA TAAATTCTA tGACCCCTAG tATTCCCTC tGATGAATTt	1440
45	gatGcatCAA tATCTCAAGT CAACGAGAAg ATTAACAGAG CCTAGCATTt ATTCTGTAAT	1500
	CCGATGAATT ATTACATAAT GTAAATGCTG gtaatCCACC ATAAATATCA tGATAACTAC	1560
	tATAATTATA GTGATTATAG TAATATTGTT ATCTTAATTG CTGTTGGACT GCTCTTATAC	1620
50	tGTaAGGCCA GAAGCACACC AGTCACACTA AGAAAGATCA ACTGAGTGGT ATAAATAATA	1680
	ttGCAATTAG TAACTAA	1697
55	<210> 2	
	<211> 574	
	<212> PRT	
	<213> respiratory syncytial virus	

&lt;400&gt; 2

5	Met Glu Leu Leu Ile Leu Lys Ala Asn Ala Ile Thr Thr Ile Leu Thr 1 5 10 15
10	Ala Val Thr Phe Cys Phe Ala Ser Gly Gln Asn Ile Thr Glu Glu Phe 20 25 30
15	Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu 35 40 45
20	Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile 50 55 60
25	Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys 65 70 75 80
30	Gln Glu Leu Asp Lys Tyr Lys Asn Ala Val Thr Glu Leu Gln Leu Leu 85 90 95
35	Met Gln Ser Thr Pro Ala Thr Asn Asn Arg Ala Arg Arg Glu Leu Pro 100 105 110
40	Arg Phe Met Asn Tyr Thr Leu Asn Asn Ala Lys Lys Thr Asn Val Thr 115 120 125
45	Leu Ser Lys Lys Arg Lys Arg Arg Phe Leu Gly Phe Leu Leu Gly Val 130 135 140
50	
55	

Gly Ser Ala Ile Ala Ser Gly Val Ala Val Ser Lys Val Leu His Leu  
 145 150 155 160

5 Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr Asn Lys  
 165 170 175

10 Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser Lys Val  
 180 185 190

15 Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile Val Asn  
 195 200 205

20 Lys Gln Ser Cys Ser Ile Ser Asn Ile Ala Thr Val Ile Glu Phe Gln  
 210 215 220

25 Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser Val Asn  
 225 230 235 240

30 Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn Ser Glu  
 245 250 255

35 Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln Lys Lys  
 260 265 270

40 Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr Ser Ile  
 275 280 285

45 Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln Leu Pro  
 290 295 300

50 Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr Ser Pro  
 305 310 315 320

55 Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu Thr Arg  
 325 330 335

Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser Phe Phe  
 340 345 350

Pro Gln Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe Cys Asp  
 355 360 365

Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys Asn Val  
 370 375 380

Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser Lys Thr  
 385 390 395 400

Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val Ser Cys  
 405 410 415

5 Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly Ile Ile  
 420 425 430

10 Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly Val Asp  
 435 440 445

Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln Glu Gly  
 450 455 460

15 Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr Asp Pro  
 465 470 475 480

20 Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln Val Asn  
 485 490 495

25 Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp Glu Leu  
 500 505 510

Leu His Asn Val Asn Ala Gly Lys Ser Thr Ile Asn Ile Met Ile Thr  
 515 520 525

30 Thr Ile Ile Ile Val Ile Ile Val Ile Leu Leu Ser Leu Ile Ala Val  
 530 535 540

35 Gly Leu Leu Leu Tyr Cys Lys Ala Arg Ser Thr Pro Val Thr Leu Ser  
 545 550 555 560

Lys Asp Gln Leu Ser Gly Ile Asn Asn Ile Ala Phe Ser Asn  
 565 570

40 <210> 3  
 <211> 897  
 <212> DNA  
 <213> respiratory syncytial virus

45 <400> 3

50

55

atgtccaaaa acaaggacca acgcaccgct aagacactag aaaagacctg ggacactctc	60
aatcatttat tattcatatc atcgggctta tataagttaa atcttaaatc tatagcaca	120
5 atcacattat ccattctggc aatgataatc tcaacttcac ttataattac agccatcata	180
ttcatagcct cggcaaacca caaagtacaca ctaacaactg caatcataca agatgcaaca	240
10 agccagatca agaacacaac cccaacatac ctcactcagg atcctcagct tggaatcagc	300
ttctccaatc tgtctgaaat tacatcacaa accaccacca tactagttc aacaacacca	360
ggagtcaagt caaacctgca acccacaaca gtcaagacta aaaacacaac aacaacccaa	420

15 acacaaccca gcaagcccac tacaaaacaa cgccaaaaca aaccacccaa caaacccaa	480
aatgatttc acttcgaagt gtttaacttt gtaccctgca gcataatgcag caacaatcca	540
20 acctgctggg ctatctgcaa aagaatacca aacaaaaaaac cagggaaagaa aaccaccacc	600
aaggctacaa aaaaaccaac cttcaagaca accaaaaaaag atctcaaacc tcaaaccact	660
aaacccaaagg aagtacccac caccaagccc acagaagagc caaccatcaa caccaccaa	720
25 acaaacatca caactacact gtcaccaac aacaccacag gaaatccaaa actcacaagt	780
caaatggaaa cttccactc aacccctcc gaaggcaatc taagcccttc tcaagtctcc	840
acaacatccg agcaccatc acaaccctca tctccacccca acacaacacg ccagtag	897

30  
 <210> 4  
 <211> 298  
 <212> PRT  
 35 <213> respiratory syncytial virus

40 <400> 4

45

50

55

Met Ser Lys Asn Lys Asp Gln Arg Thr Ala Lys Thr Leu Glu Lys Thr  
 1 5 10 15

5 Trp Asp Thr Leu Asn His Leu Leu Phe Ile Ser Ser Gly Leu Tyr Lys  
 20 25 30

10 Leu Asn Leu Lys Ser Ile Ala Gln Ile Thr Leu Ser Ile Leu Ala Met  
 35 40 45

Ile Ile Ser Thr Ser Leu Ile Ile Thr Ala Ile Ile Phe Ile Ala Ser  
 50 55 60

15 Ala Asn His Lys Val Thr Leu Thr Thr Ala Ile Ile Gln Asp Ala Thr  
 65 70 75 80

20 Ser Gln Ile Lys Asn Thr Thr Pro Thr Tyr Leu Thr Gln Asp Pro Gln  
 85 90 95

25 Leu Gly Ile Ser Phe Ser Asn Leu Ser Glu Ile Thr Ser Gln Thr Thr  
 100 105 110

Thr Ile Leu Ala Ser Thr Thr Pro Gly Val Lys Ser Asn Leu Gln Pro  
 115 120 125

30 Thr Thr Val Lys Thr Lys Asn Thr Thr Thr Gln Thr Gln Pro Ser  
 130 135 140

35 Lys Pro Thr Thr Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro Asn  
 145 150 155 160

Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile Cys

40

45

50

55



	aagcttgcca ccatggagct gctgatcctg aaaacccaacg ccatcaccgc catcctggcc	60
	gcccgtgaccc tgtgcttcgc ctccctccag aacatcaccg aggagttcta ccagtcacc	120
5	tgcctccggc tgcccaaggg ctacctgtcc gccctgcega ccggctggta cacctccgtg	180
	atcaccatcg agctgtccaa catcaaggaa aacaagtgca acggcaccga cgccaagggtg	240
	aagctgatca agcaggagct ggacaaagtac aagagcgcgg tgaccgaact ccagctgctg	300
10	atgcagtcca cccctgcccac caacaacaag tttctggct tcctgctggg cgtgggctcc	360
	gccatcgctt ccggcatcgc cgtgagcaag gtgctgcacc tggagggcga ggtgaacaag	420
15	atcaagagcg ccctgctgtc caccaacaag gccgtgggtgt ccctgtccaa cggcgtgtcc	480
	gtgctgacctt ccaaggtgtt ggatctgaag aactacatcg acaaggagct gtcgttac	540
	gtgaacaaga agtccctgtc catctccaac atcgagaccg tgatcgagtt ccagcagaag	600
20	aacaaccggc tgcggagat cacccgcgag ttctccgtga acgcccgggt gaccaccct	660
	gtgtccacctt acatgctgac caactccgag ctgctgtccc tgatcaacga catgcctatc	720
	accaacgacc agaaaaaaact gatgtccaac aacgtgcaga tcgtgcggca gcagtcctac	780
25	agcatcatga gcatcatcaa ggaagaggtg ctggcttacg tggtgcagct gcctctgtac	840
	ggcgtgatcg acaccccttg ctggaaagctg cacacctccc ccctgtgcac caccaacacc	900
	aaggagggtt ccaacatctg cctgaccgg accgaccggg gctggtaactg cgacaacgcc	960
30	ggctccgtgt ccttcttccc tctggccgag acctgcaagg tgcagtccaa ccgggtgttc	1020
	tgcgacaccca tgaactccct gaccctgcct tccgaggtga acctgtgcaaa catcgacatc	1080
	ttcaacccca agtacgactg caagatcatg accagcaaga ccgacgtgtc ctccagcgtg	1140
35	atcacctccc tggcgccat cgtgtctgc tacggcaaga ccaagtgcac cgcctccaac	1200
	aagaaccggg gaatcatcaa gaccttctcc aacggctgcg actacgtgtc caataagggc	1260
	gtggacacccg tgcgtgtggg caacacactg tactacgtga ataagcagga gggcaagagc	1320
40	ctgtacgtga agggcgagcc tatcatcaac ttctacgacc ctctgggttt cccttccgac	1380
	gagttcgacg cctccatcag ccaggtgaac gagaagatca accagtcctt ggccttcatc	1440
	cggaagtccg acgagaagct gcataacgtg gaggacaaga tcgaggagat cctgtccaaa	1500
45	atctaccaca tcgagaacga gatcgccgg atcaagaagc tgatcgccga ggcctgataa	1560
	<b>tctaga</b>	1566

50        <210> 6  
       <211> 514  
       <212> PRT  
       <213> Artificial Sequence

55        <220>  
       <223> Recombinant PreF Antigen

<400> 6

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
1 5 10 15

5 Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
20 25 30

10 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
35 40 45

Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
50 55 60

15 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
65 70 75 80

20 Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
25

30

35

40

45

50

55

	85	90	95
5	Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Phe Leu Gly Phe Leu Leu 100	105	110
	Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu 115	120	125
10	His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr 130	135	140
	Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser 145	150	155
	Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile 165	170	175
20	Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu 180	185	190
	Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser 195	200	205
	Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn 210	215	220
30	Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln 225	230	235
	Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr 245	250	255
	Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln 260	265	270
40	Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr 275	280	285
	Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu 290	295	300
	Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser 305	310	315
50	Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe 325	330	335
	Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys 340	345	350

Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser  
 355 360 365

5 Lys Thr Asp Val Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val  
 370 375 380

10 Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly  
 385 390 395 400

Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly  
 405 410 415

15 Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln  
 420 425 430

20 Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr  
 435 440 445

Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln  
 450 455 460

25 Val Asn Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp  
 465 470 475 480

30 Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys  
 485 490 495

35 Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly  
 500 505 510

**Glu Ala**

40 <210> 7

<211> 1855

<212> DNA

<213> Artificial Sequence

45 <220>

<223> Chimeric PreF-G Antigen polynucleotide sequence

<400> 7

50	aagcttgcca ccatggagct gctgatcctc aagaccaacg ccatcaccgc catcctggcc	60
	gccgtgaccc tgtgcttcgc ctccctccag aacatcacccg aagagttcta ccagtccacc	120
	tgctccggcg tgtccaaggg ctacctgtcc gcacctgcgg a cggctggta cacctccgtg	180
55	atcaccatcg agctgtccaa catcaaagaa aacaagtgc a cggcaccga cgccaaggtc	240
	aagctgatca agcaggaact ggacaagtac a aagagcgccg tgaccgaact ccagctgctg	300

atgcagtcca	cccctgccac	caacaacaag	aagtttctgg	gcttcctgct	gggcgtggc	360	
tccgccatcg	cctccggcat	cgccgtgagc	aaggtgctgc	acctggaggg	cgaggtgaac	420	
5	aagatcaaga	gcgcctgct	gtccaccaac	aaggccgtgg	tgtccctgtc	caacggcgtg	480
tccgtgctga	cctccaaggt	gctggatctg	aagaactaca	tcgacaagca	gctgctgcct	540	
10	atcgtgaaca	agcagtccctg	ctccatctcc	aacatcgaga	ccgtgatcga	gttccagcag	600
aagaacaacc	ggctgctgga	gatcacccgc	gagttctccg	tgaacgcccgg	cgtgaccacc	660	
cctgtgtcca	cctacatgct	gacaaactcc	gagctgctct	ccctgatcaa	cgacatgcct	720	
15	atcaccaacg	accaaaaaaa	gctgatgtcc	aacaacgtgc	agatcgtgcg	gcagcagtcc	780
tacagcatca	tgagcatcat	caaggaagaa	gtcctggcct	acgtcgtgca	gctgcctctg	840	
tacggcgtga	tcgacacccc	ttgctggaag	ctgcacacct	ccccctgtg	caccaccaac	900	
20	accaaagagg	gctccaacat	ctgcctgacc	cggaccgacc	ggggctggta	ctgcgacaac	960
gccggctccg	tgtccttctt	ccctctggcc	gagacctgca	aggtgcagtc	caaccgggtg	1020	
ttctgcgaca	ccatgaactc	cctgaccctg	cttccgagg	tgaacctgtg	caacatcgac	1080	
25	atcttcaacc	ccaagtacga	ctgcaagatc	atgaccagca	agaccgacgt	gtcctccagc	1140
gtgatcacct	ccctgggcgc	catcgtgtcc	tgctacggca	agaccaagtg	cacccgcctcc	1200	
aacaagaacc	gggaatcat	caagacccctc	tccaacggct	gcgactacgt	gtccaataag	1260	
30	ggcgtggaca	ccgtgtccgt	ggcaacaca	ctgtactacg	tgaataagca	ggaaggcaag	1320
agcctgtacg	tgaagggcga	gcctatcatc	aacttctacg	accctctggt	gttcccttcc	1380	
gacgagttcg	acgcctccat	cagccaggc	aacgagaaga	tcaaccagtc	cctggccttc	1440	
35	atccggaagt	ccgacgagaa	gctgcataac	gtggaggaca	agatcgaaga	gatcctgtcc	1500
aaaatctacc	acatcgagaa	cgagatcgcc	cgatcaaga	agctgatcgg	cgaggctggc	1560	
ggctctggcg	gcagcggcgg	ctccaagcag	cgccagaaca	agcctcctaa	caagcccaac	1620	
40	aacgacttcc	acttcgaggt	gttcaacttc	gtgccttgc	ccatctgctc	caacaaccct	1680
acctgctggg	ccatctgcaa	gagaatcccc	aacaagaagc	ctggcaagaa	aaccaccacc	1740	
45	aagcctacca	agaagcctac	cttcaagacc	accaagaagg	accacaagcc	tcaagaccaca	1800
aagcctaagg	aagtgcacac	caccaagcac	caccaccatc	accactgata	atcta	1855	

50 &lt;210&gt; 8

&lt;211&gt; 605

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

55 &lt;220&gt;

&lt;223&gt; Chimeric PreF-G polypeptide

&lt;400&gt; 8

EP 2 445 526 B1

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
1 5 10 15

5

10

15

20

25

30

35

40

45

50

55

Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
 20 25 30

5 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
 35 40 45

10 Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
 50 55 60

15 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
 65 70 75 80

20 Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
 85 90 95

25 Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Lys Phe Leu Gly Phe Leu  
 100 105 110

30 Leu Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val  
 115 120 125

35 Leu His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser  
 130 135 140

40 Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr  
 145 150 155 160

45 Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro  
 165 170 175

50 Ile Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile  
 180 185 190

55 Glu Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe  
 195 200 205

60 Ser Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr  
 210 215 220

65 Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp  
 225 230 235 240

70 Gln Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser  
 245 250 255

75 Tyr Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val  
 260 265 270

1 Gln Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His  
 275 280 285

5 Thr Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys  
 290 295 300

10 Leu Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val  
 305 310 315 320

15 Ser Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val  
 325 330 335

20 Phe Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu  
 340 345 350

25 Cys Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr  
 355 360 365

30 Ser Lys Thr Asp Val Ser Ser Val Ile Thr Ser Leu Gly Ala Ile  
 370 375 380

35 Val Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg  
 385 390 395 400

40 Gly Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys  
 405 410 415

45 Gly Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys  
 420 425 430

50 Gln Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe  
 435 440 445

55 Tyr Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser  
 450 455 460

60 Gln Val Asn Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser  
 465 470 475 480

65 Asp Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser  
 485 490 495

70 Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile  
 500 505 510

75 Gly Glu Ala Gly Gly Ser Gly Ser Gly Ser Gly Ser Lys Gln Arg Gln  
 515 520 525

Asn Lys Pro Pro Asn Lys Pro Asn Asn Asp Phe His Phe Glu Val Phe  
530 535 540

5 Asn Phe Val Pro Cys Ser Ile Cys Ser Asn Asn Pro Thr Cys Trp Ala  
545 550 555 560

10 Ile Cys Lys Arg Ile Pro Asn Lys Lys Pro Gly Lys Lys Thr Thr Thr  
565 570 575

Lys Pro Thr Lys Lys Pro Thr Phe Lys Thr Thr Lys Lys Asp His Lys  
580 585 590

15 Pro Gln Thr Thr Lys Pro Lys Glu Val Pro Thr Thr Lys  
595 600 605

20 <210> 9

<211> 1834

<212> DNA

<213> Artificial Sequence

25 <220>

<223> Chimeric PreF-G polynucleotide

<400> 9

30

35

40

45

50

55

	aagcttgcca ccatggagct gctgatcctc aagaccaacg ccatcaccgc catcctggcc	60
	gccgtgaccc tgtgcttcgc ctccctccag aacatcaccg aagagttcta ccagtccacc	120
5	tgctccggcg tgtccaaggg ctacctgtcc gccctgcca cccgctggta cacctccgtg	180
	atcaccatcg agctgtccaa catcaaagaa aacaagtgca acggcaccga cgccaaggtc	240
	aagctgatca agcaggaact ggacaagtac aagagcgccg tgaccgaact ccagctgctg	300
10	atgcagtcca cccctgccac caacaacaag aagtttctgg gttccctgtc gggcgtggc	360
	tccgcatecg cctccggcat cgccgtgagc aaggtgtgc acctggaggg cgaggtgaac	420
15	aagatcaaga gcgcctgtct gtccaccaac aaggccgtgg tgccctgtc caacggcgtg	480
	tccgtgtga cctccaaggt gctggatctg aagaactaca tcgacaagca gctgctgcct	540
	atcgtgaaca agcagtcctg ctccatctcc aacatcgaga ccgtgatcga gttccagcag	600
20	aagaacaacc ggctgctgga gatcacccgc gagttctccg tgaacgcccgg cgtgaccacc	660
	cctgtgtcca cctacatgtc gacaaactcc gagctgtct ccctgatcaa cgacatgcct	720
	atcacaaccg accaaaaaaa gctgatgtcc aacaacgtgc agatcgtgcg gcagcagtcc	780
25	tacagcatca tgagcatcat caaggaagaa gtccctggcct acgtcgtgca gtcgcctctg	840
	tacggcgtga tcgacacccc ttgctggaag ctgcacaccc ccccccgtg caccaccaac	900
	acccaaagagg gctccaacat ctgcctgacc cggaccgacc ggggctggta ctgcgacaac	960
30	gcgggctccg tgcctttttt ccctctggcc gagacctgca aggtgcagtc caaccgggtg	1020
	ttctgcgaca ccatgaactc cctgaccctg cttccgagg tgaacctgtg caacatcgac	1080
	atcttcaacc ccaagtacga ctgcaagatc atgaccagca agaccgacgt gtcctccagc	1140
35	gtgatcacct ccctggcgc catcggtcc tgctacggca agaccaagtg caccgcctcc	1200
	aacaagaacc gggaaatcat caagaccttc tccaacggct gcgactacgt gtccaataag	1260
40	ggcgtggaca ccgtgtccgt gggcaacaca ctgtactacg tgaataagca ggaaggcaag	1320
	agcctgtacg tgaaggcga gcctatcatc aacttctacg accctctggt gttcccttcc	1380
	gacgagttcg acgcctccat cagccaggc aacgagaaga tcaaccagtc cttggccttc	1440
45	atccggaaat ccgacgagaa gctgcataac gtggaggaca agatcgaaga gatccctgtcc	1500
	aaaatctacc acatcgagaa cgagatcgcc cgatcaaga agctgatcgg cgaggctggc	1560
	ggcaagcagc ggcagaacaa gcctcctaac aagcccaaca acgacttcca cttcgaggtg	1620
50	ttcaacttcg tgccttgctc catctgtcc aacaacccta cctgctggc catctgcaag	1680
	agaatccca acaagaagcc tggcaagaaa accaccacca agcctaccaa gaagcctacc	1740
	ttcaagacca ccaagaagga ccacaagcct cagaccacaa agcctaagga agtgcacacc	1800
55	accaagcacc accaccatca ccactgataa tcta	1834

&lt;211&gt; 598

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

5

&lt;220&gt;

&lt;223&gt; Chimeric PreF-G polypeptide

&lt;400&gt; 10

10

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
1 5 10 15

15

Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
20 25 30

20

Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
35 40 45

25

Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
50 55 60

30

Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
65 70 75 80

Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
85 90 95

35

Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Lys Phe Leu Gly Phe Leu  
100 105 110

40

45

50

55

Leu Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val  
 115 120 125

5 Leu His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser  
 130 135 140

10 Thr Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr  
 145 150 155 160

15 Ser Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro  
 165 170 175

20 Ile Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile  
 180 185 190

25 Glu Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe  
 195 200 205

30 Ser Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr  
 210 215 220

35 Asn Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp  
 225 230 235 240

40 Gln Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser  
 245 250 255

45 Tyr Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val  
 260 265 270

50 Gln Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His  
 275 280 285

55 Thr Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys  
 290 295 300

Leu Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val  
 305 310 315 320

Ser Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val  
 325 330 335

Phe Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu  
 340 345 350

Cys Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr  
 355 360 365

55 Ser Lys Thr Asp Val Ser Ser Ser Val Ile Thr Ser Leu Gly Ala Ile

370

375

380

5 Val Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg  
 385 390 395 400

10 Gly Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys  
 405 410 415

Gly Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys  
 420 425 430

15 Gln Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe  
 435 440 445

Tyr Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser  
 450 455 460

20

Gln Val Asn Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser  
 465 470 475 480

25 Asp Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser  
 485 490 495

30 Lys Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile  
 500 505 510

Gly Glu Ala Gly Gly Lys Gln Arg Gln Asn Lys Pro Pro Asn Lys Pro  
 515 520 525

35

Asn Asn Asp Phe His Phe Glu Val Phe Asn Phe Val Pro Cys Ser Ile  
 530 535 540

40 Cys Ser Asn Asn Pro Thr Cys Trp Ala Ile Cys Lys Arg Ile Pro Asn  
 545 550 555 560

45 Lys Lys Pro Gly Lys Lys Thr Thr Thr Lys Pro Thr Lys Lys Pro Thr  
 565 570 575

45

Phe Lys Thr Thr Lys Lys Asp His Lys Pro Gln Thr Thr Lys Pro Lys  
 580 585 590

50

Glu Val Pro Thr Thr Lys  
 595

&lt;210&gt; 11

&lt;211&gt; 28

55

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

EP 2 445 526 B1

<223> Isoleucine substituted GCN4 leucine zipper

<400> 11

5 Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys Ile Tyr His Ile Glu Asn  
1 5 10 15

10 Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly Glu Ala  
20 25

<210> 12

<211> 1563

<212> DNA

15 <213> Artificial sequence

<220>

<223> Codon optimized PreF nucleotide sequence

20 <400> 12

25

30

35

40

45

50

55

atggagctgc	ccatcctgaa	gaccaacgccc	atcaccacca	tcctcgccgc	cgtgaccctg	60	
tgcttcgcca	gcagccagaa	catcacggag	gagttctacc	agagcacgtg	cagcgccgtg	120	
5	agcaagggt	acctgagcgc	gctgcgcacg	ggctggtaca	cgagcgtat	cacgatcgag	180
ctgagcaaca	tcaaggagaa	caagtgcac	ggcacggacg	cgaagggtgaa	gctgtatcaag	240	
caggagctgg	acaagtacaa	gagcgcggtg	acggagctgc	agctgctgtat	gcagagcacg	300	
10	ccggcgacga	acaacaagtt	cctcggcttc	ctgctggcg	tgggcagcgc	360	
ggcatcgccg	tgagcaaggt	gctgcacctg	gagggcgagg	tgaacaagat	caagtccgcg	420	
15	ctgctgagca	cgaacaaggc	ggtcgtgagc	ctgagcaacg	gcgtgagcgt	gtgtacgagc	480
aaggtgctcg	acctgaagaa	ctacatcgac	aaggcgtgc	tgccgatcgt	gaacaaggcag	540	
20	agctgcagca	tcagcaacat	cgagaccgtg	atcgagtcc	agcagaagaa	caaccgcctg	600
ctggagatca	cgcgggagtt	ctccgtgaac	gcaggcgtga	cgacgcccgt	gtctacgtac	660	
25	atgctgacga	acagcgagct	gctcagcctg	atcaacgaca	tgccgatcac	gaacgaccag	720
aagaagctga	tgagcaacaa	cgtgcagatc	gtgcgcgcagc	agagctacag	catcatgagc	780	
atcatcaagg	aggaggtgct	ggcatacgtg	gtgcagctgc	cgctgtacgg	cgtcatcgac	840	
30	acgcctgct	ggaagctgca	cacgagcccg	ctgtgcacga	ccaacacgaa	ggagggcagc	900
aacatctgcc	tgacgcggac	ggaccggggc	tggtaactgcg	acaacgcggg	cagcgtgagc	960	
ttcttcccg	tcgcggagac	gtgcaaggtg	cagagcaacc	gcgtcttctg	cgacacgatg	1020	
35	aacagcctga	cgctgccgag	cgaggtgaac	ctgtgcaaca	tcgacatctt	caacccgaag	1080
tacgactgca	agatcatgac	gagcaagacc	gatgtcagca	gcagcgtat	cacgagcctc	1140	
40	ggcgcgatcg	tgagctgcta	cgcaagacg	aagtgcacgg	cgagcaacaa	gaaccgcggc	1200
atcatcaaga	cgttcagcaa	cggctgcgac	tatgtgagca	acaagggcgt	ggacactgtg	1260	
agcgtcggca	acacgctgta	ctacgtgaac	aaggcaggagg	gcaagagcct	gtacgtgaag	1320	
45	ggcgagccga	tcatcaactt	ctacgacccg	ctcgtgttcc	cgagcgcacga	gttcgacgcg	1380
agcatcagcc	aagtgaacga	gaagatcaac	cagagcctgg	cgttcatccg	caagagcgcac	1440	
gagaagctgc	acaacgtgga	ggacaagatc	gaggagatcc	tgagcaagat	ctaccacatc	1500	
50	gagaacgaga	tcgcgcgcac	caagaagctg	atcggcgagg	cgcacatcatca	ccatcaccat	1560
tga						1563	

&lt;210&gt; 13

&lt;211&gt; 1685

&lt;212&gt; DNA

55 &lt;213&gt; Artificial sequence

&lt;220&gt;

&lt;223&gt; PreF polynucleotide sequence with intron

&lt;400&gt; 13

5	atggagctgc tgatcctgaa aaccaacgcc atcacccgcca tcctggccgc cgtgaccctg	60
	tgcttcgcct cctcccgaaa catcacccgag gagttctacc agtccacctg ctccgcgcgtg	120
	tccaaaggcgt acctgtccgc cctgcggacc ggctggtaca cctccgtat caccatcgag	180
10	ctgtccaaca tcaaggaaaa caagtgcac acgcacccgacg ccaagggtgaa gctgatcaag	240
	caggagctgg acaagtacaa gagcgcgcgtg accgaactcc agctgctgat gcagtccacc	300
	cctgccacca acaacaagtt tctgggcttc ctgctggcg tgggctccgc catgcctcc	360
15	ggcgcgcgc tgagcaaggt acgtgtcggt acttgtgttc ccctttttt aataaaaaagt	420
	tatatatcta atgttatata catatttcct gtatgtgatc catgtgctta tgacttttt	480
	tatcatgtgt ttaggtgctg cacctggagg gcgaggtgaa caagatcaag agcgcctgc	540
20	tgtccaccaa caaggccgtg gtgtccctgt ccaacggcgt gtccgtgctg acctccaagg	600
	tgctggatct gaagaactac atcgacaagc agctgctgcc tatcgtaac aagcagtcc	660
	gctccatctc caacatcgag accgtgatcg agttccagea gaagaacaac cggctgctgg	720
25	agatcacccg cgagttctcc gtgaacgccc gcgtgaccac ccctgtgtcc acctacatgc	780
	tgaccaactc cgagctgctg tccctgatca acgacatgcc tatcacaac gaccagaaaa	840
	aactgatgtc caacaacgtg cagatcgtgc ggcagcagtc ctacagcatc atgagcatca	900
30	tcaaggaaga ggtgctggcc tacgtggtc agctgcctct gtacggcgtg atcgacaccc	960
	cttgctgaa gctgcacacc tccccctgt gcaccaccaa caccaaggag ggctccaaca	1020
	tctgcctgac ccggaccgcac cggggctggt actgcgacaa cggccgcgtcc gtgtccttct	1080
35	tccctctggc cgagacctgc aaggtgcagt ccaaccgggt gttctgcgac accatgaact	1140
	ccctgaccc gccttcccgag gtgaacctgt gcaacatcga catcttcaac cccaaagtacg	1200
	actgcaagat catgaccaggc aagaccgacg tgtcctccag cgtgatcacc tccctggcg	1260
40	ccatcgtgtc ctgctacggc aagaccaagt gcaccgcctc caacaagaac cggggaaatca	1320
	tcaagacctt ctccaacggc tgcgactacg tgtccaataa gggcgtggac accgtgtccg	1380
45	tgggcaacac actgtactac gtgaataagc aggagggcaa gagcctgtac gtgaagggcg	1440
	agcctatcat caacttctac gaccctctgg tttcccttc cgacgagttc gacgcctcca	1500
	tcagccaggt gaacgagaag atcaaccagt ccctggcctt catccggaaag tccgacgaga	1560
50	agctgcataa cgtggaggac aagatcgagg agatcctgtc caaaatctac cacatcgaga	1620
	acgagatcgc cggatcaag aagctgatcg gcgaggccgg aggtcaccac caccatcacc	1680
55	actga	1685

&lt;210&gt; 14

&lt;211&gt; 9

<212> PRT

<213> Artificial sequence

<220>

5 <223> Synthetic linker peptide

<400> 14

10 **Gly Gly Ser Gly Gly Ser Gly Gly Ser**  
1 5

<210> 15

<211> 4

<212> PRT

15 <213> Artificial sequence

<220>

<223> Furin cleavage consensus motif

20 <400> 15

**Arg Ala Arg Arg**  
1

<210> 16

<211> 4

<212> PRT

<213> Artificial sequence

30 <220>

<223> Furin cleavage consensus motif

<400> 16

35 **Arg Lys Arg Arg**  
1

<210> 17

<211> 1542

40 <212> DNA

<213> Artificial Sequence

<220>

<223> Synthetic PreF Polynucleotide

45 <400> 17

50

55

atggagctgc	tgatcctgaa	aaccaacgcc	atcacccgcca	tcctggccgc	cgtgaccctg	60	
tgcttcgcct	cctcccaagaa	catcaccgag	gagttctacc	agtccacctg	ctccgcccgtg	120	
5	tccaaagggt	acctgtccgc	cctgcggacc	ggctggtaca	cctccgtat	caccatcgag	180
ctgtccaaaca	tcaaggaaaa	caagtgcac	ggcacccgacg	ccaagggtgaa	gctgatcaag	240	
caggagctgg	acaagtacaa	gagcgcgtg	accgaactcc	agctgctgat	gcagtccacc	300	
10	cctgccacca	acaacaagtt	tctgggcttc	ctgctggcgc	tgggctccgc	catgcctcc	360
ggcatacgccg	tgagcaaggt	gctgcacctg	gagggcgagg	tgaacaagat	caagagcggcc	420	
15	ctgctgtcca	ccaacaaggc	cgtgggtgtcc	ctgtccaaacg	gcgtgtccgt	gctgacctcc	480
aagggtgtgg	atctgaagaa	ctacatcgac	aagcagctgc	tgcctatcgt	gaacaaggcag	540	
tcctgctcca	tctccaaacat	cgagaccgtg	atcgagttcc	agcagaagaa	caaccggctg	600	
20	ctggagatca	cccgcgagtt	ctccgtgaac	gccggcggtga	ccaccctgt	gtccacctac	660
atgctgacca	actcccgagct	gctgtccctg	atcaacgaca	tgcctatcac	caacgaccag	720	
aaaaaaactga	tgtccaaacaa	cgtgcagatc	gtgcggcagc	agtcctacag	catcatgagc	780	
25	atcatcaagg	aagaggtgct	ggcctacgtg	gtcagctgc	ctctgtacgg	cgtgatcgac	840
accccttgct	ggaagctgca	cacctcccc	ctgtgcacca	ccaacaccaa	ggagggctcc	900	
aacatctgcc	tgacccggac	cgaccggggc	tggtaactgcg	acaacgcccgg	ctccgtgtcc	960	
30	ttcttccttc	tggccgagac	ctgcaaggtg	cagtccaaacc	gggtgttctg	cgacaccatg	1020
aactccctga	ccctgccttc	cgaggtgaac	ctgtgcaaca	tgcacatctt	caaccccaag	1080	
tacgactgca	agatcatgac	cagcaagacc	gacgtgtccct	ccagcgtat	cacccctcg	1140	
35	ggcgccatcg	tgtcctgcta	cggcaagacc	aagtgcacccg	cctccaaacaa	gaaccgggga	1200
atcatcaaga	ccttctccaa	cggctgcgac	tacgtgtcca	ataagggcgt	ggacaccgtg	1260	
tccgtggca	acacactgta	ctacgtaat	aagcaggagg	gcaagagcct	gtacgtgaag	1320	
40	ggcgagccta	tcatcaactt	ctacgaccct	ctgggtgttcc	cttccgacga	gttcgacgcc	1380
tccatcagcc	aggtgaacga	gaagatcaac	gggaccctgg	cttcatccg	gaagtccgac	1440	
45	gagaagctgc	ataacgtgga	ggacaagatc	gaggagatcc	tgtccaaaat	ctaccacatc	1500
gagaacgaga	tcgccccggat	caagaagctg	atcggcgagg	cc		1542	

&lt;210&gt; 18

&lt;211&gt; 514

&lt;212&gt; PRT

&lt;213&gt; Artificial Sequence

&lt;220&gt;

&lt;223&gt; Synthetic PreF Polypeptide

55

&lt;400&gt; 18

EP 2 445 526 B1

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
1 5 10 15

5

10

15

20

25

30

35

40

45

50

55

Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
 20 25 30

5 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
 35 40 45

10 Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
 50 55 60

15 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
 65 70 75 80

20 Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
 85 90 95

25 Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Phe Leu Gly Phe Leu Leu  
 100 105 110

Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu  
 115 120 125

30 His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr  
 130 135 140

35 Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser  
 145 150 155 160

Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile  
 165 170 175

40 Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu  
 180 185 190

45 Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser  
 195 200 205

Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn  
 210 215 220

50 Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln  
 225 230 235 240

Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr  
 245 250 255

55 Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln  
 260 265 270

Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Tri Lys Leu His Thr  
 275 280 285

5 Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu  
 290 295 300

10 Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser  
 305 310 315 320

Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe  
 325 330 335

15 Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys  
 340 345 350

20 Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser  
 355 360 365

Lys Thr Asp Val Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val  
 370 375 380

25 Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly  
 385 390 395 400

30 Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly  
 405 410 415

Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln  
 420 425 430

35 Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr  
 435 440 445

40 Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln  
 450 455 460

Val Asn Glu Lys Ile Asn Gly Thr Leu Ala Phe Ile Arg Lys Ser Asp  
 465 470 475 480

45 Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys  
 485 490 495

50 Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly  
 500 505 510

55 Glu Ala

<210> 19  
 <211> 1542

&lt;212&gt; DNA

&lt;213&gt; Artificial Sequence

&lt;220&gt;

5 &lt;223&gt; Synthetic PreF Polynucleotide

&lt;400&gt; 19

10	atggagctgc tgatcctgaa aaccaacgccc atcaccgcca tcctggccgc cgtgaccctg	60
	tgcttcgcct cctcccgagaa catcaccgag gagttctacc agtccacctg ctccgcccgtg	120
	tccaaaggct acctgtccgc cctgcggacc ggctggtaca cctccgtat caccatcgag	180
15	ctgtccaaaca tcaaggaaaa caagtgcac acgcaccgacg ccaaggtgaa gctgatcaag	240
	caggagctgg acaagtacaa gagcgccgtg accgaactcc agctgctgat gcagtcacc	300
	cctgccacca acaacaagtt tctgggcttc ctgcaggcg tgggctccgc catgcctcc	360
20	ggcatacgccg ttagcaaggt gctgcacctg gaggcgagg tgaacaagat caagagcgc	420
	ctgctgtcca ccaacaaggc cgtgggttcc ctgtccaaacg gcgtgtccgt gctgacctcc	480
	aagggtctgg atctgaagaa ctacatcgac aagcagctgc tgcctatcgta gacaaggcag	540
25	tcctgcttca tctccaaacat cgagaccgtg atcgagttcc agcagaagaa caaccggctg	600
	ctggagatca cccgcgagtt ctccgtgaac gccggcgtga ccacccctgt gtccacccat	660
	atgctgacca actcccgagct gctgtccctg atcaacgaca tgcctatcac caacgaccag	720
30	aaaaaaactga tgcaccaacaa cgtgcagatc gtgcggcagc agtccatcag catcatgagc	780
	atcatacaagg aagaggtgct ggcttacgtg gtgcagctgc ctctgtacgg cgtgatcgac	840
	acccttgct ggaagctgca cacctcccc ctgtgcacca ccaacaccaa ggagggttcc	900
35	aaacatctgcc tgacccggac cgaccggggc tggtaactgcg acaacgcgg ctccgtgtcc	960
	ttcttccctc tggccgagac ctgcaaggtg cagtcacacc gggtgttctg cgacaccatg	1020
40	aactccctga ccctgccttc cgaggtgaac ctgtgcacca tcgacatctt caaccccaag	1080
	tacgactgca agatcatgac cagcaagacc gacgtgtcct ccagcgtat cacctccctg	1140
	ggcgccatcg tgcctgtcta cggcaagacc aagtgcaccc cctccaaacaa gaaccgggaa	1200
45	atcatcaaga ccttctccaa cggctgcgac tacgtgtcca ataagggtgtt ggacaccgtg	1260
	tccgtggca acacactgta ctacgtaat aagcaggagg gcaagagcct gtacgtgaag	1320
	ggcgagccta tcatcaactt ctacgaccct ctgggtttcc cttccgacga gttcgacgcc	1380
50	tccatcagcc aggtgaacga gaagatcaac cagtcacccgg cttccatccg gaagtccgac	1440
	gagaagctgc ataacgtgga ggacaagatc gaggagatcc tgcaccaaaat ctaccacatc	1500
	gagaacgaga tcgccccggat caagaagctg atcggcgagg cc	1542

55

&lt;210&gt; 20

&lt;211&gt; 514

&lt;212&gt; PRT

<213> Artificial Sequence

<220>

<223> Synthetic PreF Polypeptide

5

<400> 20

10

15

20

25

30

35

40

45

50

55

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
 1 5 10 15

Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
 5 20 25 30

Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
 10 35 40 45

Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
 50 55 60

Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
 15 65 70 75 80

Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
 20 85 90 95

Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Phe Leu Gly Phe Leu Gln  
 25 100 105 110

Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu  
 115 120 125

His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr  
 30 130 135 140

Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser  
 35 145 150 155 160

Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile  
 165 170 175

Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu  
 40 180 185 190

Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser  
 45 195 200 205

Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn  
 50 210 215 220

Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln  
 55 225 230 235 240

Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr  
 245 250 255

5 Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln  
 260 265 270

10 Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr  
 275 280 285

15 Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu  
 290 295 300

20 Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser  
 305 310 315 320

25 Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe  
 325 330 335

30 Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys  
 340 345 350

35 Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser  
 355 360 365

40 Lys Thr Asp Val Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val  
 370 375 380

45 Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly  
 385 390 395 400

50 Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly  
 405 410 415

Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln  
 420 425 430

55 Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr  
 435 440 445

Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln  
 450 455 460

Val Asn Glu Lys Ile Asn Gln Ser Leu Ala Phe Ile Arg Lys Ser Asp  
 465 470 475 480

Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys  
 485 490 495

EP 2 445 526 B1

Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly  
 500 505 510

5 Glu Ala

<210> 21

<211> 1542

<212> DNA

## 10 <213> Artificial Sequence

<220>

<223> Synthetic PreF Polynucleotide

15 <400> 21

20

25

30

35

40

45

50

55

atggagctgc	tgatcctgaa	aaccaacgcc	atcaccgcca	tcctggccgc	cgtgaccctg	60	
tgcttcgcct	cctcccaagaa	catcaccgag	gagttctacc	agtccacctg	ctccgcccgt	120	
5	tccaaaggct	acctgtccgc	cctgcggacc	ggctggtaca	cctccgtat	caccatcgag	180
ctgtccaaca	tcaaggaaaa	caagtgcac	ggcaccgacg	ccaagggtaa	gctgatcaag	240	
caggagctgg	acaagtacaa	gagcgcgtg	acccgaactcc	agctgtgtat	gcagtccacc	300	
10	cctgccacca	acaacaagtt	tctgggcttc	ctgcaggcg	tgggctccgc	catcgccctcc	360
ggcatcgccc	tgagcaaggt	gctgcacctg	gagggcgagg	tgaacaagat	caagagcgg	420	
15	ctgctgtcca	ccaacaaggc	cgtggtgtcc	ctgtccaacg	gcgtgtccgt	gctgacctcc	480
aagggtgctgg	atctgaagaa	ctacatcgac	aagcagctgc	tgcctatcgt	gaacaagcag	540	
20	tcctgttcca	tctccaacat	cgagaccgtg	atcgagttcc	agcagaagaa	caaccggctg	600
ctggagatca	cccgcgagtt	ctccgtgaac	gccggcgtga	ccaccctgt	gtccacctac	660	
atgctgacca	actccgagct	gctgtccctg	atcaacgaca	tgcctatcac	caacgaccag	720	
aaaaaaactga	tgtccaacaa	cgtcagatc	gtgcggcagc	agtcttacag	catcatgagc	780	
25	atcatcaagg	aagaggtgct	ggcctacgtg	gtgcagctgc	ctctgtacgg	cgtgatcgac	840
acccttgcgt	ggaagctgca	cacccccc	ctgtgcacca	ccaacaccaa	ggagggctcc	900	
aacatctgcc	tgacccggac	cgaccggggc	tggtaactgcg	acaacgccc	ctccgtgtcc	960	
30	ttcttccctc	tggccgagac	ctgcaaggtg	cagtccaacc	gggtgttctg	cgacaccatg	1020
aactccctga	ccctgccttc	cgaggtgaac	ctgtgcacca	tcgacatctt	caaccccaag	1080	
tacgactgca	agatcatgac	cagcaagacc	gacgtgtctt	ccagcgtat	cacccctctg	1140	
35	ggcgccatcg	tgtcctgcta	cgcaagacc	aagtgcaccc	cctccaacaa	gaaccgggg	1200
atcatcaaga	ccttctccaa	cggctgcgac	tacgtgtcca	ataagggcgt	ggacaccgtg	1260	
tccgtggca	acacactgta	ctacgtgaat	aagcaggagg	gcaagagcct	gtacgtgaag	1320	
40	ggcgagccta	tcatcaactt	ctacgaccct	ctgggtttcc	cttccgacga	gttcgacgcc	1380
tccatcagcc	aggtgaacga	gaagatcaac	gggaccctgg	cttcatccg	gaagtccgac	1440	
45	gagaagctgc	ataacgtgga	ggacaagatc	gaggagatcc	tgtccaaaat	ctaccacatc	1500
	gagaacgaga	tcgcccggat	caagaagctg	atcggcgagg	cc		1542
	<210> 22						
50	<211> 514						
	<212> PRT						
	<213> Artificial Sequence						
	<220>						
55	<223> Synthetic PreF Polypeptide						
	<400> 22						

Met Glu Leu Leu Ile Leu Lys Thr Asn Ala Ile Thr Ala Ile Leu Ala  
 1 5 10 15

5 Ala Val Thr Leu Cys Phe Ala Ser Ser Gln Asn Ile Thr Glu Glu Phe  
 20 25 30

10 Tyr Gln Ser Thr Cys Ser Ala Val Ser Lys Gly Tyr Leu Ser Ala Leu  
 35 40 45

Arg Thr Gly Trp Tyr Thr Ser Val Ile Thr Ile Glu Leu Ser Asn Ile  
 50 55 60

15 Lys Glu Asn Lys Cys Asn Gly Thr Asp Ala Lys Val Lys Leu Ile Lys  
 65 70 75 80

20 Gln Glu Leu Asp Lys Tyr Lys Ser Ala Val Thr Glu Leu Gln Leu Leu  
 85 90 95

Met Gln Ser Thr Pro Ala Thr Asn Asn Lys Phe Leu Gly Phe Leu Gln  
 100 105 110

25 Gly Val Gly Ser Ala Ile Ala Ser Gly Ile Ala Val Ser Lys Val Leu  
 115 120 125

30 His Leu Glu Gly Glu Val Asn Lys Ile Lys Ser Ala Leu Leu Ser Thr  
 130 135 140

35 Asn Lys Ala Val Val Ser Leu Ser Asn Gly Val Ser Val Leu Thr Ser  
 145 150 155 160

Lys Val Leu Asp Leu Lys Asn Tyr Ile Asp Lys Gln Leu Leu Pro Ile  
 165 170 175

40 Val Asn Lys Gln Ser Cys Ser Ile Ser Asn Ile Glu Thr Val Ile Glu  
 180 185 190

45 Phe Gln Gln Lys Asn Asn Arg Leu Leu Glu Ile Thr Arg Glu Phe Ser

50

55

5	195	200	205
	Val Asn Ala Gly Val Thr Thr Pro Val Ser Thr Tyr Met Leu Thr Asn		
	210	215	220
	Ser Glu Leu Leu Ser Leu Ile Asn Asp Met Pro Ile Thr Asn Asp Gln		
	225	230	235
10	Lys Lys Leu Met Ser Asn Asn Val Gln Ile Val Arg Gln Gln Ser Tyr		
	245	250	255
15	Ser Ile Met Ser Ile Ile Lys Glu Glu Val Leu Ala Tyr Val Val Gln		
	260	265	270
	Leu Pro Leu Tyr Gly Val Ile Asp Thr Pro Cys Trp Lys Leu His Thr		
	275	280	285
20	Ser Pro Leu Cys Thr Thr Asn Thr Lys Glu Gly Ser Asn Ile Cys Leu		
	290	295	300
25	Thr Arg Thr Asp Arg Gly Trp Tyr Cys Asp Asn Ala Gly Ser Val Ser		
	305	310	315
	Phe Phe Pro Leu Ala Glu Thr Cys Lys Val Gln Ser Asn Arg Val Phe		
	325	330	335
30	Cys Asp Thr Met Asn Ser Leu Thr Leu Pro Ser Glu Val Asn Leu Cys		
	340	345	350
35	Asn Ile Asp Ile Phe Asn Pro Lys Tyr Asp Cys Lys Ile Met Thr Ser		
	355	360	365
	Lys Thr Asp Val Ser Ser Val Ile Thr Ser Leu Gly Ala Ile Val		
	370	375	380
40	Ser Cys Tyr Gly Lys Thr Lys Cys Thr Ala Ser Asn Lys Asn Arg Gly		
	385	390	395
	Ile Ile Lys Thr Phe Ser Asn Gly Cys Asp Tyr Val Ser Asn Lys Gly		
	405	410	415
45	Val Asp Thr Val Ser Val Gly Asn Thr Leu Tyr Tyr Val Asn Lys Gln		
	420	425	430
50	Glu Gly Lys Ser Leu Tyr Val Lys Gly Glu Pro Ile Ile Asn Phe Tyr		
	435	440	445
55	Asp Pro Leu Val Phe Pro Ser Asp Glu Phe Asp Ala Ser Ile Ser Gln		
	450	455	460

Val Asn Glu Lys Ile Asn Gly Thr Leu Ala Phe Ile Arg Lys Ser Asp  
465 470 475 480

5 Glu Lys Leu His Asn Val Glu Asp Lys Ile Glu Glu Ile Leu Ser Lys  
485 490 495

Ile Tyr His Ile Glu Asn Glu Ile Ala Arg Ile Lys Lys Leu Ile Gly  
500 505 510

10

Glu Ala

15 **Claims**

20 1. A recombinant respiratory syncytial virus (RSV) antigen comprising an RSV F protein polypeptide without a transmembrane domain, comprising an F<sub>2</sub> domain and an F<sub>1</sub> domain of an RSV F protein polypeptide, wherein the F protein polypeptide comprises at least one modification that increases glycosylation, which at least one modification that increases glycosylation comprises a substitution wherein amino acids corresponding to positions 500-502 of SEQ ID NO:2 are selected from: NGS; NGT.

25 2. The recombinant RSV antigen of claim 1, wherein the F protein polypeptide comprises at least one modification selected from:

30 (i) an addition of an amino acid sequence comprising a heterologous trimerization domain;  
(ii) an amino acid addition, deletion or substitution that eliminates a furin cleavage site at a position corresponding to amino acids 105-109, a position corresponding to amino acids 133-136, or at both positions corresponding to amino acids 105-109 and 133-136 of the reference F protein precursor (F<sub>0</sub>) of SEQ ID NO:2;  
(iii) a deletion of one or more amino acids of the pep27 domain; and  
(iv) substitution of lysine for the leucine present at position 512 or addition of a lysine following the amino acid corresponding to residue 105 of reference SEQ ID NO:2.

35 3. The recombinant RSV antigen of any one of claims 1-2, wherein the soluble F protein polypeptide comprises the intact fusion peptide between the F2 domain and the F1 domain.

40 4. The recombinant RSV antigen of claim 2 or claim 3, wherein the at least one modification comprises the addition of an amino acid sequence comprising a heterologous trimerization domain.

45 5. The recombinant RSV antigen of claim 4, wherein the heterologous trimerization domain is positioned C-terminal to the F<sub>1</sub> domain.

6. The recombinant RSV antigen of any one of claims 2-5, comprising an F2 domain and an F1 domain with no intervening furin cleavage site.

45 7. The recombinant RSV antigen of any one of claims 1-6, wherein the F<sub>2</sub> domain comprises at least a portion of an RSV F protein polypeptide corresponding to amino acids 26-105 of the reference F protein precursor polypeptide (F<sub>0</sub>) of SEQ ID NO:2.

50 8. The recombinant RSV antigen of any one of claims 1-7, wherein the F<sub>1</sub> domain comprises at least a portion of an RSV F protein polypeptide corresponding to amino acids 137-516 of the reference F protein precursor polypeptide (F<sub>0</sub>) of SEQ ID NO:2.

55 9. The recombinant RSV antigen of any one of claims 1-8, wherein the RSV antigen is selected from the group of:

a) a polypeptide comprising SEQ ID NO:22;  
b) a polypeptide encoded by SEQ ID NO:21;  
c) a polypeptide with at least 95% sequence identity to SEQ ID NO:22.

10. The recombinant RSV antigen of any one of claims 1-9, wherein the RSV antigen comprises a multimer of polypeptides.

5           11. The recombinant RSV antigen of any one of claims 1-10, wherein the RSV antigen comprises a trimer of polypeptides.

12. An immunogenic composition comprising the recombinant RSV antigen of any one of claims 1-11, and a pharmaceutically acceptable carrier or excipient.

10           13. The immunogenic composition of claim 12, further comprising an adjuvant.

14. A recombinant nucleic acid comprising a polynucleotide sequence that encodes the recombinant RSV antigen of any one of claims 1-11.

15           15. The recombinant nucleic acid of claim 14, wherein the nucleic acid comprises a polynucleotide sequence selected from:

20           a) a polynucleotide sequence comprising SEQ ID NO:21;  
              b) a polynucleotide sequence that encodes SEQ ID NO:22;  
              c) a polynucleotide sequence with at least 95% sequence identity to SEQ ID NO:21, which polynucleotide sequence does not correspond to a naturally occurring RSV strain.

16. The use of the RSV antigen of any one of claims 1-11 or the nucleic acid of claim 15 in the preparation of a medicament for treating an RSV infection.

25           17. The use of claim 16, wherein the medicament is administered for the purpose of prophylactically treating an RSV infection.

18. The recombinant RSV antigen of any one of claims 1-11 or the immunogenic composition of any one of claims 12 to 13 for use as a medicament.

30           19. The recombinant RSV antigen of any one of claims 1-11 or the immunogenic composition of any one of claims 12 to 13 for the prevention or treatment of an RSV infection.

35           **Patentansprüche**

1. Rekombinantes Respiratorisches Synzytial-Virus (RSV)-Antigen, umfassend ein RSV-F-Protein-Polypeptid ohne eine Transmembrandomäne, umfassend eine F<sub>2</sub>-Domäne und eine F<sub>1</sub>-Domäne eines RSV-F-Protein-Polypeptids, wobei das F-Protein-Polypeptid mindestens eine Modifikation umfasst, die Glykosylierung erhöht, wobei die mindestens eine Modifikation, die die Glykosylierung erhöht, eine Substitution umfasst, wobei Aminosäuren, die den Positionen 500-502 der SEQ ID NO:2 entsprechen, ausgewählt sind aus: NGS; NGT.

40           2. Rekombinantes RSV-Antigen nach Anspruch 1, wobei das F-Protein-Polypeptid mindestens eine Modifikation umfasst, ausgewählt aus:

45           (i) Hinzufügen einer Aminosäuresequenz, umfassend eine heterologe Trimerisierungsdomäne;  
              (ii) Hinzufügen, Deletion oder Substitution einer Aminosäure, die eine Furin-Spaltstelle an einer Position besetzt, die den Aminosäuren 105-109 entspricht, einer Position, die den Aminosäuren 133-136 entspricht, oder an beiden Positionen, die den Aminosäuren 105-109 und 133-136 des Referenz-F-Protein-Vorläufers (F<sub>0</sub>) der SEQ ID NO:2 entsprechen;  
              (iii) Deletion einer oder mehrerer Aminosäuren der Pep27-Domäne; und  
              (iv) Substitution von Lysin durch das an Position 512 vorliegende Leucin, oder Hinzufügen eines Lysins nach der Aminosäure, die dem Rest 105 der Referenz-SEQ ID NO:2 entspricht.

50           3. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 2, wobei das lösliche F-Protein-Polypeptid das intakte Fusionspeptid zwischen der F<sub>2</sub>-Domäne und der F<sub>1</sub>-Domäne umfasst.

55           4. Rekombinantes RSV-Antigen nach Anspruch 2 oder Anspruch 3, wobei die mindestens eine Modifikation das Hin-

zufügen einer Aminosäuresequenz umfasst, die eine heterologe Trimerisierungsdomäne umfasst.

5        5. Rekombinantes RSV-Antigen nach Anspruch 4, wobei die heterologe Trimerisierungsdomäne C-terminal zu der F<sub>1</sub>-Domäne positioniert ist.

6        6. Rekombinantes RSV-Antigen nach einem der Ansprüche 2 bis 5, umfassend eine F<sub>2</sub>-Domäne und eine F<sub>1</sub>-Domäne ohne dazwischenliegende Furin-Spaltstelle.

10      7. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 6, wobei die F<sub>2</sub>-Domäne mindestens einen Teil eines RSV-F-Protein-Polypeptids umfasst, der den Aminosäuren 26-105 des Referenz-F-Protein-Vorläufer-Polypeptids (F<sub>0</sub>) der SEQ ID NO:2 entspricht.

15      8. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 7, wobei die F<sub>1</sub>-Domäne mindestens einen Teil eines RSV-F-Protein-Polypeptids umfasst, der den Aminosäuren 137-516 des Referenz-F-Protein-Vorläufer-Polypeptids (F<sub>0</sub>) der SEQ ID NO:2 entspricht.

19      9. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 8, wobei das RSV-Antigen ausgewählt ist aus der Gruppe aus:

20      a) Polypeptid, umfassend SEQ ID NO:22;  
b) Polypeptid, codiert durch SEQ ID NO:21;  
c) Polypeptid mit mindestens 95% Sequenzidentität zu SEQ ID NO:22.

25      10. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 9, wobei das RSV-Antigen ein Multimer aus Polypeptiden umfasst.

11. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 10, wobei das RSV-Antigen ein Trimer aus Polypeptiden umfasst.

30      12. Immunogene Zusammensetzung, umfassend das rekombinante RSV-Antigen nach einem der Ansprüche 1 bis 11 und einen pharmazeutisch verträglichen Träger oder Excipienten.

13. Immunogene Zusammensetzung nach Anspruch 12, des Weiteren umfassend ein Adjuvans.

35      14. Rekombinante Nucleinsäure, umfassend eine Polynucleotidsequenz, die das rekombinante RSV-Antigen nach einem der Ansprüche 1 bis 11 codiert.

15. Rekombinante Nucleinsäure nach Anspruch 14, wobei die Nucleinsäure eine Polynucleotidsequenz umfasst, die ausgewählt ist aus:

40      a) Polynucleotidsequenz, umfassend SEQ ID NO:21;  
b) Polynucleotidsequenz, die SEQ ID NO:22 codiert;  
c) Polynucleotidsequenz mit mindestens 95% Sequenzidentität zu SEQ ID NO:21,

45      wobei die Polynucleotidsequenz keinem natürlich vorkommenden RSV-Stamm entspricht.

16. Verwendung des RSV-Antigens nach einem der Ansprüche 1 bis 11 oder der Nucleinsäure nach Anspruch 15 bei der Herstellung eines Medikaments zur Behandlung einer RSV-Infektion.

50      17. Verwendung nach Anspruch 16, wobei das Medikament zum Zweck der prophylaktischen Behandlung einer RSV-Infektion verabreicht wird.

18. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 11 oder immunogene Zusammensetzung nach einem der Ansprüche 12 oder 13 zur Verwendung als ein Medikament.

55      19. Rekombinantes RSV-Antigen nach einem der Ansprüche 1 bis 11 oder immunogene Zusammensetzung nach einem der Ansprüche 12 oder 13 zur Prävention oder Behandlung einer RSV-Infektion.

**Revendications**

1. Antigène du virus respiratoire syncytial (RSV) recombinant comprenant un polypeptide de la protéine F du RSV sans un domaine transmembranaire, comprenant un domaine  $F_2$  et un domaine  $F_1$  d'un polypeptide de la protéine F du RSV, où le polypeptide de la protéine F comprend au moins une modification qui augmente la glycosylation, laquelle au moins une modification qui augmente la glycosylation comprend une substitution où les acides aminés correspondant aux positions 500 à 502 de SEQ ID NO : 2 sont choisis parmi : NGS ; NGT.
2. Antigène du RSV recombinant selon la revendication 1, où le polypeptide de la protéine F comprend au moins une modification choisie parmi :
  - (i) une addition d'une séquence d'acides aminés comprenant un domaine de trimérisation hétérologue ;
  - (ii) une addition, une délétion ou une substitution d'acide aminé qui élimine un site de clivage par la furine au niveau d'une position correspondant aux acides aminés 105 à 109, d'une position correspondant aux acides aminés 133 à 136, ou au niveau des positions correspondant à la fois aux acides aminés 105 à 109 et 133 à 136 du précurseur de la protéine F de référence ( $F_0$ ) de SEQ ID NO : 2 ;
  - (iii) une délétion d'un ou de plusieurs acides aminés du domaine pep27 ; et
  - (iv) la substitution de lysine à la leucine présente au niveau de la position 512 ou l'addition d'une lysine à la suite de l'acide aminé correspondant au résidu 105 de la SEQ ID NO : 2 de référence.
3. Antigène du RSV recombinant selon l'une quelconque des revendications 1 ou 2, où le polypeptide de la protéine F soluble comprend le peptide de fusion intact entre le domaine  $F_2$  et le domaine  $F_1$ .
4. Antigène du RSV recombinant selon la revendication 2 ou la revendication 3, où la au moins une modification comprend l'addition d'une séquence d'acides aminés comprenant un domaine de trimérisation hétérologue.
5. Antigène du RSV recombinant selon la revendication 4, où le domaine de trimérisation hétérologue est positionné en C-terminal par rapport au domaine  $F_1$ .
6. Antigène du RSV recombinant selon l'une quelconque des revendications 2 à 5, comprenant un domaine  $F_2$  et un domaine  $F_1$  sans aucun site de clivage par la furine intervenant.
7. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 6, où le domaine  $F_2$  comprend au moins une partie d'un polypeptide de la protéine F du RSV correspondant aux acides aminés 26 à 105 du polypeptide précurseur de la protéine F de référence ( $F_0$ ) de SEQ ID NO : 2.
8. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 7, où le domaine  $F_1$  comprend au moins une partie d'un polypeptide de la protéine F du RSV correspondant aux acides aminés 137 à 516 du polypeptide précurseur de la protéine F de référence ( $F_0$ ) de SEQ ID NO : 2.
9. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 8, où l'antigène du RSV est choisi dans le groupe de :
  - a) un polypeptide comprenant SEQ ID NO : 22 ;
  - b) un polypeptide codé par SEQ ID NO : 21 ;
  - c) un polypeptide présentant au moins 95 % d'identité de séquence avec SEQ ID NO : 22.
10. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 9, où l'antigène du RSV comprend un multimère de polypeptides.
11. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 10, où l'antigène du RSV comprend un trimère de polypeptides.
12. Composition immunogène comprenant l'antigène du RSV recombinant selon l'une quelconque des revendications 1 à 11, et un support ou un excipient pharmaceutiquement acceptable.
13. Composition immunogène selon la revendication 12, comprenant en outre un adjuvant.

14. Acide nucléique recombinant comprenant une séquence polynucléotidique qui code pour l'antigène du RSV recombinant selon l'une quelconque des revendications 1 à 11.

5 15. Acide nucléique recombinant selon la revendication 14, où l'acide nucléique comprend une séquence polynucléotidique choisie parmi :

- a) une séquence polynucléotidique comprenant SEQ ID NO : 21 ;
- b) une séquence polynucléotidique qui code pour SEQ ID NO : 22 ;
- c) une séquence polynucléotidique présentant au moins 95 % d'identité de séquence avec SEQ ID NO : 21, 10 laquelle séquence polynucléotidique ne correspond pas à une souche du RSV existant à l'état naturel.

16. Utilisation de l'antigène du RSV selon l'une quelconque des revendications 1 à 11 ou de l'acide nucléique selon la revendication 15 dans la préparation d'un médicament destiné au traitement d'une infection par le RSV.

15 17. Utilisation selon la revendication 16, où le médicament est administré dans l'objectif d'un traitement prophylactique d'une infection par le RSV.

18. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 11 ou composition immunogène selon 20 l'une quelconque des revendications 12 à 13 pour une utilisation en tant que médicament.

19. Antigène du RSV recombinant selon l'une quelconque des revendications 1 à 11 ou composition immunogène selon 25 l'une quelconque des revendications 12 à 13 pour la prévention ou le traitement d'une infection par le RSV.

25

30



35

40

45

50

55

**FIG. 1A****FIG. 1B**




FIG. 2






FIG. 3

**FIG. 4A**  
**Serology in immunized mice, CHO-preF**



# FIG. 4B


## Serology in immunized mice, CHO-preF



**FIG. 5A**

**Evaluation of CHO-preF in vivo**

**Neutralization titers**



\* Same assay, sera taken from different animal study

**FIG. 5B**  
**Evaluation of CHO-preF in vivo**  
**Neutralization titers**




FIG. 6A  
CHO-preF protection against challenge




FIG. 6B  
CHO-preF protection against challenge




FIG. 7  
Pulmonary eosinophil recruitment following challenge in mice




FIG. 8  
Serum IgG levels in mice immunized with PreF formulated with  
an oil-in-water emulsion adjuvant





FIG. 9  
Neutralizing Antibody Titers in Mice immunized with PreF  
formulated with an oil-in-water emulsion adjuvant



PROTECTION AGAINST CHALLENGE IN MICE IMMUNIZED  
WITH preF FORMULATED WITH AN OIL-IN-WATER  
EMULSION ADJUVANT  
RSV TITRATION IN LUNG HOMOGENATES  
OF CHALLENGED MICE  
SPEARMAN-KARBER FORMULA (WITH GEOMETRIC MEAN)




FIG. 10

## REFERENCES CITED IN THE DESCRIPTION

*This list of references cited by the applicant is for the reader's convenience only. It does not form part of the European patent document. Even though great care has been taken in compiling the references, errors or omissions cannot be excluded and the EPO disclaims all liability in this regard.*

## Patent documents cited in the description

- US 61334568 B [0001]
- US 61219964 B [0001]
- WO 2008114149 A [0017] [0018] [0040] [0042] [0048] [0078]
- US 20070178469 A [0046]
- WO 02074969 A [0046]
- US 5149650 A [0078]
- US 6113911 A [0078]
- US 20080300382 A [0078]
- US 7368537 B [0078]
- US 4436727 A [0084]
- US 4877611 A [0084]
- US 4866034 A [0084]
- US 4912094 A [0084]
- GB 2220211 A [0084]
- WO 9421292 A [0084] [0110]
- US 6005099 A [0086]
- EP 0729473 B1 [0086]
- WO 9514026 A [0086]
- WO 9964301 A [0086]
- WO 000462 A [0086]
- WO 0146127 A [0086]
- WO 9850399 A [0087]
- US 6303347 B [0087]
- US 6764840 B [0087]
- WO 2003011223 A [0088]
- WO 2003099195 A [0088]
- WO 2003043572 A [0094]
- WO 2002085905 A [0095]
- WO 2004071459 A [0096]
- WO 9602555 A [0097]
- WO 9933488 A [0097]
- US 6008200 A [0097]
- US 5856462 A [0097]
- US 5666153 A [0097]
- US 5278302 A [0097]
- WO 9526204 A [0097]
- US 5057540 A [0100] [0101]
- EP 0362279 B1 [0100]
- EP 0109942 B1 [0100]
- WO 9611711 A [0100]
- WO 9633739 A [0100] [0101]
- US 5726292 A [0103]
- US 4707543 A [0103]
- US 5985284 A [0103]
- US 20030044425 A [0105]
- EP 0689454 A [0110]
- US 4235877 A, Fullerton [0113] [0119]
- US 4372945 A, Likhite [0113] [0119]
- US 4474757 A, Armor [0113] [0119]
- US 5194595 A [0133]
- WO 61219964 A [0150]
- WO 61334568 A [0150]

## Non-patent literature cited in the description

- E. W. MARTIN. Remington's Pharmaceutical Sciences. Mack Publishing Co, 1975 [0035]
- CALDER *et al.* *Virology*, 2000, vol. 271, 122-131 [0039]
- MORTON *et al.* *Virology*, vol. 311, 275-288 [0039]
- CONNOLLY *et al.* *Proc. Natl. Acad. Sci. USA*, 2006, vol. 103, 17903-17908 [0039]
- HARBURY *et al.* *Science*, 1993, vol. 262, 1401-1407 [0040]
- ZHANG ; HENZEL. *Protein Sci.*, 2004, vol. 13, 2819-2824 [0041]
- SMITH ; WATERMAN. *Adv. Appl. Math.*, 1981, vol. 2, 482 [0042]
- NEEDLEMAN ; WUNSCH. *J. Mol. Biol.*, 1970, vol. 48, 443 [0042]
- HIGGINS ; SHARP. *Gene*, 1988, vol. 73, 237 [0042]
- HIGGINS ; SHARP. *CABIOS*, 1989, vol. 5, 151 [0042]
- CORPET *et al.* *Nucleic Acids Research*, 1988, vol. 16, 10881 [0042]
- PEARSON ; LIPMAN. *Proc. Natl. Acad. Sci. USA*, 1988, vol. 85, 2444 [0042]
- ALTSCHUL *et al.* *Nature Genet.*, 1994, vol. 6, 119 [0042]
- ALTSCHUL *et al.* *J. Mol. Biol.*, 1990, vol. 215, 403 [0042]
- SCHARF *et al.* *Results Probl Cell Differ*, 1994, vol. 20, 125-62 [0046]
- BITTER *et al.* *Methods in Enzymol*, 1987, vol. 153, 516-544 [0046]
- OTTE *et al.* *Biotechnol. Prog.*, 2007, vol. 23, 801-807 [0046]
- GIROD *et al.* *Nature Methods*, 2007, vol. 4, 747-753 [0046]
- LEVITSKY *et al.* *Bioinformatics*, 1999, vol. 15, 582-592 [0046]

- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 1989 [0047]
- **SAMBROOK et al.** Molecular Cloning: Laboratory Manual. Cold Spring Harbor Press, 2001 [0047]
- **AUSUBEL et al.** Current Protocols in Molecular Biology. 1992 [0047]
- **AUSUBEL et al.** Short Protocols in Molecular Biology: A Compendium of Methods from Current Protocols in Molecular Biology. Wiley & Sons, 1999 [0047]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press, 2001 [0049]
- **TIJSSEN.** Hybridization With Nucleic Acid Probes, Part I: Theory and Nucleic Acid Preparation, Laboratory Techniques in Biochemistry and Molecular Biology. Elsevier Science Ltd, 1993 [0049]
- **AUSUBEL et al.** Short Protocols in Molecular Biology. John Wiley & Sons, 1999 [0049]
- **SAMBROOK et al.** Molecular Cloning: A Laboratory Manual. Cold Spring Harbor Laboratory Press [0051]
- **AUSUBEL et al.** Short Protocols in Molecular Biology. John Wiley & Sons, Inc, [0051]
- **PAYNE et al.** Plant Cell and Tissue Culture in Liquid Systems. John Wiley & Sons, Inc, 1992 [0056]
- Plant Cell. Tissue and Organ Culture; Fundamental Methods Springer Lab Manual. Springer-Verlag, 1995 [0056]
- The Handbook of Microbiological Media. CRC Press, 1993 [0056]
- **VAN HEEKE ; SCHUSTER.** *J Biol Chem*, 1989, vol. 264, 5503-5509 [0057]
- **GRANT et al.** *Methods in Enzymology*, 1987, vol. 153, 516-544 [0059]
- **SANDANA.** Bioseparation of Proteins. Academic Press, Inc, 1997 [0066]
- **BOLLAG et al.** Protein Methods. Wiley-Liss, 1996 [0066]
- **WALKER.** The Protein Protocols Handbook. Humana Press, 1996 [0066]
- **HARRIS ; ANGAL.** Protein Purification Applications: A Practical Approach. IRL Press, 1990 [0066]
- **SCOPES.** Protein Purification: Principles and Practice. Springer Verlag, 1993 [0066]
- **JANSON ; RYDEN.** Protein Purification: Principles High Resolution Methods and Applications. Wiley-VCH, 1998 [0066]
- **WALKER.** Protein Protocols on CD-ROM. Humana Press, 1998 [0066]
- **FRESHNEY.** Culture of Animal Cells, a Manual of Basic Technique. Wiley- Liss, 1994 [0067] [0125]
- **E.W. MARTIN.** Remington's Pharmaceutical Sciences. Mack Publishing Co, [0079]
- **SABROE et al.** *Jl*, 2003, 1630-5 [0088]
- **KAISHO ; AKIRA.** *Biochimica et Biophysica Acta*, 2002, vol. 1589, 1-13 [0089]
- **LACAILLE-DUBOIS, M ; WAGNER H.** *A review of the biological and pharmacological activities of saponins.* *Phytomedicine*, 1996, vol. 2, 363-386 [0099]
- **KENSIL, C. R.** Saponins as vaccine adjuvants. *Crit Rev Ther Drug Carrier Syst*, 1996, vol. 12 (1-2), 1-55 [0100]
- **BOMFORD et al.** *Vaccine*, 1992, vol. 10 (9), 572-577 [0100]
- **LOWELL et al.** *J. Exp. Med.*, 1988, vol. 167, 658 [0103]
- **LOWELL et al.** *Science*, 1988, vol. 240, 800 [0103]
- **LYNCH et al.** *Biophys. J.*, 1984, vol. 45, 104 [0103]
- **LOWELL.** New Generation Vaccines. Marcel Dekker, Inc, 1997, 193 [0103]
- Proteosomes for Improved Nasal, Oral, or Injectable Vaccines. **LOWELL GH.** New Generation Vaccines. New York. Marcel Dekker, Inc, 1997, 193-206 [0104]
- Pharmaceutical Biotechnology. Vaccine Design-the subunit and adjuvant approach. Plenum Press, 1995, vol. 61 [0113] [0119]
- New Trends and Developments in Vaccines. University Park Press, 1978 [0113] [0119]
- *Biochemistry*, 1997, vol. 36, 10230-10239 [0131]
- *Eur. J. Biochem.*, 2004, vol. 271, 4284-4292 [0131]

## Szabadalmi igénypontok

1. Rekombináns légbúti óriásszíjtes vírus (RSV) antigén, amely tartalmaz transzmembrán domén nélküli, RSV F-féhérje polipeptid F<sub>2</sub> és F<sub>1</sub> doménjéi tartalmazó RSV F-féhérje polipeptidet, ahol az F-féhérje polipeptid tartalmaz legalább egy olyan módosítást, amely fokozza a glikolizációt, amely legalább egy, glikolizációt fokozó módosítás magában foglal olyan szubsztitúciót, ahol a SEQ ID NO:2 szerinti szekvencia 500-502. pozíciójának megfelelő aminosavak szekvenciája NGS és NGT közül van kiválasztva.

2. Az 1. igénypont szerinti rekombináns RSV-antigén, ahol az F-féhérje polipeptid tartalmaz legalább egy, a következők közül kiválasztott módosítást:

(i) heterológ trimerizációs domén tartalmazó aminosav-szekvencia addíciója,

(ii) SEQ ID NO:2 szerinti vonatkoztatási F-féhérje prekurzor (F<sub>0</sub>) 105-109. aminosavainak, 133-136. aminosavainak vagy mind a 105-109., mind a 133-136. aminosavainak megfelelő pozícióban furin hasítási helyet elmináló aminosav-addíció, -deléció vagy -szubsztitúció,

(iii) a pep27 domén egy vagy több aminosavának deléciója, és

(iv) a vonatkoztatási SEQ ID NO:2 szekvencia 512. pozíciójában lévő leucin szubsztitúciója lizinnel vagy a 105. aminosavnak megfelelő aminosav után lizin addíciója.

3. Az 1. vagy 2. igénypont szerinti rekombináns RSV-antigén, ahol az oldható F-féhérje polipeptid az F<sub>2</sub> és az F<sub>1</sub> domén között tartalmazza az intakt füziós fehérjét.

4. A 2. vagy 3. igénypont szerinti rekombináns RSV-antigén, ahol a legalább egy módosítás tartalmazza heterológ trimerizációs domén tartalmazó aminosav-szekvencia addícióját.

5. A 4. igénypont szerinti rekombináns RSV-antigén, ahol a heterológ trimerizációs domén az F<sub>1</sub> doménhez képest C-terminálisan van pozicionálva.

6. A 2-5. igénypontok bármelyike szerinti rekombináns RSV-antigén, amely F<sub>2</sub> és F<sub>1</sub> domén tartalmaz közbeeső furin hasítási hely nélkül.

7. Az 1-6. igénypontok bármelyike szerinti rekombináns RSV-antigén, ahol az F<sub>2</sub> domén tartalmazza a SEQ ID NO:2 szerinti hivatkozási F-féhérje prekurzor polipeptid (F<sub>0</sub>) 26-105. aminosavainak megfelelő RSV F-féhérje polipeptid legalább egy részét.

8. Az 1-7. igénypontok bármelyike szerinti rekombináns RSV-antigén, ahol az F<sub>1</sub> domén tartalmazza a SEQ ID NO:2 szerinti hivatkozási F-féhérje prekurzor polipeptid (F<sub>0</sub>) 137-516. aminosavainak megfelelő RSV F-féhérje polipeptid legalább egy részét.

9. Az 1-8. igénypontok bármelyike szerinti rekombináns RSV-antigén, ahol az RSV-antigén a következők csoportjából van kiválasztva:

a) SEQ ID NO:22 szerinti szekvenciát tartalmazó polipeptid,

b) SEQ ID NO:21 szerinti szekvencia által kódolt polipeptid,

c) SEQ ID NO:22 szerinti szekvenciával legalább 95%-ban azonos szekvenciájú polipeptid.

10. Az 1-9. igénypontok bármelyike szerinti rekombináns RSV-antigén, ahol az RSV-antigén tartalmaz egy polipeptid-multimert.

11. Az 1-10. igénypontok bármelyike szerinti rekombináns RSV-antigén, ahol az RSV-antigén tartalmaz egy polipeptid-trimert.

12. Immunogén készítmény, amely tartalmaz 1-11. igénypontok bármelyike szerinti rekombináns RSV-antigént és gyógyászatilag elfogadható hordozót vagy segédanyagot.
13. A 12. igénypont szerinti immunogén készítmény, amely tartalmaz adjuvánt is.
14. Rekombináns nukleinsav, amely 1-11. igénypontok bármelyike szerinti rekombináns RSV-antigént kódoló polinukleotid-szekvenciát tartalmaz.
15. A 14. igénypont szerinti rekombináns nukleinsav, ahol a nukleinsav tartalmaz a következők közül választott polinukleotid-szekvenciát:
  - a) SEQ ID NO:21 szerinti szekvenciát tartalmazó polinukleotid,
  - b) SEQ ID NO:22 szerinti szekvenciát kódoló polinukleotid,
  - c) SEQ ID NO:21 szerinti szekvenciával legalább 95%-ban azonos szekvenciájú polinukleotid-szekvencia, amely polinukleotid-szekvencia nem felel meg természetesen előforduló RSV-törzsnek.
16. Az 1-11. igénypontok bármelyike szerinti RSV-antigén vagy a 15. igénypont szerinti nukleinsav alkalmazása RSV-fertőzés kezelésére szolgáló gyógyszer előállításában.
17. A 16. igénypont szerinti alkalmazás, ahol a gyógyszer RSV-fertőzés megelőző kezelésének céljából van beadva.
18. Az 1-11. igénypontok bármelyike szerinti rekombináns RSV-antigén vagy a 12-13. igénypontok bármelyike szerinti immunogén készítmény gyógyszerként történő alkalmazásra.
19. Az 1-11. igénypontok bármelyike szerinti rekombináns RSV-antigén vagy a 12-13. igénypontok bármelyike szerinti immunogén készítmény RSV-fertőzés megelőzésére vagy kezelésére.

A meghatalmazott:

DANUBIA

Szabadalmi és Jogi Iroda Kft.

Dr. Fethő Árpád  
szabadalmi ügynövő